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Abstract
The aims of this study were to characterize the gut, oral, and vaginal microbiotas of pregnant
women with varying nutritional status and to determine if daily supplementation with
probiotic yogurt containing Lactobacillus rhamnosus GR-1 and ground Moringa leaves,
would ‘normalize’ the microbiota and improve pregnancy outcomes. For the latter, a clinical
study was performed in Mwanza, Tanzania, in which consumption of yogurt for 88 ± 31
days, starting from the second trimester, did not result in excess weight gain, altered
pregnancy outcomes or increased blood nutrient levels compared to an under-nourished
group not taking the yogurt. Ingestion of the probiotic yogurt did not cause a significant shift
in the gut microbiota, consistent with previous studies. However, Bifidobacterium abundance
increased in the gut of infants from mothers who consumed the yogurt. Furthermore, blood
levels of mercury and arsenic were lower in these women compared to controls.
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Chapter 1

1

Introduction

Reproduction is the most vital process of all living things as it ensures the continuation of
a species. In humans it is an intensive and intricate process that is mainly female oriented,
thus the health and nutritional status of the mother has a significant impact on the
pregnancy outcomes and health of the fetus as well as longevity and quality of life of the
newborn. The human microbiome is a powerful ecosystem that is involved in many of the
biological processes of the human host. It is known that an aberrant microbiome can be
the cause of many human ailments such as dental carries and periodontal disease in the
oral cavity, inflammatory bowel disease, irritable bowel syndrome and antimicrobialassociated diarrhea in the gut and bacterial vaginosis in the vagina. In addition, with the
obesity epidemic plaguing North America and other countries, studies are showing an
increased correlation between variations in the gut microbiome and obesity. However,
little is known about the microbiome in pregnancy and in under-nutrition, albeit evidence
for its importance exists. Thus, the purpose of this thesis is to define the gut, oral, vaginal
and human milk microbiome in under-nourished, overweight/obese and normal/healthy
weight pregnant women. Furthermore, the impact of a micronutrient enriched probiotic
yogurt on the microbiome of under-nourished women will be examined.

1.1 Stages of Pregnancy
Human pregnancy can be divided into two main stages; embryogenesis, which starts with
fertilization of the female ova by the male sperm, and fetal development which begins at
approximately 11 weeks of pregnancy and continues until birth (Figure 1). By the time
the female fetus is twenty weeks old, the 1 million oocytes that she will possess through
her lifetime have formed from meiotic divisions of diploid stem cells. An oocyte will
undergo further meiotic divisions to become an ovum approximately every 28 days once
the female has reached reproductive maturity. The mature ovum is surrounded by an
extracellular matrix called the zona pellucida, which is composed of three types of
glycoproteins, one of which contains an oligosaccharide that acts as a sperm receptor 1-3.

2

The ovum and zona pellucida are further surrounded by cumulus cells, which are
suspended in an extracellular matrix composed of hyaluronic acid. The matrix of cumulus
cells not only helps support fertilization, but it also allows transport of the ovum from the
ovaries through the oviduct by allowing for adhesion with the oviductal fimbrae 1. Once
the ovum is in the oviduct, there is a very short window of less than a day, for successful
fertilization to occur with the sperm.
Sperm are produced in the seminiferous tubules of the male testes by the thousands every
second. The newly produced sperm then enter the epididymis, where they undergo further
maturation and modifications before being stored in the cauda of the epididymis where
they remain in a functionally inactive state and are unable to fertilize eggs 3,4.
Capacitation, or maturation to a state of fertilization competence, occurs once the sperm
have left the male and entered the female reproductive tract3. Millions of sperm are
released during ejaculation, but only a few hundred will actually meet the ovum. It has
been suggested that the lactobacilli of the healthy vaginal microbiota play a protective
role in preserving sperm motility and viability5. Under diseased vaginal states, such as
bacterial vaginosis (BV), an increase in radical oxygen species is observed which has a
negative impact on sperm motility and viability. Those sperm that survive the journey to
the ovum penetrate the outer matrix of cumulus cells before aiding in the success of one
sperm carrying out a sequence of five sperm-egg interactions, which result in the
activation of the ovum and initiation of zygotic development. The first of these
interactions involves the binding of the sperm to the zona pellucidia. The exact molecules
and mechanism involved in this binding reaction are still being elucidated as in vitro
experiments do not translate in vivo and these reactions are species specific 1,6. The
second interaction is the acrosome reaction, which involves a number of molecules on the
plasma membrane of the sperm head that recognize and bind molecules in the zona
pellucida. This binding initiates a series of reactions that leads to fusion of the acrosomal
membrane with the plasma membrane and release of the acrosomal contents 7. The third
interaction involves penetration of the zona pellucida. This is achieved by the motility of
the sperm as well as enzymatic hydrolysis of the extracellular matrix of the zona
pellucida, by released acrosomal contents, such as the serine protease acrosin 7. The
fourth and fifth interactions involve binding and fusion of the sperm with the ovum

3

plasma membrane, which leads to activation of the ovum and initiation of embryonic
development. The fertilized egg is now called the zygote and is impenetrable by
additional sperm.

Figure 1: Stages of pregnancy
The zygote then continues its journey through the oviduct by contractions of the smooth
muscle and the cilia lining the duct. It takes three days for the zygote to migrate through
the oviduct to the uterus, but by 30 hours after fertilization the zygote has undergone its
first mitosis and cellular divisions. The cell division at this stage is called cleavage, due
to the appearance of furrows in the embryo as the cytoplasm divides. During this stage
the zona pellucida is still present and cleavage will continue up to 3 days post fertilization
until the embryo becomes a morula, composed of 16-32 cells. At four days post
fertilization the morula has entered the uterus and is now called a free blastocyst due to
the formation of a hollow blastocystic cavity. The embryo at this stage is further
characterized by an inner cell mass of blastomeres, which will become the fetus, with an
outer layer of trophoblast cells that form an epithelial arrangement with tight junctions.
These trophoblast cells transform into a syncytium, which will become the placenta, and
are involved in implantation of the embryo to the uterine lining which occurs around 5-6
days post fertilization. Implantation of the embryo to the uterine lining can be affected by
vaginal health. Studies have shown that BV negatively affects both in vitro and natural
fertilization and implantation and is also associated with an elevated risk of preclinical
pregnancy loss8-10. Growth of the embryo continues and by day 13 post fertilization the
exta-embryonic mesoderm, choronic cavity, primitive streak and definitive yolk sac have
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formed. By day 16, the notochordal process develops and the amniotic cavity expands
over the yolk sac. Somites and the neural groove form by day 20 and by day 22 the neural
folds begin to fuse to form the neural tube and the cardiac loop starts to appear. By day
24, optic invagination begins and by day 28 the upper limb buds are distinct, the lung
buds begin to appear and 3 brachial arches have now formed. At day 32 both the upper
and lower limb buds are visible and the optic vesicle is now distinct. The embryo
continues to develop with the legs, arms, eyes, body and brain becoming more mature
and by day 46 spontaneous movements have begun to occur. By day 52-post fertilization
all major body areas have become definite and the embryonic period draws to a close.
Pinpointing the exact effects of under-nutrition on fertilization in humans is difficult to
assess and most of our knowledge comes from animal studies. Studies in rats have shown
that under-nutrition at the time of conception can lead to fewer cells in the inner cell mass
blastomeres of the embryo which can result in reduced birth weight, postnatal growth and
an altered organ/body weight ratio11. However, proper nutrition and its effects on brain
development are well known and supplementation studies during pregnancy have shown
that folic acid, iron and vitamin D are extremely important for proper neurodevelopment
which begins during fertilization12,13.
Despite all major structures of the fetus being formed during embryogenesis, ending at
approximately 10 weeks post fertilization, these structures continue to grow and develop
during the fetal development period, which begins approximately 11 weeks after
fertilization14. Continued development of the cardiovascular system leads to the heartbeat
being detected at approximately 21 weeks post fertilization. Muscle, bones, nails and skin
all continue to grow and develop and by 21 weeks the fetus has become more active. The
nervous system also continues to grow and develop and by 26 weeks it has developed
enough to start to control some bodily functions. Gas exchange becomes possible in the
fetal respiratory system during the end of the canalicular stage of respiratory development
occurring approximately 16 to 26 weeks post fertilization. By twenty weeks all major
tissue components of the mature gut have developed, while the accessory structures such
as glands will continue to develop past this stage. During fetal development, intrauterine
growth is measured in terms of changes in weight or size in relation to gestational age.
Early fetal growth is largely dependent on the genome, but later stages of fetal growth
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can become restricted by the environment or epigenetic factors. Fetal growth rates are
determined by the increase in tissue weight (expressed in grams) divided by the total
body weight (expressed in kilograms) divided by the gestational age (in days). A healthy
human fetus should grow 15 g/kg per day from about 24 weeks post fertilization to 37-39
weeks gestation. This growth rate then flattens to 6 g/kg per day for the last 2-3 weeks of
gestation14.
Nutrient supply to the fetus occurs through three different avenues. Nutrients can be
supplied either directly across the placenta from the maternal circulation, they can be
synthesized in the placenta and released into fetal circulation, or the fetal tissues
themselves can produce certain nutrients14. The major nutrient that diffuses across the
placental membrane from maternal circulation is oxygen, while glucose is transported
mainly by facilitated diffusion, amino acids through active transport and free fatty acids
through a number of transport proteins. During under-nutrition there is no change in
oxygen consumption by the developing fetus, thus a reduction in fetal growth rate occurs
to maintain the balance of supply and demand for nutrients14. This leads to a change in
contributions of glucose and amino acids to fetal energy and carbon balances.

1.1.1 Pregnancy and Nutrition
The importance of a proper nutritional, physical and emotional environment for optimal
fetal growth and development cannot be disputed. It has been shown that a variety of
factors and behaviors prior to pregnancy, during pregnancy and after giving birth, as well
as during lactation, can have major implications in infant development14,27, cognitive
development47,72 and susceptibility to adult diseases, all of which can be passed on to
future generations31. The developing fetus relies solely on its mother to provide the
nutrients and energy needed for development. This puts a metabolic demand on the
mother that may be increased due to a number of additional factors. For instance, teenage
mothers have a greater metabolic demand as they require nutrients and energy for their
own growth as well as that of the fetus. Furthermore, physical labor during pregnancy as
well as stress due to infections or environmental and emotional factors will require a
greater metabolic demand, as the amount of nutrient loss from the body is increased. The
number of previous pregnancies as well as timing of pregnancies can also be a factor in
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the nutrient and energy needs of the mother. The types and amounts of nutrients needed
at different stages of pregnancy varies, thus further adding to the importance of the
mother being in a state of optimal physical and emotional health prior too and during her
pregnancy for good birth and infant health outcomes. The prevalence of under-nutrition is
extremely high in low and middle-income countries, which translates to increased
mortality and disease burden for mothers and their infants. Additionally, a number of
factors mentioned above that further compound the effects of under-nutrition are also
highly prevalent in low and middle-income countries. In Tanzania specifically, a
demographic and health survey conducted in 2010, found that 5% of women interviewed
had births 18 months apart, while 16% had births less than 2 years apart within the five
years preceding the survey 15. Furthermore, 56 % of women are mothers by the age of 20.
In comparison, the average age of mothers in Canada in 2010 was 29.6 years, while births
to teenage mothers between the ages of 14 and 19 were only 11.4 per 1000 births. Prenatal care and birthing practices also vary widely between developed and developing
countries, influenced by a lack of education of mothers in developing countries. In
Tanzania, only 15% of pregnant women make their first visit to a health-care facility
before their fourth month of pregnancy and 48% of deliveries occur at home without the
presence of a skilled medical attendant 15.
Despite a number of factors that influence birth outcomes, growth of the fetus is
characterized by a net deposition of tissue, which ultimately requires the availability of
the proper amount of energy and nutrients14. Malnutrition is an aberrant nutritional status
that is characterized by the decreased or excessive intake of one or more nutrients such as
protein, energy or vitamins, and the frequent infections and disorders that result16. There
are three types of malnutrition: secondary malnutrition occurs when the body is unable to
utilize fully the food eaten; over-nutrition which occurs by ingesting too many calories;
and under-nutrition when the diet does not provide enough calories or protein for the
growth and maintenance of the body16. It is well known that the lack of certain
micronutrients, such as vitamins and minerals, can play a critical role in fetal
development. However, evidence is beginning to mount that both a reduced and
excessive intake of macronutrients can also produce adverse outcomes. Thus, the effects
of improper nutrition during pregnancy can be caused by both over and under-nutrition.
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1.1.1.1

Maternal Over-Nutrition

Although obesity is an exponentially growing epidemic in developed countries,
developing countries are also beginning to see a rise in obesity as processed, sugar-rich,
high fat foods become more readily available. The number of overweight and obese
women in Tanzania as of the 2010 survey was 15% and 6% respectively15. In contrast,
the percent of overweight and obese women in Canada as of 2008 was 31.5% and 24.2%
respectively. Maternal overweight and obesity results in adverse outcomes for both the
mothers and infants. In a meta analysis conducted by Chu et al.17, it was found that
overweight and obese women had an increased risk of still births compared to normal
weight woman17. Furthermore, an increased risk of miscarriage is observed in
obese/overweight women as well as gestational hypertension, pre-eclampsia and
gestational diabetes18. A second meta analysis found that obese and severely obese
women were 2 and 3 times more likely to give birth by cesarean section compared to
normal weight women19,20. Cesarean sections in overweight and obese women present
further complications as these operations are more difficult to perform and anaesthetical
and surgical complications such as infections and excessive bleeding, are more likely to
occur21. This results in overweight and obese women being hospitalized for longer
periods of time, putting a strain on health care systems and increasing the cost of
obstetrical care. Maternal overweight and obesity can increase the risk of congenital
anomalies such as spina bifida, cardiovascular anomalies, cleft lip and limb reduction
anomalies in developing infants, as shown in a meta analysis performed in 200922. There
is also an increased risk of neural tube defects in infants born to obese and overweight
mothers22,23. Furthermore, studies have shown that children born to obese mothers, and to
overweight and obese mothers with maternal diabetes, are at an increased risk of being
obese by two years of age and of developing other metabolic syndromes such as
hypertension, low high-density lipoprotein levels, elevated triglyceride levels and glucose
intolerance 24-26.

1.1.1.2

Maternal Under-Nutrition

The first study that showed the adverse effects of under-nutrition was unfortunately due
to a natural event, the Dutch Hunger Winter in 1944. The famine resulted from the
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Netherlands being invaded by Germany in 1941, which lead to the rationing of all
available food. These rations became smaller as time went on and by 1944 they had
reached the lowest with individuals receiving less than 1000 kcal per day. Furthermore,
this food consisted only of bread, potatoes and sugar beets, so micronutrients were scarce.
Low birth weight infants, increased mortality of mothers and infants, as well as increased
congenital anomalies were observed as a result of this famine 27. What was most
revealing, however, were follow-up studies conducted on adults who were born to
mothers that were pregnant when the rations were at its lowest. These studies found that
infants conceived to women who were pregnant during the lowest food rations had
reduced glucose tolerance, raised insulin levels, increased airway disease and increased
heart disease later in life 28. Furthermore, women who were conceived during the famine,
had a five times higher risk of developing breast cancer 28. Follow-up on males conceived
by mothers exposed to the famine during the 1st half of pregnancy, had higher incidence
of obesity than males conceived by mothers who were exposed to the famine during the
latter half of pregnancy, providing some of the first evidence that timing of nutrient
deprivation plays a crucial role in the lasting-effects on the development of the unborn
infant 29. Since the Dutch Hunger Winter, the problem of under-nutrition during
pregnancy has become more prevalent in middle and low income countries than in high
income countries as the basic causes of under-nutrition are environmental, economic and
sociopolitical, with the underlying causes being poverty, food insecurity and inadequate
care and lack of health care services.
The World Health Organization (WHO) defines undernourished individuals as having a
BMI less than 18.5 kg/m2. In Canada only 2.5% of women over 18 years of age have a
BMI of less than 18.5 kg/m2, as compared to 11% of women in Tanzania15. A number of
studies have shown that inadequate nutrition during pregnancy can result in low maternal
weight gain leading to increased occurrences of pre-term birth, low birth weights (weight
< 2500g) and small for gestational age (SGA) infants (weight below the 10th percentile
for gestational age)30. Meta analysis has shown that SGA and pre-term infants have an
odds ratio of 4.51 for growing to be a stunted child31. If the stunted child is female, then
she will grow to be a woman with short stature (height less than 145cm). This has major
implications as maternal short stature puts the infant at risk for term and pre-term SGA,
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thereby creating a vicious cycle that could span generations if micro- and macronutrient
deficiencies during pregnancy are not corrected31 (Figure 2). Furthermore, maternal short
stature has also been found to increase the risk of cesarean section when giving birth32.
This poses a significant problem in developing countries due to the limited access to
health care facilities to perform these operations, especially in rural areas. Finally, short
stature in pregnant mothers has also been shown to increase the chances of mortality of
her offspring33. Thus, maternal short stature, as well as anemia, increase the risk of
maternal mortality and account for 20% of all maternal deaths34. In Tanzania 454
maternal deaths occur per 100,000 live births, while in Canada the rate is only 7.8. In
addition, 40% of woman between the ages of 14-49 in Tanzania are anemic15. Anemia in
pregnancy is mainly attributed to iron deficiency, while folic acid deficiency can also
occur. The implications of anemia during pregnancy can affect both the mother and fetus
and anemia during the first and second trimesters influences birth weight and pre-term
deliveries which may or may not be associated with adverse perinatal outcomes
depending on the population35,36.
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Figure 2: Overview of the effects (blue boxes) and adverse outcomes (red circles) of
inadequate micro- and macronutrient intake during pregnancy. Improper nutrition
can lead to long-term effects on fetal development as well as a vicious cyclic process
whereby children of women with micro and macronutrient deficiencies grow to be
mothers with micro and macronutrient deficiencies. IUGR: Intrauterine growth
restriction.

1.1.1.3

Essential Micronutrients for the First 1000 Days and
Beyond*

Maternal under-nutrition can be largely attributed to insufficient ingestion of essential
micronutrients before and during pregnancy. A number of micronutrients are particularly
critical during pregnancy for the mother, developing fetus and the newborn infant (Figure
3). This next section will describe a selection of micronutrients of most importance to
pregnancy and their implications during the first 1000 days of life, as well as highlight

*A version of this chapter has been published281
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studies investigating the effect and timing of supplementation. The first 1000 days refers
to the moment of fertilization up until the child’s second birthday. During this time the
fetus, neonate and infant are increasingly susceptible to environmental and nutritional
factors that can affect their development. As discussed above, these effects have the
ability to span generations, thus longitudinally perpetuating the problem. Therefore,
targeting the first 1000 days for proper nutritional interventions has the potential to have
a profound effect on a child’s ability to grow, learn and rise out of poverty, thereby
improving long term health, stability and prosperity to society.

1.1.1.3.1

Zinc

Zinc is an essential component of enzymes and transcription factors and is important in
cell growth, development and differentiation37,38. In addition, it is required for immune
system function, cognitive function and reproduction38,39. One of the main clinical
features of zinc deficiency is growth restriction, and since the period of rapid growth
development is greatest during the first three years of life, zinc supplementation during
this time is essential (Figure 3). For instance, a meta-analysis of studies done on zinc
supplementation of infants less than five years old showed that supplementation for a
period of 24 weeks, had a positive effect on linear growth40. Notably the mere addition of
zinc to the diet does not necessarily equate to increased blood levels as found in some
African studies41. The reason appears to be a leaky gut and aberrant gut microbiota that
lowers zinc uptake.
Zinc supplementation can reduce the incidence of diarrhea by ~20%, pneumonia and
lower respiratory infections by ~15% and can reduce mortality by 6%, but only if
supplementation is given to children 12 months and older42. Infants benefit from the
antimicrobial effects of zinc from their mother’s milk, thus maternal zinc
supplementation is needed for those deficient, especially during the first 6 months after
the child is born when exclusive breastfeeding should occur. In addition, maternal zinc
supplementation starting daily at 10-14 weeks of gestation can improve fetal autonomic
regulation as assessed at 54 months of age43.
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Figure 3. The first 1000 days from conception to 2 years of age. Nutrients deemed to
be important in aiding and alleviating under-nutrition and the adverse health effects
that result are listed, along with predicted time periods of administration based on
randomized clinical trials reviewed from the literature.

1.1.1.3.2

Iodine

Iodine is an essential component of hormones produced by the thyroid gland, thus, iodine
deficiencies can affect all ages and the disorders that result are some of the most common
human diseases44. Severe iodine deficiencies in the fetus are known to lead to abortion,
still birth, congenital anomalies, and perinatal mortality; while deficiencies in the neonate
can increase infant mortality and endemic cretinism44. The recommended dietary intake
of iodine for non pregnant women is 150 µg/day and increases to 250 µg/day when
pregnant45, due to an increase in thyroid hormone production by the mothers and passing
of iodine to the fetus for fetal thyroid hormone production46. A meta-analysis showed that
children with iodine deficiencies had lower IQ’s by 13.5 points47, making iodine
deficiencies a preventable cause of mental retardation. In fact, a study in China showed
that the administration of iodine before the third trimester of pregnancy resulted in
improved cognitive development of infants48.
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1.1.1.3.3

Folate

Folate is a water-soluble B vitamin that is involved in many bodily functions including
purine and thymidylate biosynthesis, amino acid metabolism and formate oxidation49.
Since purine and thymidylate are important in DNA and RNA synthesis and repair, a
deficiency can have many devastating effects, especially for fetal development, which
relies on this process. Folate supplementation is highly recommended during pregnancy
and should be increased by an additional 200-300 µg/d of folic acid to supplement dietary
folate in order to prevent deficiency49. In countries where the prevalence of anemia is
high such as Asia, Thailand and Nicaragua, iron-folic acid supplementation has shown to
be effective in reducing maternal mortality and increasing hemoglobin levels and should
be regularly implemented in supplementation programs in Africa50.

1.1.1.3.4

Vitamin A and D

Vitamin D is a prohormone that can be synthesized from sunlight through the skin with
the use of a derivative of cholesterol51. Vitamin D is essential throughout life and is
important in the formation of bone. Maternal Vitamin D deficiency impacts fetal bone
health and skeletal development, tooth enamel formation and general fetal growth and
development52. In addition, the active form of vitamin D, 1,25-dihydroxyvitamin D
promotes the production of the antimicrobial peptide cathelicidin by monocytes. Elevated
levels of 1,25-dihydroxyvitamin D are also found in maternal and fetal cells of the
placenta, however, its function at this location is unknown but it may aid in combating
pathogens that could cause adverse pregnancy outcomes53. Studies have shown that
Vitamin D supplementation from the 12th week of gestation onward, lead to mothers with
greater weight gain and protein-calorie nutrition54 and infants with higher birth weights
and weight gain then the unsupplemented group54,55. In addition, children of unsupplemented mothers at three years of age have higher rates of defect in dental enamel
formation56. Rickets is attributed to inadequate vitamin D intake and can affect infants
and young children, with a peak incidence occurring between 3 and 18 months of age.
Breast milk may not be a sufficient source of Vitamin D, so it is recommended that
infants start to receive 400 IU/day of Vitamin D at 2 months of age and that this
continues throughout infancy and adolescence52.
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Vitamin A plays a number of important roles in the body including immune cell
differentiation and proliferation, integrity of epithelial cells, vision and differentiation of
the cornea, conjunctival membranes and photoreceptor cells of the retina57,58. Vitamin A
deficiencies can also result in the reduction of the number of lymphocytes, natural killer
cells and CD4+ T cell counts and can affect mucosal immunity by altering the integrity of
the mucosal epithelia of the eyes, respiratory, gastrointestinal and genitourinary tracts58.
In addition, vitamin A deficiencies are linked to higher rates of mortality and morbidity
in young children with measles, respiratory infections and diarrhea. Three studies have
shown that giving newborn infants a single 50,000 IU dose of vitamin A within several
days after birth, reduces all cause mortality during the first 6 months of life by 15%59,
22%60and 64%61. The effect of vitamin A supplementation in pregnant women from
developing countries, however, is inconclusive. One study showed that weekly
supplementation can decrease maternal mortality by 40%62, while others have shown no
affect on maternal or infant mortality63-65. This indicates that especially in populations
who are under-nourished, other micronutrient deficiencies could be a factor in preventing
positive outcomes of a single nutrient supplement. Despite the inconclusive results of the
benefits of vitamin A supplementation on maternal mortality, a recent study suggests that
weekly vitamin A supplementation of pregnant women, may reduce the prevalence of
BV, which is thought to be associated with pre-term birth as discussed below. The study
was done in Bangladesh and pregnant mothers were given 25000 IU beginning in their
first trimester and continuing to three months postpartum. This resulted in a 30-40%
reduction in the incidence of BV as compared to the placebo66.

1.1.1.3.5

Iron

Iron deficiency is particularly prevalent in developing countries, with an estimated 24.8%
of the world population affected67. Iron deficiency anemia (IDA) in children can cause
suboptimal motor and mental development, which could potentially be irreversible later
in life. A study comparing South African mothers who were non-anemic, anemic
receiving daily iron supplementation and anemic receiving a placebo, showed that anemic
mothers without supplementation displayed “negative mothering” characteristics and
their children were developmentally delayed68. IDA is also responsible for 18% mortality
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in maternal women due to low hemoglobin levels resulting in postpartum
hemorrhaging69. Maternal iron supplementation has been shown to decrease preterm
births, neonatal mortality70, long term mortality and reduce the number of low birth
weight infants71. Iron found in milk of a healthy mother is sufficient for the newborn to
sustain hematopoiesis for the first six months of life, thus the WHO recommends that
women of reproductive age in developing countries receive weekly iron and folic acid
supplementation, which increases to daily once pregnant69.

1.1.1.3.6

Summary

Many nutrients, especially zinc, iron, copper, folate, iodine and vitamin D are critical for
the various stages of organ, vascular and skeletal growth72-75. The rapid rate of growth of
the brain in the third trimester and the early postnatal stage makes it vulnerable to an
inadequate diet, with long-term implications for cognitive development72. It is this
cognitive impairment, which is believed to be a major barrier to education and economic
empowerment in many developing countries. A community-based, double-blind,
randomized controlled trial of 676 children in Nepal, showed that iron/folic acid given
pre-natally, and not iron/folic acid/zinc, or multiple micronutrients containing these plus
11 other micronutrients or vitamin A alone, resulted in improved intellectual and motor
function76. This emphasizes that it is not simply a case of administering multi-vitamins
and nutrients to optimize pregnancy outcomes, but rather a selective supplementation that
works best. In fact, the optimal state may even require a more sophisticated and targeted
approach with certain supplements being administered at times in the pregnancy to match
specific developmental processes. For example, an animal study using rats, showed that
maternal iron restriction initiated prior to conception and during the first trimester caused
problems with auditory brainstem development, while iron restriction initiated early in
the third trimester did not have the same effect77. Such windows of vulnerability most
certainly exist for other parts of the developing fetus.
The effects of under-nutrition on the mother, developing fetus and newborn infant are
complex, and the timing of the deficiencies can add further dimensions to the issue. Thus,
many organizations such as the WHO, The International Micronutrient Malnutrition
Prevention and Control, the Bill and Melinda Gates Foundation, United Nation agencies
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and the World Bank have launched nutrition strategies based on the first 1000 days to
promote maternal and fetal health, mainly through micronutrient supplementation and
education in proper nutrition. Thirteen highly cost-effective interventions have been
proposed to combat under-nutrition in the first 1000 days of life and improve maternal
malnutrition. These include promoting good nutritional practices such as breastfeeding,
increasing intake of vitamins and minerals, micronutrient provision through food
fortification and, therapeutic feeding for malnourished children with ready-to-use
therapeutic food. The estimated cost to implement these interventions is approximately
$11.8 billion annually, with about $1.5 billion coming from households financially able
to pay food related expenses. Such efforts have the potential to succeed in order to
permanently eradicate under-nutrition, but will involve continual funding. An ideal
solution would be one that is self-sustaining; especially in developing countries where a
large underlying cause of under-nutrition is poverty.

1.2

Microbiome

Microbiome is the term coined by Joshua Lederberg of Rockefeller University to define
the complex community of commensal, symbiotic and pathogenic microorganisms that
share and inhabit our body space. It is well known that the number of microbial cells that
reside in and on the human body, outnumber our own cells. Furthermore, the number of
genes encoded by the members of this ecosystem is estimated to outnumber the genes
expressed by the cells of the body by a factor of 100 to 1. Due to the development of
high-throughput DNA sequencing technologies, it has become feasible to study the
structure, function and interaction of the microbiome with the human body, and studies in
this area have become an important aspect of understanding health and disease. In 2008,
the Human Microbiome Project (HMP) was launched to identify and characterize the
diverse microbial communities that make-up our microbiome. In 2012, the HMP
published a landmark paper that described these communities inhabiting 18 different
body sites in 242 healthy men and women78. The HMP found that each body site
sampled was characterized by one or a few signature taxa with the less dominant taxa
being highly personalized among individuals. However, despite this personalization,
certain pathways expressed by bacterial community members were universal among
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individuals and body habitats and the configuration at each site was quite distinct from
those associated with disease perturbations. For the purpose of this thesis, only three of
the 18 body sites (gut, oral and vaginal) will be reviewed, along with the less
characterized microbiome of human milk.

1.2.1

Vaginal Microbiome

As with all microbial communities residing on and within the human body, the vaginal
microbiome exists in a delicate balance with the host. The host provides nutrients to
support bacterial growth, while the resident microbes protect the host from the
colonization by pathogenic organisms. The composition of the ‘normal’ vaginal
microbiome varies among women within the same ethnic group, as well as between
women of different ethnic groups. Compared to the gut or oral microbiome, the vaginal
microbiome has the least diversity78. From classic laboratory culturing techniques, it was
believed that Lactobacillus was the characteristic organism of a healthy vaginal
microbiome, further supported by the fact that members of this species produce lactic
acid, thereby maintaining the vaginal pH between 3.5 and 4.5. Culture independent
techniques have revealed that a healthy vaginal microbiome can be characterized by the
dominance of one of four Lactobacillus sp., (L. crispatus, L. iners, L. gasseri or L.
jensenni), but in a small portion of women, an apparently aberrant profile composed of an
array of strict facultative anaerobes such as Atopobium, Prevotella, Sneathia and
Mobiluncus can be found, despite a lack of infectious symptoms or signs79. Furthermore,
studies have shown that American women of different ethnic backgrounds tend to have
different community profiles. For instance, a Lactobacillus dominated vaginal
microbiome is much more prevalent in Asian and Caucasian women who have a median
vaginal pH of 4.2-4.4, while Hispanic and African American women have a higher
prevalence of a non Lactobacillus dominated vaginal microbiome and a higher median
vaginal pH of 4.7-5.079-81. This has lead to classification of the vaginal microbiota into
five community state types in order to define a healthy vaginal microbiome in North
American populations82. Furthermore, temporal investigations have revealed that women
can fluctuate between different state types depending on the menstrual cycle, sexual
activity and community state, indicating that these fluctuations may be associated with
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increased susceptibility to disease82. Limited studies have investigated the vaginal
microbiota profiles in healthy women from different geographical locations. One study
investigating the vaginal microbiota of African women with HIV, found that the
microbial profiles of healthy women could be grouped into two clusters dominated either
by L. iners or L. crispatus83.When the delicate balance of the resident microbes in the
vagina is disrupted, a range of various urogenital diseases could potentially result, such as
BV, vulvovaginal candidiasis, pelvic inflammatory disease and sexually transmitted
diseases including Chlamydia and HIV. Classically, BV has been characterized as a
reduction in Lactobacillus in the vagina and a shift to a more mixed vaginal biota with
increased Gardnerella vaginalis, Bacteroides spp., Mobiluncus spp., Mycoplasma
hominis and Atopobium84,85. Clinical manifestations of BV include an increased vaginal
pH, milky creamy discharge and a amine or fishy odor, although in certain cases these
characteristics are absent84,86,87. Hummelen et al., found that BV in African women with
HIV was characterized by four distinct profiles, dominated by Prevotella bivia,
Lachnospiracease or a mixture of different species88. BV is also a major risk factor for
pregnancy complications and pre-term birth, the extent of which will be discussed below.

1.2.2

Oral Microbiome

The oral microbiome is composed of a complex community of microorganisms. The term
oral microbiome is defined as the microbial communities that are found on the teeth,
gingival sulcus, tongue, cheeks, hard and soft palates and tonsils, all of which have a
distinct species composition. There are six dominant phyla found in the oral cavity,
Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Spirochaetes and
Fusobacteria, with the most dominant genera being Streptococcus89. Sampling of oral
cavities in different countries does not reveal geographical or ethnic differences in oral
microbial community composition90. Certain resident members of the oral microbiota are
responsible for disease affecting the oral cavity if conditions arise, which promote their
overgrowth. For instance, dental caries occur when aciduric organisms such as
Streptococcus mutans, Lactobacillus species, Bifidobacterium species and
Propionibacterium species are able to over multiply in the presence of a low pH in the
oral cavity91-93. Gingivitis is a periodontal disease, characterized by swollen, inflamed
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gums, which results from the build-up of plaque on the tooth enamel. Plaque is composed
of a biofilm of Gram positive and negative anaerobic species. These organisms are
usually prevented from forming overly dense biofilms due to standard oral hygiene
practices. The initial organisms involved in formation of the biofilms are Streptococcus
spp. and Actinomyces spp., which bind to the deposition of salivary pellicle on the tooth
surface94. Studies have shown that periodontal diseases can pose a significant risk factor
to pre-term birth95, likely because of bacterial entry into the bloodstream and induction of
inflammatory processes.

1.2.3

Gut Microbiome

Due to the abundance of microbes residing in the gut and ease of stool collection, the gut
microbiome has been the most extensively studied in both disease and healthy states.
From these studies a number of factors have been identified which influence the
composition of gut microbial communities. Age is associated with changes in diversity,
while diet, illness and antibiotic use also have effects 96-98. From the age of three, when
the adult like bacterial profile develops, the microbiome remains relatively stable99 until
old age (>65 years) when changes occur, characterized by a decrease in overall diversity
within individuals and an increased variability between individuals of this age
group100,101. Geography also influences the gut microbial profile of children and adults as
shown by the identification of different enterotypes in the gut microbiota which are
linked to differences in diet98,102,103. Enterotypes are distinct clusters of microbial profiles
and metagenomes that are usually driven by species composition. Three enterotypes have
been documented; Enterotype 1 which is abundant in Bacteroides, enterotype 2 abundant
in Prevotella and enterotype 3 abundant in Ruminococcus104. Enterotype 1 has been
attributed to individuals who consume diets high in protein and animal fats105, while
enterotype 2 has been attributed to individuals who consume diets rich in carbohydrates,
the later being commonly found in adults and children in countries in West Africa such as
Malawi and in Venezuela, while enterotype 3 is less characterized98,102. Diet also has a
profound impact on the microbiome, which will be discussed in more detail below.
Family kinship also affects the composition of the gut microbiome, as members within
the same family have a more similar bacterial community structure than individuals from
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different families106. This familial relatedness has been observed in different countries
and can be further characterized by the carriage amounts of specific organisms98,107.
Moreover, pregnancy and route of delivery have been shown to create major shifts and
affect the structure of the gut microbiome, which will be discussed in separate sections
below. Disease and treatment can significantly affect the gut microbial composition. For
example, antibiotic use can lead to destabilization of the microbiome as well as loss of
particular bacterial species, which may not be recovered if perturbations continue108,109.
Use of antibiotics can be especially damaging to pre-term infants who already have an
altered microbial landscape as discussed below110. A number of diseases and disorders
such as psoriasis111, asthma112, inflammatory bowel disease113,114, colorectal
carcinoma115,116 and cardiovascular disease117 have also been associated with
perturbations in the gut microbial landscape. Understanding these perturbations and their
triggers have huge implications for the treatment and prevention of these diseases.
Early gut microbial colonizers can exert physiologic, metabolic and immunologic effects
well into adulthood99. Thus, if a mother is under- or over-nourished, she could be passing
on her potentially altered and diseased microbiota to her infant, thereby contributing an
additional factor that may increase her child’s chances of developing metabolic disorders
later in life. Indeed, studies have shown there are a number of factors that can influence
the composition of the infant’s microbiome.

1.2.4

Development of the Infant Microbiome

It has traditionally been believed that the developing fetus is microbiologically sterile and
the first exposure to organisms occurs during delivery. However, recent studies have
detected microbial species in the umbilical cord blood, amniotic fluid, meconium and
placental and fetal membranes 118, suggesting that the fetus may be exposed to microbes
at the beginning of pregnancy. Exactly how this exposure occurs as well as how it
influences the developing fetus still needs to be explored. However, it is postulated that
rather than colonizing the developing fetus, this initial exposure plays a role in early
immune development. A recent study investigating the meconium of term and preterm
infants, found that gestational age was negatively correlated with the taxa Enterobacter,
Enterococcus, Lactobacillus and Tannerella, all of which create inflammatory responses
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. A number of studies have given support to the belief that delivery mode has an effect

on initial microbiome colonization in infants. Sampling of multiple body sites (skin, oral
cavity and meconium) on infants born either vaginally or by cesarean section, found that
the dominant taxa across all sites were dependent on the mode of delivery with
Lactobacillus and other vaginal organisms being dominant in vaginally born infants, and
Staphylococcus spp. being dominant in infants delivered via cesarean120. Furthermore, the
bacterial community profiles in infants delivered by cesarean are less diverse than in
infants delivered vaginally121,122 and the former can persist well past birth and up to two
years of age122. Colonization by Bacteroidetes is also delayed in infants born by cesarean
which could have implications in proper immune development 122-124. Evidence exists
that pre-term infants (gestational age of less than 37 weeks) develop a different gut
microbiome than term infants. The methods used to assess the microbial profile in the
preterm population differ across studies, thus, further investigations using standardized
high-throughput sequencing techniques need to be performed in order to confirm these
differences. Despite this, studies have shown decreased diversity of gut microbial profiles
in preterm infants as compared to term. In addition, preterm infants who develop
necrotizing enterocolitis have a dominance of Proteobacteria and increased abundance of
Enterobacteriaceae and S. epidermidis125-127.
Assembly of the gut microbiome and understanding its development from birth to
establishment of the adult like configuration is of great interest due to the influence of the
microbiome on the human host. If the development of the microbial gut communities is
understood in health and disease, then specific interventions for promoting a healthy
microbiome throughout the lifetime of the host could be conceived. Three important
studies have been conducted that provide a greater insight into the initial gut microbial
assembly. Two studies investigating multiple infants found that variability in the overall
gut microbial profiles between infants was greater than the variability observed between
adults and that this persisted from birth up until either the establishment of the adult like
configuration at three years of age98 or until the study was completed at one year of age96.
Furthermore, differences observed in the profiles of the adult gut microbiota due to
geographic location were also found in the gut microbiota of their infants98. A detailed
study following one infant over 2.5 years found that illness and antibiotic use as well as
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weaning produced significant shifts in the relative abundance of observed operational
taxonomic units (OTUs)97. These data suggest that differences in development of an
infant’s gut microbiota is influenced by environmental factors96,97.
The typical colonizers of the infant gut are the facultative anaerobes Staphylococcus,
Streptococcus and Enterobacteria96,128. It is assumed that these bacteria consume oxygen
and create an anaerobic environment into which other species enter and take over from a
few days after birth up to the introduction of solid food. The dominant organisms at this
time are Bacteroides, Bifidobacterium and Clostridium128. However, these changes are
dependent on whether the infant receives formula or breast milk.

1.2.4.1

Microbiome of Human Milk

Human milk is a rich source of molecules and microbes that provide nutrition to the
infant, as well as aid in its immune development129. During the first six months of life,
the microbial community of human milk likely has the most influence on the composition
of the infant’s gut microbiota. On average, infants consume approximately 788 mL of
milk per day, which contains approximately 1 x 106 colony forming units per milliliter130.
This means that infants can ingest close to 1 million bacteria per day. The major
phylotypes found in breast milk are Staphylococcus and Streptococcus, presumably
originating from the skin and infant saliva respectively. Other organisms have been
detected such as Serratia, Ralstonia, Prevotella and Corynebacterium, with Lactobacillus
and Bifidobacterium also being detected, but at a lower abundance131-133. Besides aiding
in immune development, the bacteria in human milk may also play a protective role in the
infant gut. A trial involving formula milk and formula milk supplemented with
Lactobacillus fermentum (a human milk commensal), showed that infants fed the formula
milk supplemented with L. fermentum had a lower incidence and severity of infections
such as upper respiratory tract infections and gastrointestinal infections as compared to
the control134. Other studies have shown that this protective effect may be accomplished
by competitive exclusion and production of antimicrobial compounds135,136. In addition,
the oligosaccharides found in breast milk are extremely important and evidence has
shown that they positively select for bifidobacteria and lactic acid producing species in
the healthy infant gut137,138. The important influence of human milk on the infant gut
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microbiota has been shown in studies comparing breastfed and formula fed infants.
Bifidobacteria are dominant in the gut microbiota of breastfed infants, while formula fed
infants have higher proportions of Bacteroides and Clostridium species139,140.

1.2.5

Maternal Microbiome and Healthy Pregnancy

As discussed above, the maternal microbiome could have major implications on the
developing fetus. So far, only changes in the gut and vaginal microbiome during a
healthy pregnancy have been studied. Only two studies have used high throughput
sequencing technologies to monitor the vaginal microbiome during a healthy pregnancy.
The first looked at a total of 24 women, 16% Hispanic American, 13% African American
and the rest Caucasian, and no distinction was found between the ethnic groups141.
Sampling occurred a maximum of 3 times during the pregnancy, but in the final analysis,
all samples were grouped together. This study found that the vaginal microbiome of
pregnant woman had distinct community profile clustering compared to the vaginal
microbiome of non-pregnant women, suggesting changes due to hormonal alterations.
This study also found an overall reduction in species richness and diversity with an
increased abundance of L. iners, L. crispatus, L. jensenni and L. johnsonni141. The second
study performed a longitudinal analysis on the vaginal microbiome of 22 healthy
pregnant women, analyzing a median of 6.5 samples per subject from recruitment to
birth142. The investigators also collected serial samples from non-pregnant women for
comparison and found that the abundance of L. vaginalis, L. crispatus, L. gasseri and L.
jensenii were enriched in pregnant women who delivered at term compared to nonpregnant woman. Furthermore, they also observed in pregnant women a lower abundance
of 22 phylotypes found in non-pregnant individuals. The researchers noted that the
vaginal microbiome in healthy pregnant women was more stable over time than nonpregnant women, perhaps due to cessation of the menstrual cycle and very few pregnant
women had a non Lactobacillus dominated community type. Of further interest, the
majority of women both in the pregnant and non-pregnant cohorts were African
American, and as previously reported by Ravel et al., community state types dominated
by Lactobacillus are less common in non-pregnant individuals of this ethnic group79. This
could indicate that physiological changes occurring during pregnancy may select for the
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preferential growth of Lactobacillus, independent of the woman’s community state type
prior to conception.
Only two studies have been conducted using high-throughput sequencing technologies to
investigate the differences between the gut microbiota of pregnant and non-pregnant
states. The first study compared the fecal microbiomes of women in their first trimester,
third trimester and one month post partum143. The researchers found an expansion in β
diversity (variability between samples) with gestational age and an increase in the relative
abundance of Proteobacteria and Actinobacteria in over 50% of the study subjects,
between the first and third trimesters. Furthermore, there was a reduction in the number
of OTUs as women progressed to their third trimester, and the changes observed were
still present at 1-month post partum. Koren et al., also observed characteristics of
metabolic inflammation in the third trimester women, and studies in germ-free mice led
them to predict that the changes in microbial profiles drove this outcome144. However, the
microbiota observed in the third trimester differed from women with metabolic syndrome
in that the relative abundance of Firmicutes and Bacteroidetes remains the same in
pregnancy, while it changes in obesity144. Another interesting finding was that the infant
gut microbial profile at one month was more similar to the mother during the first
trimester than the third. Unfortunately, infant stool samples were not collected at birth to
determine if the microbial profile at this time was similar to the mothers gut microbial
profile observed during the third trimester. A second study, investigated the gut microbial
profile of pregnant women in their third trimester and one-month post-partum145. They
found that the microbial profile was stable between the two time points, as found by
Koren et al.144, and they also observed an increase in short chain fatty acids and
calprotectin, indicative of metabolic changes and low grade inflammation, again
consistent with the previous findings. However, Jost et al. 145 did not observe the same
changes in the gut microbial profile in the third trimester as Koren et al. 144, perhaps due
to different methodologies, as Koren et al. 144 amplified the V1V2 variable region of the
16s rRNA gene, while Jost et al. 145 amplified the V5V6 region.
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1.2.6

Dysbiosis of the Maternal Microbiome During Pregnancy and
Adverse Outcomes

There is evidence that perturbations in the microbiome contribute to adverse pregnancy
outcomes. This is especially important in developing countries where access to proper
medical care during pregnancy is limited and assessment of microbial shifts is not
commonly practiced. The clearest link between alterations in the microbiome and adverse
pregnancy outcomes is in relation to changes of the vaginal microbiota. Recently, a study
found decreased diversity of the vaginal microbiome was related to occurrence of preterm birth146. However, limitations of this study included a small sample size and the use
of Sanger sequencing which limited the amount of samples sequenced and reads
produced. Thus, more studies using cost-effective high-throughput sequencing
technologies should be performed to validate this. Another clear connection between
adverse pregnancy outcomes and dysbiosis of the vaginal microbiome is due to BV. A
number of studies and a meta-analysis published in 2003, have shown that BV early in
pregnancy increases a woman’s risk of having preterm labor and spontaneous abortion
147-149

. The prevalence of BV in developing countries such as Tanzania has been

monitored. In a study conducted in 2013, 28.5% of 284 women delivering at a tertiary
care hospital in Mwanza, Tanzania had BV at time of delivery150. The rates of BV in
Africa are not necessarily higher in proportion than in Canada as BV prevalence in subSaharn Africans does range from 6.4% in Burkina Faso to as high as 58.3 % in South
Africa151. However, the rates of BV in non-pregnant Tanzanian women is between 2030% which is in stark contrast to the BV prevalence in Canada at approximately 7.1%151.
Thus, the increased incidence of BV can contribute an additional factor to the high rates
of adverse pregnancy outcomes for mothers in developing countries.
Furthermore, as discussed above, obese and overweight mothers are at risk of
complications during pregnancy and delivery, and their infants are at a greater risk of
disease, both in infancy and later in life. Differences have been observed in the microbial
composition of the gut between overweight and normal weight mothers152,153 and changes
in this composition have also been associated with excessive weight gain during
pregnancy152,153. Interestingly, pre-pregnancy weight and weight gain during pregnancy
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affect the mother’s gut microbial composition which has an additional effect on the
microbiota development of the infants154. This could indicate that altered gut microbial
configurations due to nutrition or disease could be passed on from mother to infant,
thereby providing yet another factor in adverse outcomes for the newborn. The potential
to correct adverse development patterns in infants, through modulation of the mothers
microbiome has been suggested155. Probiotic supplementation of mothers four weeks
prior to delivery and six months postnatal, appeared to reduce excessive weight gain in
their children during the first year of life155.

1.2.7

Microbiome and Diet

The beneficial role that the gut microbiome plays in helping its human host utilize
nutrients from the diet that would other wise be unattainable, has been known for some
time. Due to the obesity epidemic plaguing North America and the trouble that obese and
overweight individuals have in losing their excess weight, researchers questioned if it
was something more than just food consumption perpetuating the disease. The first
studies to spark an interest in the relationship between obesity and the gut microbiota
came from mice. In 2004, Backhed and co-workers found conventional mice had 42%
more body fat then germ free (GF) mice, despite the conventional mice consuming 29%
less than their GF counterparts156. They also found that if the caecal contents of
conventional mice were spread on the fur of young GF mice, their total body fat
increased by 57% after 14 days, but did not result in a difference in total body weight
from the conventional mice. Then in 2005, Ley and coworkers analyzed the 16S rRNA
gene sequences of the microbiota from lean and obese mice (who had a mutation in the
leptin gene to produce obesity) and found that obese mice had a significant reduction in
the number of Bacteroidetes as compared to lean mice and a greater proportion of
Firmicutes157. Instead of amplifying the 16S rRNA genes, the researchers performed
shotgun sequencing of the entire microbiota obtained from the obese and lean mice and
found the same trend characterized in their previous study. They also found that the obese
microbiome was enriched for enzymes involved in the breakdown of indigestible dietary
polysaccharides as well as for transport and generation of the end products of
fermentation. Furthermore, they observed that the feces of obese mice had significantly
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less energy than that of lean mice and when GF mice were transplanted with the
microbiota from the caecum of obese and lean donors, the recipients of the obese
microbiota had more Firmicutes and 47% more body fat than the recipients of the lean
microbiota, who only had a 27% increase in body fat158. Studies then shifted to human
populations, and a landmark paper showed that changes in diet and weight loss can also
promote changes in the gut microbial composition. This study showed that members from
the phyla Bacteroidetes were lower in individuals who were obese, but increased with
weight loss independent of whether or not an individual was on a carbohydrate reduced
or fat reduced diet159. By analyzing the gut microbiota in obese and lean monozygotic
and dizygotic twin pairs, the same group found that obesity is not only linked with the
microbial composition but also with the expression of a set of “core” obesity associated
genes within the microbiome106.
Due to the incredible differences observed between a normal and obese gut microbiota,
studies shifted to determine whether standard dietary factors might also produce these
major changes. Specifically, one of the earliest indications that dietary factors within
ethnic groups can shape the microbiome was observed in the Japanese population, where
on average 14.2 g of seaweed is consumed daily. It was found that a common gut
symbiont, Bacteriodes pleibus, has acquired genes for prophyranases and agarases
needed to digest the polysaccharides from seaweeds, whereas these genes are absent from
North American metagenomes103. Yatsunenko et al.’s (2012)98 study then showed
differences between the composition of Western populations gut microbitota and those of
Malawians and Amerindians. These differences were attributed to differences in diet, as
both Malawians and Amerindians consume diets high in maize and plant derived
polysaccharides, while Westerners consume diets higher in fats and fructose corn syrup.
This difference in gut microbiome composition of individuals from developing countries
and those from developed countries was also noted by De Filippo et al. 102. They
compared the fecal microbiota of European children to that of children from Burkina
Faso. The diets of the latter were low in fat and animal protein and rich in fiber, starch
and plant polysaccharides and were mainly vegetarian. The researchers found that the
microbiota of children from Burkina Faso was dominated by Prevotella (also observed in
the Yatsunenko study), Xylanibacter and Treponema, while that of children from Europe

28

had higher proportions of Firmicutes102. Yet another study supported the findings of
Yatsunenko and De Filippio, showing that diet had a greater effect on gut microbial
composition than ethnicity160. In this study, Prevotella dominated the gut of native
Africans, while the gut of African Americans was dominated by Bacteroides160.
Furthermore, saccharolytic fermentation was lower, proteolytic fermentation was higher
and secondary bile acid production was higher in African Americans, likely due to how
their gut microbiotas processed their high meat and fat diet160. Differences in diet are also
reflected in the gut microbiotas of vegans and omnivores, as strict vegans have
significantly lower counts of Bacteroides spp., Bifidobacterium spp., Escherichia coli and
Enterobacteriaceae spp., than omnivorous controls161. Furthermore, as observed with
obese individuals, switching between diets can also produce changes in the composition
of the gut microbiome as well as in the metabolic pathways and genes expressed by the
different communities162. These changes can occur within twenty four hours of switching
diets, but the core enterotype remains stable105,162,163. This could imply that in order to
make long lasting changes to the microbiome, long-term changes in dietary habits must
be instigated.
Very few studies have been conducted investigating the microbiome of under-nourished
individuals. Two studies released in 2011 compared malnourished children in India to
nourished controls. Although both utilized high-throughput sequencing techniques, their
methodology differed from standard practice and both studies were limited by small
sample size164,165. Nevertheless, a difference in the gut microbiota composition of
malnourished children was found to differ from that of the healthy controls in both
studies. An in depth analysis conducted in 2013 on the gut microbiome of twin pairs
discordant for Kwashiorkor (a form of protein malnutrition) revealed that the gut
microbiome of children with Kwashiorkor failed to follow the same development
trajectory to an adult-like configuration as observed in their healthy twin counterpart,
even with a therapeutic food intervention166. The power of this study lay in an adjoined
gnobiotic mouse model used to assess the effect of the Kwashiorkor microbiome on
microbial community structure, metabolism and host-microbial co-metabolism. Mice
were transplanted with fecal microbiota samples from twins with Kwashiorkor and cotwins without Kwashiorkor and fed a diet modeled after that consumed by Malawians.
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Greater weight loss was observed in the mice transplanted with the Kwashiorkor
microbiota, but if the mice were fed a standard chow diet they maintained their weight
and if they were fed a therapeutic food their weight rapidly increased166. There were also
observed differences between the community profiles of mice with the Kwashiorkor
microbiota and these profiles shifted with the introduction of the therapeutic food166.

1.3 Probiotics
The definition of probiotics introduced by the Food and Agriculture Organization of the
United Nations and the WHO is “live microorganisms which when administered in
adequate amounts, confer a health benefit on the host.”167.The benefits of fermented
foods date back over 900 years, but the observations of Elie Metchnikof are regarded as a
stepping stone to the renewed interest in the field. He believed that lactic acid bacteria in
fermented milk, helped prolong life by displacing toxic bacteria in the gut, caused by
aging. The book he wrote on the subject168, inspired a Japanese scientist, Minoru Shirota,
to be the first to culture a strain of Lactobacillus casei for promoting human health.
Shirota then went on to produce the world’s first probiotic product in 1935, a fermented
milk product called Yakult, which is still being used today. Most of the organisms used in
probiotic products and studied today are from the genera Lactobacillus and
Bifidobacterium, because of their history of safe use. Probiotics can be strain specific in
their action169-171, for example in a study investigating the effects of two Lactobacillus
fermentum strains on the intestinal barrier integrity following hemorrhagic shock, only
one strain was found to reduce endotoxin levels and bacterial translocation using a
hemorrhagic shock model in rats169. For other conditions, however, a mixture of different
strains can be therapeutic such as in the treatment of necrotizing enterocolitis in pre-term
infants172.
For many probiotics, the mechanism of action is still poorly understood as it can vary
from strain to strain and depend on route of administration and dosage. Overall,
probiotics are thought to enhance the epithelial cell barrier function in the gut, thereby
protecting from pathogen invasion and inflammation173,174, promote immunity through
production of antibodies and reduction of inflammation175-177, as well as act as antimicrobials through secretions of antimicrobial peptides and compounds178,179. Probiotics
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have been shown to aid in the treatment of acute infectious diarrhea180, irritable bowel
syndrome181,182, necrotizing enterocolitis in preterm infants183,184, cardiovascular
disease185, and recurrent urinary tract infections186,187, vulvovaginal candidiasis188 and
BV189. All of these observations make probiotics a desirable therapeutic agent for the
developing world, yet few products are available or affordable in developing countries.
Thus, simpler and sustainable means of introducing probiotics are needed.
Dairy foods are the most common delivery system for probiotics as the milk acts as a
buffer to ensure the survival of probiotics during fermentation and storage271. Yogurt is a
popular food product that is one such dairy food used as a delivery system for probiotics.
It provides a suitable option for bringing probiotics to developing countries as it is simple
to make and is stable at room temperature, the later being especially important if
electricity is restricted or fridges are not available. Furthermore, the normal yogurt
cultures Streptococcus thermophiles and Lactobacillus delbreukii subspecies bulgaricus
do not survive in the intestinal tract272. In 2003 a group of faculty and staff at Western
University decided to try and have local women in Tanzania develop and distribute
probiotic yogurt to individuals suffering from HIV/AIDS. The driving force was the gut
and immune benefits of the probiotics, the empowerment of women and the self-creation
of a nutritious therapeutic food. From this, Western Heads East was formed, a project that
trains and empowers women’s groups to produce and distribute probiotic yogurt using
Lactobacillus rhamnosus GR-1, in Mwanza, Tanzania 190-192. Since the projects
implementation in 2004, 10 kitchens have emerged in the Mwanza region (Figure 4) and
the project is spreading to Kenya and Rwanda193. L. rhamnosus GR-1 was originally
isolated from the urogenital tract of healthy women273. Since then it has been shown to be
a beneficial and safe probiotic in a number of studies including women’s vaginal
health274-276, supporting immune function in HIV/AIDS individuals277 and more recently
a study was released showing L. rhamnosus GR-1 supernatant could attenuate
lipopolysaccharide-induced inflammation and pre-term birth in a mouse model278. L.
rhamnosus GR-1 has also been shown to colonize the intestinal tract279 and our lab has
shown that it can also sequester heavy metals such as mercury in vitro (un-published
data). Furthermore, it has been suggested that probiotic food products contain at least 106

31

colony forming units (CFU)/100g280 and it has been shown that L. rhamnosus GR-1 can
maintain these counts in yogurt for up to a month after inoculation281.

Figure 4: Location of Western Heads yogurt kitchens in the Mwanza region of
Tanzania.
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1.4

Moringa

The milk used to make probiotic yogurt provides animal fat, protein and other nutrients
that otherwise may be unattainable in the limited diets of poor rural populations.
However, milk is lacking in important nutrients such as iron, zinc and vitamin A, which
are beneficial during pregnancy. Moringa oleifera could be an option for a sustainable
source of micronutrients in developing countries, as it is a highly nutritious, fast growing
deciduous tree native to northern India, Pakistan and Nepal. It has also been successfully
cultivated in all tropical and sub tropical regions of the world, such as Africa and
especially those regions most ravaged by malnutrition (Figure 5).

Figure 5: Areas of the world where Moringa has been successfully cultivated and
grows natively compared to areas of the world ravaged by under-nutrition.
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It is commonly referred to as either the ‘drumstick tree,’ or the ‘horse radish’ tree in
English and in swahili, it is called ‘Mlonge.’ Moringa can grow to between 5 and 10 m in
height and is drought tolerant and viable from sea level to an elevation of 1400 m 194.
Most of the tree is edible and the fruits (pods), leaves (Figure 6), flowers, roots and seed
oil have been used as traditional medicines, while recent studies have been investigating
its use as a potential cancer therapy drug195,196. The leaves are extremely nutrient rich
(Table 1), and when dried they can be added to a number of different foods like yogurt,
with very little change to the flavor197. Knowledge regarding the many benefits of
Moringa has been starting to spread to areas of Africa. A survey done in Nigeria found
that a number of ethnic groups use Moringa as a food source as well as a medicinal
treatment for various ailments including HIV/AIDS198. A second study in Zimbabwe
found that 68% of individuals on antiretroviral therapy had taken Moringa oleifera, due
to advice from family or community members199. Despite the knowledge of its health
benefits, it is still widely underused and understudied. The addition of Moringa leaf
powder to probiotic yogurt produced by the Western Heads East Kitchens provide a
means for us to examine its nutritional value in pregnant women in Mwanza, Tanzania197.
Although the addition of Moringa reduces the sensory properties of the yogurt it is not
disliked and the combination of Moringa and probiotic yogurt, could have major success
if marketed as a health product.
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Figure 6: Moringa oleifera tree (A) and leaves (B) growing on the grounds of a
community center in Mwanza Tanzania.
Table 1: Micro and macronutrient properties contained in 100 grams of dried
Moringa oleifera leaves.
Nutrient
Calories (kcal)
Protein (g)
Fat (g)
Carbohydrates (g)
Fibre (g)
Minerals (g)
Calcium (mg)
Cooper (mg)
Iron (mg)
Potassium (mg)
Magnesium (mg)
Phosphorus (mg)
Manganese (mg)
Zinc (mg)
Vitamins
Vitamin A (IU)
Vitamin B1 – Thiamin (mg)
Vitamin B2- Riboflavin (mg)
Vitamin B3- Nicotinic Acid (mg)
Vitamin E – Tocopherols Acetate (mg)

Amount
205.0
29 ± 6
8 ±2.5
38 ± 7
10 ± 3
11 ± 2.2
1924 ± 288
1.0 ± 0.2
28 ± 6
1384 ± 420
422 ± 52
267 ± 49
8.4 ± 2.4
2.5 ± 0.6
Amount
15620 ± 6475
2.6
20.5
8.2
113
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1.5 Purpose and Aims
The health and nutritional status of a mother during the first 1000 days of life of her
infant has major effects on the development and lifelong health of that child. As
discussed above, evidence indicates that the gut micobiome is altered in individuals who
are obese/overweight but the microbiome of individuals who are under-nourished has
barely been studied. Although under- and over-nutrition are a global issue and can result
in adverse pregnancy outcomes, under-nutrition is not as prevalent in developed
countries, thus we decided to perform a study of the microbiome of under-nourished
pregnant women in Tanzania in order to determine whether the microbiome of women in
their second trimester differs based on their nutritional status. It was hypothesized that a
difference in the microbiome would be observed, especially in the gut. Adequate intake
of essential nutrients has been shown to improve birth outcomes and continued nutrition
after birth has been shown to improve the health status of children. The microbiome is a
compounding factor that affects the health status of an individual. Passage of an adverse
microbiome from mother to infant can also effect the development and life long health of
that infant. Probiotic yogurt has been shown to have many beneficial effects to those who
consume it. The ease of producing this yogurt in rural settings in Mwanza, Tanzania
made it an excellent candidate for nutritional interventions in developing countries. Thus,
the current study also set out to determine if supplementation of mothers with probiotic
yogurt containing Moringa would have an effect on either the mother’s health status or
birth outcomes. Moringa contains a number of nutrients such as zinc and vitamin A that
are important for pregnant mothers, especially more so for mothers in resource poor
settings (see Table 2 and the discussion above), thus, it was also hypothesized that
combining Moringa with the benefits of probiotics could improve birth outcomes and the
health status of at risk populations. Finally, fish is a staple food among individuals living
in Mwanza and the Mwanza region is home to a number of large gold mines that leach
mercury into the soil and lake. In vitro studies in our lab have shown that the probiotic
strain Lactobacillus rhamnosus GR-1 has the ability to sequester mercury, thereby
providing evidence that it could be beneficial in vivo for protecting against heavy metal
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exposure. Due to poverty, women in rural areas of Mwanza cannot afford to change their
diet and fish is among the cheaper sources of protein. Thus, it was hypothesized that
consumption of probiotic yogurt during pregnancy could protect against mercury
exposure and absorption.
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Chapter 2

2

Materials and Methods

2.1 Human Study in Mwanza, Tanzania
This pilot study was designed to investigate the microbiome of undernourished,
nourished and obese/overweight pregnant woman and to determine if micronutrient
enriched probiotic yogurt supplementation altered the microbiota profiles and/or
improved pregnancy outcomes.

2.1.1 Study Location and Ethics Statement
This study was organized with assistance from the National Institute of Medical Research
(NIMR) and Nyerere Dispensary in Mwanza, Tanzania. The study was conducted in two
locations in Mwanza. Sample processing and storage was done at NIMR, while
participant recruitment and visits and sample collection were carried out at Nyerere
Dispensary in Buswelu, a sub-rural municipality located 30 minutes from Mwanza
(Figure 7). Upon completion of the study, all samples were shipped to Canada on dry ice.
The study protocol was approved and received ethical clearance from both the Ministry
of Health in Tanzania (Appendix 2) as well as from the Health Sciences Research Ethics
Board at Western University (Appendix 1). Prior to sample collection, participants signed
a consent form after having had the study and procedures fully explained to them in
Swahili. Those who could read were given a copy of this consent form, also in Swahili,
which outlined the study and procedures (Appendix 3).

38

Figure 7: Location and relative distance of study locations in the Mwanza region of
Tanzania

2.1.2 Study Population and Recruitment
The antenatal nursing staff at Nyerere Dispensary were trained to screen women
attending the antenatal clinic. Screening included standard antenatal assessment, as well
as completion of an Eligibility Questionnaire, which included an additional assessment of
the woman’s nutritional status (Appendix 4). Women were invited to meet the research
staff if they met the inclusion criteria of being between 12 and 24 weeks pregnant and
being between 18 and 40 years of age. Consented participants were designated either
nourished, under-nourished or obese which were defined based on a nurses assessment,
as well as mid-upper arm circumference (MUAC) measurements and deviations from the
expected weight based upon height and gestational age as predicted by Gueri et al.
(1982)200. Participants who were defined as under-nourished and nourished were
randomly assigned to receive Moringa supplemented probiotic yogurt. This resulted in
five groups; under-nourished (UN), under-nourished receiving probiotic yogurt
supplemented with Moringa (UNP), nourished (N), nourished receiving probiotic yogurt
supplemented with Moringa (NP) and overweight/obese (O).
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2.1.3 Defining Nutritional Status
In resource poor settings, pre-pregnancy records of weight and other health indicators are
not kept. Defining nutritional status is commonly based upon body mass index (BMI),
calculated from a non-pregnant weight measurement in kilograms and height in meters.
Since women were recruited in their second trimester, defining their nutritional status
based on BMI could not be done. Gueri et al. (1982) constructed a table of weight-forheight based on week of pregnancy200, and this along with the MUAC, was used to
determine nutritional status and group placement. The nursing staff at Nyerere dispensary
determined the gestational age based upon last menstrual period and symphysis fundus
height. They also measured height within 1 cm. Weight was measured in kilograms using
an analogue scale. Furthermore, the MUAC of the participants was measured to the
nearest millimeter using a tape measure. There is no universal MUAC cut-off value for
pregnant women in resource poor settings that are a reliable indicator of adverse
pregnancy outcomes201. Studies on various populations have shown that MUAC
measurements between 21.0 cm and 24.0 cm can be associated with pre-term delivery
and intra-uterine growth restriction (IUGR), resulting in low birth weight infants (LBW)
or SGA infants201. Thus, an MUAC of less than 23.5 cm was arbitrarily set as an
indicator of under-nourishment and an MUAC greater than 36.0 cm was set as a cut-off
for determining over-nourishment. From the tables constructed by Gueri et al (1982)200,
height and gestational age were used to determine the expected weight. If the actual
weight deviated from the expected weight by 90% or less, then an undernourished
classification was assigned. If the actual weight deviated from the expected by 110% or
greater, then an over-nourished classification was assigned.

2.1.4 Preparation and Consumption of Moringa Supplemented
Probiotic Yogurt
Participants in the supplementation group received 250 mL of yogurt six days a week. A
trained study driver, who was instructed to observe the participants drink the yogurt in
order to ensure compliance, delivered the yogurt to the participants. Furthermore, in order
to monitor consumption, a detailed log book was kept by the driver for each day of
delivery and participants receiving the yogurt were given unique tokens, which they were
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instructed to give to the driver for each cup of yogurt they received. Upon delivery, the
driver added 1 tablespoon of Moringa (approximately 4.3 grams) to each cup (see Table
2).
The yogurt was prepared daily at a Western Heads East Community Kitchen. Women at
the community kitchen were trained to ensure proper yogurt preparation. Seven liters of
fresh cow’s milk was boiled in a stainless steel pot over coals for 30 minutes, before
being removed and cooled by continual stirring to approximately 30oC. Once the milk
was cool, it was transferred to a clean plastic container and approximately 140 mL of
store bought plain yogurt was used as a starter culture and was stirred in, along with 280
mL of Lactobacillus rhamnosus GR-1 milk culture. The container was then sealed and
left to incubate overnight before being put in the fridge the following morning. Samples
of the yogurt were collected weekly to monitor the number of GR-1 CFU/mL in the final
yogurt product.
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Table 2: Nutritional content of 250 mL yogurt, with 4.3 grams of Moringa
Nutrient
Protein (g)
Fat (g)
Carbohydrates (g)
Fibre (g)
Minerals (g)
Calcium (mg)
Copper (mg)
Iron (mg)
Potassium (mg)
Magnesium (mg)
Phosphorus (mg)
Manganese (mg)
Zinc (mg)
Vitamins
Vitamin A (µg retinol)
Vitamin B1 – Thiamin
(mg)
Vitamin B2- Riboflavin
(mg)
Vitamin B3- Nicotinic
Acid (mg)
Vitamin E –
Tocopherols Acetate
(mg)

Amount in 250 mL
Yogurt

Amount in 4.3
grams Moringa

8.75
8.25
11.75
302.5
387.5
30
237.5
-

1.2
0.344
1.634
0.43
0.473
82.73
0.043
1.204
59.5
18.12
11.48
0.36
0.108

% of RDI for
Pregnant
Women*
13
8
2
39
4
4
10
14
36
72
1

67.5

201.5

35

-

0.112

8

0.25

0.882

81

0.25

0.353

3

0

4.86

32

*RDI: Recommended Dietary Intake. This was calculated from the Canadian dietary
references, as Tanzania does not posses their own standard guidelines.

2.1.5

Preparation of Lactobacillus rhamnosus GR-1 Milk Cultures

Two liters of Lactobacillus rhamnosus GR-1 milk cultures were prepared each week at
NIMR to be used for the production of the probiotic yogurt. GR-1 stock cultures were
maintained using de Man, Rogosa and Sharpe (MRS) broth and MRS agar (Difco). Each
week an overnight culture of GR-1 in MRS grown at 30oC in a sealed test tube was used
to inoculate 1 liter of fresh cow’s milk in a 1 liter glass screw top bottle, sterilized at
121oC for 15 minutes. The GR-1 cultures in milk were then incubated for 24 hours at
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30oC. Following incubation, a small sample was taken to determine the CFUs/mL in the
milk cultures and bottles were stored in a fridge until delivery to the kitchen.

2.1.6 Enumeration of Lactobacillus rhamnosus GR-1
Enumeration of GR-1 CFUs/mL in the yogurt samples and samples from the GR-1 milk
cultures was performed by drop plating. To begin, 100 µL of sample was suspended in
900 µL of Phosphate Buffered Saline (PBS) (Sigma-Aldrich) and serially diluted.
Triplicate 10 µL drops of the 10-9, 10-8, 10-7 and 10-6 dilutions were plated on MRS agar
plates containing 50 µg/mL of Vancomycin (Sigma-Aldrich). The plates were then
incubated at 30oC in a candle jar for 24 hours before enumerating drops containing
between 3 and 30 colonies to determine the final CFUs/mL in the yogurt and milk
cultures.

2.1.7 Pre-Birth Participant Visits and Sample Collection
Participants were asked to return for follow-up visits every month until birth. Each
received 5,000 tsh ($3.33) per visit as well as mandazi (African donut), banana, nuts and
soda. At each visit, a trained study translator administered a 48-hour dietary recall
(Appendix 5). In addition, weight using an analogue scale and MUAC were measured
using a tape measure to the nearest 0.1 kg and 1 mm respectively. The participants then
visited the clinical officer who performed a physical exam and completed the clinical
questionnaire (Appendix 6), which included measurement of the blood pressure, heart
rate and general medical history. The clinical officer also swabbed the vagina with three
CultureSwab polyster-tipped swabs (BD Biosciences). Two of the swabs were put into 2
mL screw top polypropylene tubes (VWR) and their ends cut off and stored on ice in a
cool box. The swabs were then transported to NIMR where they were stored at -20oC,
before being shipped to Canada for microbial DNA extractions and metabolite analysis.
The third swab was used to streak a glass microscope slide for Nugent scoring, which
was conducted at NIMR. The two tubes and slide were labeled with a unique barcode and
ID.
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The participant then visited the lab technician who instructed them to collect a stool
sample using a weigh boat and fecal collection container (VWR). The lab technician then
used a small amount of the stool sample to perform microscopic analysis for parasites,
the results of which were recorded in the clinical questionnaire. The remaining sample
was labeled with a unique barcode and ID and placed on ice in a cool box before
aliquoting small amounts into two 2 mL screw cap polypropylene tubes (also labeled
with a unique barcode and ID) which were then stored in a cool box for shipment back to
NIMR where they were kept at -80oC before being sent to Canada.
The lab technician instructed the participant on the proper collection of a urine sample in
a 50 mL container (Laja Pharmacy, Mwanza, Tanzania). The urine sample was then
analyzed using a multi-test dipstick system (Rapid Response Urine Dipstick, BTNX
Urinalysis, Laja Pharmacy, Mwanza, Tanzania) and the results were recorded in the
clinical questionnaire. The urine collection container was labeled with a unique barcode
and ID and stored in a cool box before being brought to NIMR for storage at -20oC until
shipment to Canada.
The lab technician also performed a finger prick to obtain a small amount of blood to
determine the levels of hemoglobin using a HemoCue® Hb 201+ machine (HemoCue) as
well as to perform Malaria and syphilis testing using Bioline Malaria Ag P.F./Pan
(Standard Diagnostics) and Syphilis Ultra Rapid Test Device (ABON). In addition, the
HIV status of the participants was determined by first using Determine™ HIV -1/2
(Alere) test, followed by a confirmatory test using Uni-Gold™ HIV (Trinity Biotech) if
the Determine™ test gave a positive result. Table 3 depicts the timing of sample
collection as well as the type of samples and information collected at each visit prior to
birth.
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Table 3: Heat map of pre-birth visits conducted. Timing of the visits, as well as
samples collected and analysis conducted are given. Grey boxes indicate that
particular information was not collected, while the boxes with diagonal lines
indicate it was.

Timing *

1
Recruitment

2

3

4
Mid Point

5

12-24 weeks

16-28
weeks

20-28
weeks

28 weeks

32 weeksbirth

Samples collected
Urine
Fecal
Vaginal Swabs
Saliva
Venous blood
Tests conducted
HIV
Syphilis
Malaria
Measurements
Height
Weight
MUAC
Hemoglobin
Blood Pressure
Lab Analysis
Parasite
analysis
Urine dipstick
Other
48 hour Dietary
Recall
Clinical
Questionnaire
*Timing of each visit varied, as it was dependent on gestational age at recruitment.

2.1.8 Birth and Final Participant Visits and Sample Collection
The participants were instructed to contact the study staff within 48 hours of giving birth.
At this time, they were asked to come to the clinic with their infant within three days.
This visit followed the same format as the pre-birth visits, however samples and
anthropometric measurements were collected from the infants as well as breast milk from
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the mothers. Infant weight was measured on an analogue baby scale to the nearest 0.1 kg.
Head circumference, length and MUAC were also measured using a tape measure to the
nearest 0.1 cm. In addition, the sex of the infant, place of birth, and whether the baby was
born vaginally or by caesarean section were recorded (Appendix 7). Fecal samples were
collected from the infant’s diaper, and infant saliva samples were collected using a
BBL™ CultureSwab™ (BD diagnostics). The tip of the swab was then put in a 2 mL
polypropelene tube. All samples were transported back to NIMR where they were stored
at -20oC (saliva, vaginal and milk samples) and -80oC (fecal samples) before being
shipped to Canada on dry ice.
For analysis of birth data, if the participant gave birth in a hospital and the infant weight
recorded at the time of birth, this weight was used in the analysis. However, if the birth
weight was not available, then the weight measured at the birth visit (approximately 3
days after birth) was used as the birth weight. Furthermore, accurately accessing preterm
birth in this population was difficult due to the lack of an ultra sound machine at the
clinic. Common practice at rural clinics for assessing gestational age is via an
approximation by the nurse who takes into consideration the pregnant woman’s recall of
her last menstrual period (LMP) and measurement of the fundal height at her first
antenatal visit. Both recall of LMP and measurement of fundal height have their flaws,
thus, for the purpose of this study, both LMP and the nurse approximation (NA) were
taken into consideration when assessing gestational age at birth.
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Table 4: Heat map outlining samples collected and analysis conducted for the birth
and final visits.
Visits
Timing
Samples collected
Mother
Urine
Fecal
Vaginal Swabs
Saliva
Venous blood
Breast milk
Infant
Fecal
Saliva Swab
Tests conducted
HIV
Syphilis
Malaria
Measurements
Mother
Weight
MUAC
Hemoglobin
Blood Pressure
Infant
MUAC
Head Circumference
Weight
Length
Lab Analysis
Parasite analysis
Urine dipstick
Other
48 hour Dietary Recall
Clinical Questionnaire

Birth
Approx. 3 days
after birth

Final
1 week after birth
visit
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2.1.9 Calculation of Hemoglobin Levels
Anemia is difficult to assess in pregnancy as a normal increase in blood volume starting
at the 6th week of gestation occurs, which is greater than the increase in hemocrit, leading
to an observed reduction in hemoglobin levels. Despite this, WHO states that hemoglobin
levels between 100-109 g/L in pregnant women is indicative of mild anemia, while levels
between 70-99 g/L is indicative of moderate anemia and levels less than 70 g/L is
indicative of severe anemia202. Furthermore, elevation can affect hemoglobin levels and
the WHO states that hemoglobin measurements taken at 1000 m above sea level should
be adjusted by -2 g/L. Since Mwanza is located at an elevation of 1147 m, all hemoglobin
levels taken were adjusted by this amount. The hemoglobin measurements were averaged
for each woman by trimester and then by group. The pregnancy trimester was determined
using recall of the LMP and if this was unavailable then the NA was used. Weeks 12 to
26 were classified as the second trimester while weeks 26 to birth were classified as the
third trimester. In addition, the two measurements taken after delivery were averaged for
each woman and then again by group to give the hemoglobin measurements for lactating
woman. Furthermore, the amount of iron intake for each woman was assessed from the
48 hour dietary recalls and used as an indicator of anemia related to iron deficiency or
other factors.

2.2 Dietary Recall Analysis
Forty-eight hour dietary recall interviews were conducted at each visit. Information from
these interviews was analyzed for nutritional content and caloric intake using the ESHA
Food Processor SQL (version 9.8). Although this program utilizes North American food
composition tables, nutritional data for local Tanzanian foods and recipes were imputed
into the software from Tanzanian food composition tables prepared by Muhimbli
University of Health and Allied Sciences, Tanzania Food and Nutrition Center and
Harvard School of Public Health 203. In addition, when serving sizes or sizes of specific
vegetables were not clearly stated in the interview, the average portion size as outlined by
the Tanzanian Food Composition Tables was used. Nutritional data for Moringa were
obtained from Broin, 204 and also inputted into ESHA. In total, 308 48-hour dietary
recalls were used for the final analysis. The average intake of calories, protein, calcium,
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vitamin A, vitamin D, folate and zinc were calculated over the 48-hour period. In
addition, for analysis pertaining to heavy metals, the average consumption of fish in
grams for each 48-hour period was used to determine the average daily intake of fish
during the study. For each participant, the values of the above listed nutrients were then
averaged with all values obtained from each 48-hour dietary recall collected during the
pre-birth visits to obtain a value representing the daily average intake of specific nutrients
during pregnancy. The same was done for the 48-hour dietary recalls collected at the
birth and final visits, to obtain a value representing the daily average intake of specific
nutrients during lactation.

2.3 Blood Collection and Analysis
2.3.1 Blood Collection
Blood samples were collected from the participants at the first, mid and final visits
(Tables 3 and 4). The lab technician drew approximately 20 mL of blood; 10 mL each
into a royal blue and lavender top vacutainer tube (BD Biosciences). Approximately,
thirty minutes after collection of the blood, 1 mL was removed from the royal blue
vacutainer tube and transferred to a 2 mL screw top polypropylene tube to be used for
heavy metal analysis. The vacutainer tubes were then centrifuged at 4500 g for 15
minutes. After centrifugation, two 1 mL plasma aliquots from the royal blue vacutainer
tube and one 1 mL aliquot from the lavender purple tube were transferred into 2 mL
screw top polypropylene tubes. The buffy coat was removed from the lavender tube and
the remaining red blood cells were transferred to a 2 mL screw top polypropylene tube.
All tubes were labeled with a unique barcode and ID and were placed in a cool box for
transfer back to NIMR where they were stored at -20oC before being shipped back to
Canada.

2.3.2 Heavy Metal Blood Analysis
Twelve participants from both the nourished and undernourished groups who were
receiving moringa supplemented probiotic yogurt were selected for further analysis of the
heavy metal concentration in whole blood samples based on a greater than 75%
consumption compliance one month prior to their final visit. These subjects were
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matched to 12 participants who did not receive probiotic yogurt based on MUAC and fish
consumption from their first and final 48-hour dietary recall interviews. The 1 mL aliquot
of whole blood from the royal blue vacutainer tubes was used for heavy metal analysis,
specifically mercury, lead, arsenic and cadmium. The Trace Elements Laboratory through
the London Laboratory Services Group in London, Ontario, Canada, conducted analysis
of the heavy metals in the whole blood by High Resolution Sector Field Inductively
Coupled Mass Spectrometry.

2.3.3

Blood Nutrient Analysis

The plasma aliquoted from the purple top vacutainer tubes was used for analysis of
Vitamin A and protein. The Core Laboratory through the London Laboratory Services
Group in London, Ontario, Canada conducted the analysis of plasma Vitamin A levels by
HPLC, while the total plasma protein levels were determined by a colorimetric Biuret
assay. Due to hemodilution that occurs during pregnancy, only samples from women who
were in their second trimester of pregnancy were used in analysis for the visit 1 samples.
This resulted in 3 women being removed from this analysis, one in each of the UN, UNP
and N groups.

2.4 Breast Milk Analysis
The breast milk samples collected at birth and at the final visit for all women in the study
were analyzed for fat, protein and lactose content. From the calculated lactose amount,
total carbohydrates were estimated. A total of 12 breast milk samples were excluded from
this analysis due to the provider being HIV positive. The values obtained were averaged
as these samples were taken approximately one week apart. Samples were homogenized
for 10 seconds prior to a 500 µL aliquot being removed for DNA extraction using a
sonicator (VCX 130; Chem- ical Instruments AB, Sollentuna, Sweden). The remaining
sample (approximately 500 µL – 1 mL) was used for nutrient analysis. Lactose content
was measured as described by Fusch et al, 205. In brief a Waters ACQUITY Tandem
Quadruple Dector coupled to an ACQUITY UPLC (waters Corporation, Manchester,
UK) was used in negative ion mode with source temperature, capillary voltage, and cone
voltage set at 150oC, 2.00 kV and 22 V respectively. Quantification of lactose was done
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by using multiple reactions and labeled lactose as a control. Fat was extracted from the
milk using Mojonnier ether extraction and then gravimetrically analyzed to get total fat
content206. Protein content of the breast milk was determined as per the methods of Choi
et al.)206. In brief, the nitrogen content and non-protein nitrogen in the breast milk
samples was measured using an elemental analyser (Vario PYRO cube, Elementar
Americas Inc.). The true protein content was then determined by subtracting the nonprotein nitrogen from the total nitrogen and multiplying this by 6.25207.

2.5 Microbial DNA Extractions
DNA was extracted from all samples using the PowerSoil®-htp 96 Well Soil DNA
Isolation Kit from MoBio (Carlsbad, California). The extraction was carried out as per
the manufacturer’s protocol. However, two changes were made; one was the addition of a
10-minute incubation step at 65oC in a dry bath before the bead-beating step and the other
was doubling the centrifugation times, due to using a centrifuge that only reached a
maximum of 2500 xg. Approximately 250 mg of fecal sample, 500 µL of saliva and 500
µL of breast milk were used for the extractions. The vaginal swabs and infant oral swabs
were cut directly into the wells using scissors sterilized with RNAse Away™ Reagent
(Life Technologies). In total, 1131 samples were extracted for sequencing.

2.6 Sequencing and Microbial Community Analysis
Samples were sequenced by amplifying the V4 hypervariable region of the 16SrRNA
gene using bacterial/archaeal primers 515F and 806R, and the PCR conditions used were
those described by the Earth Microbiome Project. Sequencing of the obtained pool of
16SrRNA amplicons was carried out on the Illumina MiSeq platform as outlined in the
methods of Caporaso et al, 2012208. Obtained reads were quality filtered and demultiplexed using the open source software QIIME209. A total of 1105 samples were
sequenced yielding 17944744 sequences total with an average of 16,240 ± 11,856 per
sample. Samples that generated less than 1000 sequences were discarded after the initial
filter. This resulted in 22 human milk, 3 vaginal, 19 oral and 10 fecal samples being
discarded from further analysis. The remaining sequences were then binned into
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operational taxonomic units (OTUs) using closed-reference otu-picking based on 97%
identity using the Greengenes reference database (May 2013 release)210. After matching
to OTU’s in Greengenes, an additional 17 samples were discarded due to having less than
1000 matches per sample. A total of 1034 samples were used for further downstream
analysis. Beta diversity analysis was conducted using QIIME scripts and PCoA plots
were visualized using the open source tool EMPeror211. In addition, alpha diversity of the
vaginal samples at both the first and final visits was determined using the Shannon index
in QIIME.
The following analysis was conducted in R270. To compare differences between the gut
microbiota of participants of varying nutritional status at baseline, a differential
abundance test of OTUs grouped by genus annotation was run using the ALDEx version
2 package (Fernandas et al, 2014 accepted. The open source tool can be downloaded
here: https://github.com/ggloor/ALDEx2). A Welches t-test was used and the resulting P
values were corrected for multiple comparisons by a Benjaminin-Hochberg post-test and
a false discovery rate (FDR) of <0.05. The results are represented as MW plots that show
the difference between conditions versus the maximum difference within conditions.
Variability of the microbial profile of infant fecal samples is quite high, especially during
the first few months98. Because of this, only samples from infants who were between ten
and twenty days old at the final visit were used for analysis. Furthermore, infant fecal
samples born to mothers in the probiotic group who had less than 80% compliance during
the month before the final visit were excluded from analysis. Thus, 29 infant fecal
samples were analyzed. ALDEx was also performed on these samples as described above
and MW plots were created to determine differences between the groups at the genus and
phyla taxonomic designations. In addition, the proportion of the top five representative
genera were calculated and this data was managed and statistical analysis performed in
GraphPad Prism 5 (version 5.0a). A one-way ANOVA was performed to determine
differences between the five groups, along with a Bonferroni post-test to compare
differences between pairs of groups.
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Bar plots representing the genera and phyla of each sample for participants at the baseline
and final visits were also created in R.

2.7 Statistical Analysis
Data obtained for weight gain, nutrient intakes, hemoglobin, blood levels of vitamin A,
protein and heavy metals and nutrient levels of breast milk were managed in GraphPad
Prism 5 (version 5.0a). Statistical analysis on these data was also performed using this
software. To assess differences between groups, a one-way ANOVA was used.
Furthermore to compare differences between pairs of groups a Bonferonni’s Multiple
Comparisons test was used. For comparison of alpha diversity observed in the vaginal
samples at the first and final visits, a Wilcoxon matched pairs t-test was used.
Significance was set at a confidence interval of 95%.

53

Chapter 3

3

Results

3.1 Anthropometric Baseline Data of Study Participants
Nutritional status is difficult to assess among pregnant women, especially in resource
poor settings. Furthermore, a survey of Tanzanian Demographics and Health published in
2010 stated that only 39% of women living in rural areas visit the antenatal clinic more
than four times during the course of their pregnancy. The majority of women (54.5%)
visit the antenatal clinic only 2-3 times during their pregnancy and the first of these visits
occurs after the fourth or fifth month of pregnancy in 49.9% of women, while 31% wait
until their sixth or seventh month 15. Thus, it is very uncommon to know pre-pregnancy
weight for calculation of body mass index and assessment of nutritional status. As a
result, two methods were employed; MUAC and weight for gestational age, in order to
assess nutritional status. Table 5 outlines the average percent deviation from the expected
weight for gestational age based on the tables by Gueri et al. 200 of participants in all
study groups.
Table 5: Average percent deviation of actual weight-for-height of participants in
each group from the predicted value described in Gueri et al. 200.
Groups
UN

UNP

N

NP

O

83.4 ± 6.0

82.0 ± 4.7

98.2 ± 8.8

94.7 ± 5.9

132.3 ± 21.9
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In total, 60 women were recruited into the study. Eight were excluded from the final
analysis, as they did not return for more than three follow-up visits. The most common
reason for not returning for follow-up visits was due to moving out of the study area.
Figure 8 is a heat map showing all sixty women recruited into the study and the visits
attended and samples collected at each visit. At the first study visit, weight, age, height,
HIV and malaria status, along with information regarding pregnancy history were
collected. Table 6 outlines the baseline demographics of the 52 women used for the final
analysis in the five different groups.
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Figure 8: Heat-map depicting visits attended by all women recruited into the study.
Dark grey boxes denote visits attended and samples collected, while light grey boxes
denote visits missed and samples not collected. Black boxes and bold study ID’s
indicate participants excluded from the final analysis due to not returning for more
than three follow-up visits.

Group

23.6 ± 3.1

Nourished
(n=9)

Obese
(n=5)

19.6 ± 3.3

21.2 ± 2.4

19.7 ± 5.7

21 ± 4.3

20.5 ± 4.3

Gestational
Age
(weeks)***

345 ± 31.7

268 ± 18.3

275 ± 20.5

262 ± 23.7

255 ± 22.0

MUAC
(mm)**

1.6 ±
0.08

1.6 ±
0.06

114.6 ±
12.1

1.6 ±
0.04

101.9 ±
19

110.2 ±
7.9

1.6 ±
0.07

1.6 ±
0.06

104.3 ±
16.7

110.6 ±
16.7

Height
(m)

Hb
(g/L)*

82.8 ±
16.2

59.8 ±
4.7

64.1 ±
6.4

51.6 ±
3.9

53.5 ±
4.6

Weight
(kg)

*Hb: Hemoglobin **MUAC: Mid-upper arm circumference ***Gestational age
was calculated from the last menstrual period to recruitment date. If last
menstrual period was unknown, then nurse approximation was used

31.2 ± 4.0

22.7 ± 3.3

23.7 ± 5.1

Undernourished
+ Probiotic
(n=14)

Nourished +
Probiotic
(n=9)

24.9 ± 5.9

Undernourished
(n=15)

Age (years)
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Table 6: Baseline demographics of women participating in the micronutrient enrich
probiotic yogurt trial in Mwanza, Tanzania.

Group

16.9 ± 7.6

Nourished
(n=9)

Obese
(n=5)
20 ± 5.4

30 ± 2.6

19.1 ± 3.0

Undernourished
+ Probiotic
(n=14)

Nourished +
Probiotic
(n=9)

19.1 ± 3.9

Undernourished
(n=15)

Fundal size
(cm)

6.0 ± 3.5

1.3 ± 3

2.2 ± 3.4

2.1 ± 3.0

1.7 ± 3.0

Nugent
Score

1

8

6

9

11

Negative

1

0

2

1

2

Intermediate

BV Status

3

1

1

2

2

Positive

5.5 ± 0.5

5.4 ± 0.5

5.4 ± 0.3

5.4 ± 0.4

5.4 ± 0.2

Vaginal pH
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Group

1.4 ± 1.1

Nourished
(n=9)

Obese
(n=5)

2.2 ± 1.6

1.6 ± 1.1

1.5 ± 2.1

Undernourished
+ Probiotic
(n=14)

Nourished +
Probiotic
(n=9)

1.9 ± 1.7

Undernourished
(n=15)

No. of Living
Children

21.6 ± 4.0

20.2 ± 3.7

20.6 ± 3.1

18.4 ± 2.7

19.3 ± 1.7

Age of First
Pregnancy
(years)

2.2 ± 1.6

1.6 ± 1.1

1.6 ± 1.4

2.9 ± 1.9

2.4 ± 1.4

No. of Live
Births

0.4 ± 0.9

0

0

0.3 ± 0.9

0

No. of Csections

2.2 ± 2.4

1.7 ± 1.4

1.6 ± 1.4

2.6 ± 2.1

2.4 ± 1.4

No. of
Vaginal
Deliveries

3.2 ± 1.9

1.7 ± 1.5

1.7 ± 1.5

2.4 ± 2.4

2.2 ± 1.5

No. of
Previous
Pregnancies
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0
0
104.0 ± 8.9
68 ± 13.0
Obese
(n=5)

0
0
111.1 ± 9.3
68 ± 7.1
Nourished +
Probiotic
(n=9)

2
3
67 ± 8.7
Group

Nourished
(n=9)

104.4 ± 8.8

2
3
65 ± 6.7
Undernourished
+ Probiotic
(n=14)

110.0 ± 18.1

1
1
105.3 ± 9.2
66 ± 9.9
Undernourished
(n=15)

BP Diastolic

BP Systolic

Malaria
Positive

HIV
Positive

59

3.2 Compliance of Participants on Probiotic Yogurt
Due to the strict system in place for monitoring probiotic yogurt consumption,
compliance was high in the undernourished and nourished groups receiving it.
Compliance, however, was not 100% due to women travelling to different cities during
the study, making probiotic yogurt delivery impossible. Average compliance during the
course of the study, and compliance during the month before the last visit is given in
Table 7. In addition, the average total number of days on yogurt is given in Table 7.
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Table 7: Compliance and total number of days participants received the probiotic
yogurt supplemented with Moringa. Percent and total days are given, along with the
standard deviation.
UNP (n=14)

NP (n=9)

Average total compliance
(%)

87 ± 8

84 ± 16

Average compliance month
before final visit (%)

79 ± 33

87 ± 27

Average total days on
yogurt (days)

91 ± 27

85 ± 37

3.3 Probiotic Yogurt with Moringa Supplementation During
Pregnancy Has No Effect on Weight Gain
Figure 9 shows the weight gain of women in each group as pounds per week from the
first visit till birth. There was no difference in the mean weight gain between groups who
received the probiotic yogurt supplemented with Moringa, as compared to those who did
not (p>0.05). The Institute of Medicine (IOM) guidelines for weight gain during
pregnancy state that during the second trimester, underweight and normal weight woman
should gain an average of 1 lb per week, with an acceptable range being between 1-1.3
lbs/week and 0.8-1lbs/week respectively, while obese woman should gain an overage of
0.5 lbs/ week during the second and third trimester of pregnancy 212. As seen in Figure 9,
the mean weight gain for the UN group was 1.01 ± 0.87 lbs/week, 1.17 ± 1.04 lbs/week
for the UNP group, 0.46 ± 0.80 lbs/week for the N group, 0.55 ± 0.71 for the NP group
and -0.01 ± 0.75 lbs/week for the O group. Although the average for the UN and UNP
group meet the IOM recommendations, 71% of the women in the UNP group had
inadequate weight gain during their second and third trimesters, while 53% in the UN
group and 16.7% in the UNP group had excessive weight gain. This does not reach
statistical significance, but the results are still revealing as are the finding that 77.8% of
the N group and 55.6% of the NP group had inadequate weight gain. One woman and
three women had excessive weight gain in each group respectively, and one woman in
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the O group had appropriate weight gain as outlined by IOM while the other four had
inadequate weight gain.

Figure 9: Average weight gain of woman in each group from time of recruitment to
the visit before birth. The purple dashed line indicates the IOM recommended
average weight gain per week for all classes of obese/overweight women (0.5
lbs/week). The black dotted line represents the IOM recommended average weight
gain for normal weight and underweight women (1 lbs/week).

62

3.4 Dietary and Activity Assessment During Pregnancy
Total kilocalorie intake, calcium, Vitamins B12, B1 and A, folate, iron and zinc as well
as percent consumption of carbohydrates, protein and fat for the participants in all five
groups were calculated from the 48-hour dietary recalls. The means of the total average
consumption per day and percent consumption during the 48-hours prior to the first visit
are given in Table 8. There was no difference in the daily caloric intake between the five
groups at baseline (p > 0.05,). Furthermore, there was no difference in daily intake of any
other macro- and micronutrients as assessed from the 48-hour dietary recalls collected at
the first visit.
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Table 8: Average nutrient intakes per day (macro- and micronutrients) based on the
two days prior to the first visit for all participants in each of the five groups. Values
are given as a percent of average daily intake or total average daily intake with
standard deviation.
UN (n=15)

UNP
(n=14)

N (n=9)

NP (n=9)

O (n=5)

1746 ± 878

1817 ± 650

1779 ± 636

1705 ± 957

1989 ± 249

18.34 ±
4.25

22.6 ± 6.29

19.54 ±
3.81

17.3 ± 2.31

18.84 ±
3.05

Protein (%)

4.55 ± 1.55

3.97 ± 1.33

3.55 ± 1.12

4.33 ± 1.12

3.53 ± 0.95

Total fat (%)

3.82 ± 1.61

3.03 ± 1.38

2.91 ± 1.37

3.64 ± 1.51

2.46 ± 0.55

Saturated fat (%)

2.53 ± 1.24

2.05 ± 1.24

2.04 ± 1.11

2.65 ± 1.30

1.70 ± 0.60

Monounsaturated
fat (%)

0.62 ± 0.30

0.41 ± 0.23

0.36 ± 0.15

0.39 ± 0.15

0.29 ± 0.08

Polyunsaturated
fat (%)

0.35 ± 0.11

0.31 ± 0.15

0.24 ± 0.06

0.28 ± 0.04

0.26 ± 0.09

Vitamin B1
(Thiamine) (mg)

0.90 ± 0.41

0.87 ± 0.34

0.91 ± 0.5

0.72 ± 0.43

1.17 ± 0.48

Vitamin B12 (µ
µg)

1.03 ± 0.84

0.59 ± 0.65

0.64 ± 0.75

0.90 ± 0.64

0.93 ± 0.62

Vitamin A (RAE)

619.4 ±
683.0

544.6 ±
586.5

912.0 ±
830.0

581.1 ±
518.5

454.8 ±
346.6

Calcium (mg)

228.1 ±
195.6

181.3 ±
132.2

248.9 ±
145.8

216.4 ±
94.6

185.0 ±
45.8

Folate (µ
µg)

268.9 ±
160.5

285.1 ±
246.4

336.3 ±
255.9

216.7 ±
135.1

348.8 ±
244.0

Iron (mg)

35.4 ± 44.2

47.9 ± 46.9

48.9 ± 36.7

51.1 ± 59.2

46.8 ± 28.2

Zinc (mg)

5.74 ± 2.11

5.96 ± 2.93

6.20 ± 2.87

4.76 ± 2.24

6.94 ± 3.30

Total Kilocalories
Carbohydrate
(%)
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In order to gain an understanding of the activity levels of participants, an estimation of
kilometers walked per day as well as whether or not participants held a job was gathered
at the first visit. The results are presented in Table 9, and there was no significant
difference in the level of activity as based on kilometers walked per day between the five
groups (p > 0.05).
Table 9: Average kilometers walked per day of participants in each of the five
groups as well as number of participants who were employed at time of recruitment.

Kilometers
walked per day

UN (n=15)

UNP
(n=14)

N (n=9)

NP (n=9)

O (n=5)

1.25 ± 0.92

1.42 ± 1.01

2.16 ± 3.27

1.38 ± 0.88

1.3 ± 0.97

3

6

3

7

5

Employed

Total kilocalorie intake, calcium, Vitamins B12, B1 and A, folate, iron and zinc as well
as percent consumption of carbohydrates, protein and fat was averaged from all 48-hour
dietary recalls collected from the first visit until birth. The means of the total average
consumption per day and percent consumption are given in Table 10. There was a
significant difference in calcium consumption between the groups during the course of
the study. The NP and UNP groups had significantly higher average calcium
consumption per day as compared to the other groups (p < 0.0001). There was also a
significant difference between the Vitamin A intakes of the NP group compared to the
UN group (p=0.0099).
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Table 10: Average nutrient intakes per day (macro- and micronutrients) for all
participants in each of the five groups from time of recruitment until birth. Values
are given as a percent of average daily intake or total average daily intake with the
standard deviation.
UN (n=15)

UNP
(n=14)

N (n=9)

NP (n=9)

O (n=5)

1615 ± 534

1948 ± 490

1888 ± 485

1968 ± 433

1746 ± 412

18.72 ±
6.11

18.74 ±
4.24

19.40 ±
3.99

18.04 ±
3.74

19.02 ±
0.41

Protein (%)

4.19 ± 0.58

3.74 ± 0.72

3.76 ± 0.81

3.80 ± 0.77

3.70 ± 0.07

Total fat (%)

3.62 ± 1.98

3.36 ± 1.40

3.33 ± 1.42

3.47 ± 0.97

3.35 ± 0.09

Saturated fat (%)

2.38 ± 1.42

2.26 ± 1.01

2.29 ± 1.09

2.38 ± 0.85

2.28 ± 0.08

Monounsaturated
fat (%)

0.59 ± 0.34

0.51 ± 0.25

0.49 ± 0.22

0.48 ± 0.08

0.48 ± 0.01

Polyunsaturated
fat (%)

0.32 ± 0.10

0.31 ± 0.13

0.27 ± 0.06

0.30 ± 0.07

0.30 ±
0.006

Vitamin B1
(Thiamine) (mg)

0.79 ± 0.18

0.96 ± 0.19

0.86 ± 0.18

0.93 ± 0.18

0.97 ± 0.25

Vitamin B12 (µ
µg)

1.12 ± 0.46

1.41 ± 0.56

0.91 ± 0.42

1.23 ± 0.46

0.80 ± 0.26

Vitamin A (RAE)

432.1 ±
257.0

632.5 ±
236.8

666.6 ±
294.4

865.3 ±
366.0

430.5 ±
309.2

Calcium (mg)

178.7 ±
84.3

432.5 ±
84.8

216.9 ±
71.2

470.2 ±
72.4

190.0 ±
80.8

Folate (µ
µg)

195.8 ±
67.1

278.6 ±
97.1

277.2 ±
86.3

299.6 ±
79.3

298.1 ±
151.0

Iron (mg)

31.5 ± 17.4

37.4 ± 16.1

41.3 ± 12.5

46.6 ± 22.7

32.4 ± 15.5

Zinc (mg)

5.25 ± 1.08

6.38 ± 1.89

5.92 ± 1.34

5.97 ± 0.83

5.72 ± 1.19

Total Kilocalories
Carbohydrate
(%)
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The average daily intake of micro- and macronutrients consumed during pregnancy was
also compared to the Canadian Reference Dietary Intakes (RDI) for pregnant women.
This was done to assess if pregnant women in this population meet the recommended
intakes of certain micro- and macronutrients for a healthy pregnancy. The calculated
average daily intakes in Table 10 are expressed as a percent of the Canadian RDI and are
given in Table 11 for the participants in this study. Based on the 48-hour dietary recalls,
participants in all groups only met the RDI of carbohydrates and iron. Participants in the
NP group met the RDI for daily vitamin A intake and were close to meeting the RDI for
protein intake (92%, Table 9). For all other micro- and macronutrients, all groups were
below 90% of the RDI.
Table 11: Percent RDI based on Canadian values of the mean daily intake of microand macronutrients consumed by study participants during pregnancy.
UN (n=15)

UNP
(n=14)

N (n=9)

NP (n=9)

O (n=5)

Carbohydrate

142

320

176

177

162

Protein

79

87

83

92

86

Vitamin B1
(Thiamine)

56

69

61

66

69

Vitamin B12

43

54

35

47

31

Vitamin A

56

82

87

112

56

Calcium

18

56

28

61

25

Folate

33

46

46

50

50

Iron

117

139

153

173

120

Zinc

48

58

54

54

52

67

Forty-eight hour dietary recalls were also collected at the birth visit, which occurred
approximately three days after birth, and the final visit, which occurred approximately
one week after the birth visit. Daily average intakes were determined for the same
nutrients listed in Table 10 for each participant and were used to determine the average
daily intake and standard deviation for the group. If participants only attended one of the
two post-partum visits, then the average of the 48-hour dietary recall collected at that
visit was used for analysis of the group average. The results are listed in Table 12. There
was no significant difference between the daily average intake of any of the micro- and
macronutrients between the groups except for calcium. The daily average intake of
calcium was significantly higher in the UNP and NP groups as compared to the other
groups (p >0.05). However, the daily average intake of calcium was not significantly
different between the UNP and NP groups (p < 0.05).
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Table 12: Average daily intakes of micro- and macronutrients for all participants
after giving birth. Values are based on the averages from 48-hour dietary recalls
collected at the birth and final visits.
UN (n=13)

UNP
(n=12)

N (n=8)

NP (n=9)

O (n=4)

1988 ± 483

1955 ± 625

1871 ± 273

1965 ± 451

2066 ± 804

20.79 ±
4.60

18.59 ±
6.49

19.40 ±
5.08

17.25 ±
3.52

18.65 ±
7.66

Protein (%)

3.96 ± 0.86

4.21 ± 1.38

4.76 ± 2.50

3.85 ± 0.90

3.94 ± 1.48

Total fat (%)

2.91 ± 1.39

2.94 ± 1.15

2.34 ± 0.56

3.37 ± 1.36

3.86 ± 1.76

Saturated fat (%)

1.91 ± 1.12

1.84 ± 0.72

1.46 ± 0.45

2.28 ± 1.09

2.36 ± 1.09

Monounsaturated
fat (%)

0.45 ± 0.24

0.50 ± 0.34

0.36 ± 0.19

0.56 ± 0.19

0.93 ± 0.44

Polyunsaturated
fat (%)

0.29 ± 0.09

0.31 ± 0.13

0.28 ± 0.06

0.26 ± 0.11

0.26 ± 0.19

Vitamin B1
(Thiamine) (mg)

0.93 ± 0.27

1.05 ± 0.37

1.04 ± 0.15

0.97 ± 0.28

1.11 ± 0.33

Vitamin B12 (µ
µg)

0.70 ± 0.68

1.22 ± 0.77

0.62 ± 0.75

1.53 ± 0.74

1.66 ± 1.16

Vitamin A (RAE)

216.9 ±
259.7

308.4 ±
388.0

272.2 ±
265.2

371.6 ±
267.3

377.6 ±
197.3

Calcium (mg)

139.4 ±
143.0

343.0 ±
111.7

96.8 ± 39.1

431.2 ±
94.3

99.6 ± 60.1

Folate (µ
µg)

157.64 ±
66.9

182.2 ±
92.6

165.6 ±
66.6

156.1 ±
51.5

125.5 ±
101.1

Iron (mg)

55.3 ± 37.0

59.0 ± 33.1

65.1 ± 37.4

39.7 ± 28.1

39.1 ± 18.1

Zinc (mg)

6.32 ± 1.55

6.40 ± 2.76

6.11 ± 1.15

5.56 ± 1.35

7.09 ± 2.47

Total Kilocalories
Carbohydrate
(%)
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The average daily intakes of the micro- and macronutrients listed in Table 11 were
compared to the Canadian Dietary Reference Intakes for lactating women. The average
daily intakes in Table 12 were calculated as a percent of the Canadian RDI for each
micro- and macronutrient and these values are given in Table 13. All participants met the
Canadian RDI for carbohydrate intake and were significantly over the RDI for iron intake
(Table 13). Furthermore, the UNP and N groups met the RDI for protein intake while the
rest of the groups had intakes of greater than 90% (Table 13). For all other nutrients,
intakes of all groups were below 80% of the RDI (Table 13).
Table 13: Percent RDI based on Canadian Recommended Dietary Intakes of microand macronutrients for lactating women.
UN (n=13)

UNP
(n=12)

N (n=8)

NP (n=9)

O (n=4)

Carbohydrate

164

152

154

150

154

Protein

93

101

112

99

96

Vitamin B1
(Thiamine)

66

75

74

69

79

Vitamin B12

25

44

22

55

59

Vitamin A

17

24

21

29

29

Calcium

14

34

10

43

10

Folate

32

36

33

31

25

Iron

611

655

724

444

433

Zinc (mg)

53

53

51

46

59
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3.5 Prevalence of Anemia in Study Groups
In 2002, the WHO listed iron deficiency anemia as the most important contributing factor
to the global burden of disease. The greatest at-risk populations are pregnant women and
children and in Tanzania 40% of woman between the ages of 15 and 49 are anemic 15. At
each visit, Hb levels were measured. These values were averaged to give a total value by
trimester. In addition, the Hb measurements taken after birth were averaged to give the
mean Hb levels of lactating women in each group. Table 14 outlines the mean Hb levels
of each group during their second and third trimester of pregnancy, as well as during
lactation. There were no significant differences between the mean Hb levels of each
group at any stage of the study (p > 0.05).
Table 14: Mean Hb levels of participants in each group during the second and third
trimesters as well as after birth (lactation).
Mean Hb levels (g/L)
Group

2nd Trimester

3rd Trimester

Lactation

UN

106.3 ± 16.0

108.0 ± 11.6

106.1 ± 15.4

UNP

109.2 ± 12.0

101.8 ± 12.6

104.7 ± 15.7

N

109.1 ± 11.0

101.6 ± 9.8

102.9 ± 12.1

NP

110.7 ± 10.9

98.6 ± 15.9

100.4 ± 17.3

O

114.2 ± 8.3

105.1 ± 12.1

99.3 ± 8.2

Furthermore, Table 15 outlines the percentage of women in each group who were
classified as mild, moderate or severely anemic as defined by the WHO Hb cutoff values
for pregnant women. During pregnancy, none of the women in any group had severe
anemia. However, anemia did appear to increase in the groups between the second and
third trimesters.
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Table 15: Percentage of participants in each group with various stages of anemia as
outlined by WHO guidelines.
Hemoglobin cutoff levels (g/L)
Group

Mild
(100-109)

Moderate
(70-99)

Severe
(<70)

2nd
Trimester

3rd
Trimester

2nd
Trimester

3rd
Trimester

2nd
Trimester

3rd
Trimester

UN

7

14

33

21

0

0

UNP

15

14

23

50

0

0

N

50

22

13

56

0

0

NP

11

43

11

43

0

0

O

40

40

0

20

0

0

3.6 Moringa Enriched Probiotic Yogurt Maintains Mercury
and Arsenic Levels in Pregnant Women
Lactobacillus sp. have the ability to sequester mercury from solution in vitro. In order to
determine if probiotic yogurt consumption could have the same effect on mercury
sequestering or removal in vivo, blood samples collected at the first and final visits in the
this study, were used to measure the concentration of heavy metals. Samples from 24 of
the pregnant subjects were used in this analysis; 12 in the group receiving probiotic
yogurt with a greater than 75% compliance during the last month of the study and 12 not
receiving probiotic who were matched to the supplement group based on MUAC and fish
consumption before the first and final visits. Participants in the supplement group
consumed the yogurt on average 99 ± 18 days from time of recruitment to the final visit.
Fish consumption from the time of enrollment to the final visit was determined from the
48-hour recalls. The amount of fish reported consumed over two days prior to the study
visit was averaged and this amount was again averaged with the amounts reported at each
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visit from baseline to the final visit to determine an estimate of grams of fish per day
consumed. There was no significant difference in the amount of fish consumed per day
between participants in the control and probiotic group (Figure 10). Furthermore, when
the amount of fish consumed per kg of body mass was calculated for the two days prior
to blood collection at baseline and the final visit, no significant difference was observed
between the two groups using a unpaired t-test with Welch’s correction (Figure 11). Of
note, I organized the sample collection and yogurt consumption, as well as participated in
the fish collection and preformed all data analysis and report writing, but Jordan Bisanz, a
PhD student in our lab, oversaw the actual heavy metal analysis at the London
Laboratory Services Group.

Figure 10: Comparison of daily fish consumption during the course of the study
between the group receiving probiotic yogurt and the control group (p >0.05).
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Figure 11: Fish Consumption over a 48 hour period represented as grams per
kilogram of body weight before blood collection at baseline (A) and blood collection
at the final visit (B). There was no significant difference between the two groups at
both baseline (p=0.9365) and the final visit (p=0.6461).
Levels of lead (Pb), mercury (Hg), arsenic (As) and cadmium (Cd) were measured in the
whole blood of all 24 women. The amount of the four heavy metals measured in the
blood of all women used in this analysis at baseline is given in Table 18. For comparison,
the reference values of the same heavy metals found in the blood of women between the
ages of 20 and 39 in Canada is also given. The change in concentration of the four heavy
metals in the blood was calculated between the baseline and the final visits. Using a
paired t-test, a significant difference was observed between the change in blood mercury
and arsenic levels in the probiotic group as compared to the control group (p=0.0484 and
p=0.0054 respectively) (Figure 12). Levels of both metals seemed to increase in the
control between the baseline and final visits, while they remained relatively the same in
the probiotic group between the baseline and final visits. However, there was no
significant difference between the two groups in the change of cadmium and lead blood
levels from baseline to the final visit (p=0.1039 and p=0.3819 respectively) (Figure 12).
What is interesting to note, is that the average amount of fish consumed per kilogram of
body mass calculated for the two days prior to blood collection decreased between the
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baseline and final visits for both groups (2.67 ± 2.26 g/kg and 1.67 ± 1.18 g/kg
respectively for the probiotic group and 2.75 ± 2.79 g/kg and 1.89 ± 1.12 g/kg
respectively for the control group, p > 0.05 for both groups), even though the levels of
mercury appeared to increase in the control group between the baseline and final visits.
Table 16: Average blood metal levels at baseline of pregnant women used for heavy
metal analysis and compared to average levels observed in Canadian women aged
20-39.
Canadian
Reference
Fold
Average
Average1
Range2
Difference
Range
(±SD)
22.6 ± 9.6
7.3 - 40.5
8.9
0.0 – 45.0
2.5
Pb (µg/L)
8.8 ± 3.1
4.0 – 16.0
3.5
0.0 – 18.0
2.5
Hg (nmol/L)
3.0 ± 1.6
1.3 – 6.7
11.7
0.0 – 21.4
- 3.9
As (nmol/L)
1.1 ± 0.6
0.0 – 2.7
3.2
0.0 – 8.9
- 2.9
Cd (nmol/L)
1
Canadian averages obtained from the Canadian Health Measures Survey (2007-2009)213
2
Reference range provided by the London Laboratory Services group
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Figure 12: Change in blood levels between the baseline and final visits of mercury,
arsenic, lead and cadmium. Significant differences were observed between the
probiotic and control group for the change in mercury and arsenic (p=0.0484 and
p=0.0054 respectively), but no significant difference was observed between the
changes in blood concentration of lead and cadmium (p=0.1039 and p=0.3819).
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3.7 Plasma Protein and Retinol Levels
Venous blood was collected at visit 1 (baseline) and the final visit to assess the nutritional
status of the study subjects. Plasma protein levels were determined by a colometric assay,
while plasma retinol levels were determined by HPLC. The results of this analysis are
shown in Table 19. The nutrient levels are also expressed as a ratio of µmol
retinol/protein, as Sapin et al.214 determined that this could correct for the hemodilution
effect observed in pregnancy. There was no difference in the ratio of retinol blood levels
to protein blood levels at baseline between the groups (p>0.05). There was also no
difference in the ratio of retinol blood levels to protein blood levels at the final visit
between the groups, however, there was a significant difference in this ratio between the
UNP and O group (p < 0.05,).
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Table 17: Results of blood nutrient analysis at visit 1 and the final visit of
participants in each group. Values are given as a mean with the standard deviation.
Visit 1
Group

Retinol
(µ
µmoL/L)

Final

Protein

Retinol/

(g/L)

Protein

Retinol
(µ
µmoL/L)

Protein

Retinol/

(g/L)

Protein

(µ
µmoL/g)

(µ
µmoL/g)

UN (n=14)

0.99 ±
0.36

64.1 ±
5.09

0.015 ±
0.005

1.24 ± 0.44

69.8 ± 8.27

0.018 ±
0.006

UNP(n=13)

1.02 ±
0.25

67.4 ±
3.89

0.015 ±
0.004

1.48 ± 0.62

67 ± 8.94

0.023 ±
0.010

N (n=8)

1.08 ±
0.58

61 ±
9.26

0.018 ±
0.013

1.46 ± 0.63

62.4 ±15.4

0.025 ±
0.013

NP (n=9)

0.74 ±
0.21

59.4 ±
12.10

0.013 ±
0.003

1.44 ± 0.33

63.4 ± 7.18

0.023 ±
0.006

O (n=5)

1.10 ±
0.36

52.8 ±
12.4

0.021 ±
0.008

1.85 ± 0.21

56.5 ± 8.58

0.033 ±
0.009

Reference
Range*

1.01 -1.71

57-69

-

1.2-2.8

64-83

-

*Reference ranges for serum retinol and total protein in the second trimester (visit 1)
were taken from Abbassi-Chanavati et al.215 and the reference ranges for both retinol and
protein at the final visit were retrieved from the London Laboratory Services Group web
page
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3.8 Nutrient Content of Human Milk does not Vary Between
Study Groups
The average total fat and protein content of human milk collected at the birth and final
visits were determined as well as an estimate of the average total carbohydrate content
based on calculation of lactose. There were no significant differences in total fat, protein
and carbohydrate content of the milk samples between the groups, Figure 13 depicts the
average carbohydrate, fat and protein content of the human milk samples from
participants in each of the five groups.

Figure 13: Average carbohydrate, fat and protein content of human milk samples
, for example) indicates a participant
from study participants. Each symbol (
sample.
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3.9 Microbiota of Study Participants
All biological samples collected during the study were extracted using the PowerSoil®htp 96 Well Soil DNA Isolation Kit from MoBio (Carlsbad, California). Figure 14
represents all sample types collected during the entire study and shows that each sample
type clusters separately on an unweighted PCoA plot, with infant oral (large transparent
orange dots) and fecal samples (large transparent blue dots) clustering closest to the
human milk samples (red dots)

Figure 14: Unweighted unifrac distances of 1034 fecal, oral, vaginal and human
milk samples collected at every time point for each study participant, plotted in
PCoA space. Clustering is seen based upon sample type. The large transparent
orange and blue circles represent the infant oral and fecal samples respectively, seen
clustering around the human milk samples.
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3.9.1

Comparison of Gut Microbiota between Groups at Baseline

After filtering out samples that produced less than 1000 reads from sequencing, and
filtering for samples that matched to more than 100 OTUs, a total of 47 subjects were
used for the comparison of the gut microbiota at baseline between groups of varying
nutritional status. Two subjects were removed from the undernourished group, one from
the nourished and one from the nourished probiotic group due to either filtering or failed
sequencing, resulting in an n-value of 14 for the undernourished probiotic group, an nvalue of 13 for the undernourished group, an n-value of 7 for the nourished group, an nvalue of 8 for the nourished probiotic group and an n-value of 5 for the obese group. The
average number of reads per sample after filtering was 14216 ± 8687. The genus and
phylum level of the resulting samples were examined and the OTUs were further filtered
to remove any that were present as singletons across the entire sample set. As a result, the
adult fecal samples at baseline contained 188 representative genus OTUs and 15
representative phyla OTUs. The most abundant genus represented by the top OTUs were
Prevotella, Succinivibrio, Bacteriodes, Ruminococcus, Faecalibacterium, Treponema and
Ruminobacter. The most abundant phyla represented by the top OTUs in the fecal
samples were Bacteroidetes, Firmicutes and Proteobacteria. Figure 16 is a bar plot
summarizing the genus level OTU profile of individuals in each group and Figure 15 is a
bar plot summarizing the phylum level OTU profile of individuals in each group.

81

Figure 15: Bar plot of representative phyla in fecal samples at baseline of each
participant separated by group. UN=undernourished, UNP=undernourished
probiotic. N=nourished, O=obese. The y-axis denotes the relative abundance of each
taxa.
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Figure 16: Bar plots representing OTUs at genus level for fecal samples of all
participants at baseline. The legend lists the top 25 OTUs in descending order of
abundance. UN=Undernourished, UNP=Undernourished Probiotic, N=Nourished,
NP=Nourished Probiotic, O=Obese. The y-axis denotes the relative abundance of
each taxa.
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In order to assess whether or not the gut microbial composition differs between mothers
of varying nutritional status, a differential abundance test using ALDEx version 2 of
OTUs grouped by genus annotation was used. First, randomization of participants in the
undernourished and nourished groups did not result in any microbial community biases.
The results, revealed that there was no difference between the gut microbiota of
participants in the undernourished group randomized to receive probiotic yogurt versus
those randomized to not to receive yogurt (Figure 17 B). Furthermore, there was no
difference of representative OTUs grouped by genus annotation in the gut microbiota
between participants in the nourished group randomized to receive probiotic yogurt
versus those who were randomized to not receive probiotic yogurt (Figure 17 A). This
indicates that randomization did not result in a significant difference between those who
were to receive probiotic versus those who were not.

Figure 17: ALDEx2 results showing no difference in fecal OTUs at the genus level
between participants in the nourished group randomized to receive probiotic yogurt
and those randomized not to receive probiotic yogurt (A) and participants in the
undernourished group randomized to receive probiotic yogurt and those
randomized not to receive probiotic yogurt (B).
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Furthermore, there was no difference of representative OTUs grouped by genus
annotation at baseline of the gut microbiotas between participants who were classified as
nourished and those who were classified as under-nourished (Figure 18 A). Nor was there
a significant difference of representative OTUs grouped by genus annotation at baseline
of the gut microbiota of those classified as nourished and those classified as obese
(Figure 18 B). The same was observed between those classified as undernourished and
those classified as obese (Figure 18 C). These results indicated that the gut microbiota of
pregnant women in their second trimester did not differ based on the criteria used to
define nutritional status used in this study. The same analysis was carried out for each
group using representative OTUs at the phyla annotation, but again no significant
differences were observed (data not shown).
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Figure 18: ALDEx2 results showing no difference in fecal OTUs at genus level
between participants in the undernourished group and those in the nourished group
(A), those in the nourished group and those in the obese group (B) and those in the
undernourished group and those in the obese group (C).
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3.9.2

Oral Microbiota at the First Visit

Oral samples were collected at every visit. The bacterial DNA was extracted and
amplification and sequencing of the V4 region of the 16s rRNA gene were carried out as
per the methods above. However, due to time constraints, only the oral samples collected
at the first visit were analyzed for this thesis. Sequencing of the oral samples at the first
visit resulted in 14,598 ± 12,306 reads per sample. These reads were annotated to 205
representative OTUs at the genus level, the top five most abundant OTUs representing
members form the taxa Streptococcus, Prevotella, Haemophillus, Neisseria and
Veillonella. A barplot representing the oral microbiota profiles of each participant is
given in Figure 19.
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Figure 19: Oral microbiota profiles of participants at the first visit. The top 25 most
abundant OTUs annotated at the genus level are given in the legend in increasing
order of abundance. UN=undernourished, UNP=undernourished probiotic,
N=nourished, NP=nourished probiotic, O=obese. The y-axis denotes the relative
abundance of each taxa.

88

3.9.3 Vaginal Microbiota at the First and Final Visit
Vaginal samples were collected at every visit. All samples were sequenced as per the
methods above, however, due to time constraints only the vaginal samples at the first and
final visits were analyzed. At the first visit, 51 out of 52 vaginal samples were
successfully sequenced and passed all filtering steps (UN=15, UNP=14, N=8, NP=9,
O=5). The average number of reads per sample was 14,102 ± 5,022. After filtering out
OTUs that were present as singletons across all samples, 151 representative OTUs at the
genus annotation remained. The most abundant taxa at the genus level was Lactobacillus,
and as seen in Figure 20, OTUs representing this taxa were the most abundant across all
samples in each group. The next most abundant taxa were Megasphaera, Gardnerella
and Sneathia (Figure 20). The profiles observed after sequencing are in accordance with
the results of Nugent scoring in Table 20. Also, Figure 21 is the samples represented in
weighted Unifrac space and the negative Nugent score samples (Lactobacillus dominant),
cluster together, while intermediate and positive samples spread out along PC1, most
likely do to an lesser abundance of Lactobacillus in these samples.
Table 18: Nugent scoring results at visit 1 and the final visit, for all participants.
N=normal (0-3), I=intermediate (4-6), P=positive (7-10).
Nugent Scoring Results
Study ID
UN
MNIH09UP
MNIH21U
MNIH23U
MNIH31U
MNIH34U
MNIH37U
MNIH39U
MNIH43N
MNIH45N
MNIH48N
MNIH49N
MNIH50N
MNIH55N
MNIH56N
MNIH58N

Result
N
P
N
N
N
I
I
N
N
N
N
P
N
N
N

Visit 1
Number Score
0
9
0
0
0
5
4
0
0
0
0
7
0
0
0

Result

Final
Number Score
ND

P
P
NBS

10
7
ND
ND

N
P
P

0
8
8
ND
ND

N

3
ND

N

3
ND
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UNP
MNIH01UP
MNIH02UP
MNIH05UP
MNIH06UP
MNIH14UP
MNIH16UP
MNIH18UP
MNIH20UP
MNIH83NP
MNH84NP
MNH88NP
MNIH90NP
MNIH92NP
MNIH95NP
N
MNIH41N
MNIH47N
MNIH51N
MNIH52N
MNIH57N
MNIH59N
MNIH60N
MNIH86NP
NP
MNIH81NP
MNIH82NP
MNIH85NP
MNIH87NP
MNIH93NP
MNH94NP
MNIH96NP
MNIH97NP
MNIH99NP
O
MNIH61O
MNIH62O
MNIH63O
MNIH64O
MNIH65O

N
N
P
N
NBS
N
N
P
N
N
I
N
N
N

0
0
7
0

N
N
N
N
N
P
N
I

0
0
0
0
0
8
0
6

N
P
N
N
N
N
N
N
N

3
9
0
0
0
0
0
0
0

I
P
P
N
P

6
7
9
0
8

0
0
8
2
3
5
0
0
0

NBS
ND
P
N
N

8
3
3
ND
ND

I
I
P

4
5
8
ND
ND

NBS
NBS
N

0
ND

P

8
ND

NBS
P
P

7
9
ND
ND
ND

NBS
N

0
ND
ND

NBS
ND
N

2

I
NBS

6
ND

N
N

2
0

Note: ND=Not collected, not sequenced, or did not pass filtering, NBS=No bacteria on
the slide so Nugent scoring could not be preformed
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Figure 20: Bar plot representing microbial profiles of each participant, annotated at
the genus level of vaginal samples collected at the first visit. The 25 most abundant
taxa are given in the legend in increasing order of abundance. UN=undernourished,
UNP=undernourished probiotic, N=nourished, NP=nourished probiotic, O=obese.
The y-axis denotes the relative abundance of each taxa.
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Figure 21: Weighted Unifrac distances of vaginal samples at the first and final visits
plotted in PCoA space. Samples are colored based on their Nugent score
(Negative=0-3, Intermediate =4-6, Positive=7-10, NA=Nugent score not available).
PC1 represents 42% of the variation between the samples, while PC2 represents
12% and PC3 represents 6%.
For analysis of the vaginal samples collected at the final visit, women who were in both
the UNP and NP groups that had less than 80% yogurt consumption compliance in the
month before their final visit were excluded in this analysis. This resulted in 4 women
from the UNP group being excluded, leaving a total of 32 subjects. A number of vaginal
samples were not collected due to women having heavy bleeding from giving birth. The
average number of reads was 14070 ± 8825 per sample. In comparison to the first visit
with only 151 representative OTUs, the vaginal microbiota at the final visit contained 197
representative OTUs at the genus level. The most abundant OTU in the final vaginal
samples was matched to Sneathia, followed by Prevotella and then Lactobacillus (Figure
22). The vaginal profiles differed substantially from the profiles seen at the first visit
(Figure 20) and appeared to be more representative of individuals with BV. However, the
microbial profiles observed from sequencing were not in accordance with the Nugent
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scoring results in Table 20. Furthermore, as observed when the weighted Unifrac
distances were plotted in PCoA space (Figure 21), distinct clustering of the samples
based on the Nugent score did not occur and the samples were spread along PC1. Alpha
diversity was also assessed in the vaginal samples at both the first and final visits, and a
significant increase in diversity was observed between the first and final visits (p <
0.0001,).
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Figure 22: Bar plot showing microbial profiles, based on the genus level annotation
of vaginal samples collected at the final visit. The top 25 annotated OTUs are given
in the legend in increasing order of abundance. UN=undernourished,
UNP=undernourished probiotic, N=nourished, NP=nourished probiotic, O=obese.
The y-axis denotes the relative abundance of each taxa.
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3.9.4 Analysis of Infant Microbiota at the Final Visit
After giving birth, participants were asked to come to the clinic with their infants, within
three days. Following this birth visit, women and their infants were asked to return
approximately one week afterwards for a final visit, during which fecal, oral, vaginal and
breast milk samples were collected from mothers and oral and fecal samples from the
infants. The number of samples used in the final analysis was less than samples analyzed
at baseline due to women either withdrawing from the study or not giving birth by the
time the study closed; samples not being provided at time of visit, or due to the death of
infants (one in the UN group and one in the NP group). Furthermore, only fecal samples
from infants between the ages of 10 to 20 days, and from mothers in the probiotic group
who had compliance greater than 80% during the month before their final visit were used.
This resulted in a total of 29 infant fecal samples used in the final analysis (UN=9,
UNP=6, N=3, NP=7 (two twin sets), O=4). After sequencing and filtering, 170 OTUs
annotated at the genus level were present in the infant fecal samples with an average
number of 16,124 ± 14878 reads/sample. Figure 23 is a bar plot summarizing the
representative OTUs at the genus level in the fecal samples of the infants and Figure 24 is
a bar plot summarizing the relative abundance of phyla detected in the infant fecal
samples. One hundred and seventy genera were detected in the infant fecal samples,
belonging to thirteen phyla. The top six OTUs found in the infant fecal samples annotated
to the taxa Bifidobacterium, Enterobacteriaceae, Veillonella, Streptococcus, Bacteroides
and Prevotella. The most abundant phyla found within the infant fecal samples were
Firmicutes, Actinobacteria, Proteobacteria and Bacteroidetes. The age of the infants in
each of the five groups at the time of the final visit is seen in Figure 25, and there was no
significant difference between the groups.
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Figure 23: Bar plot of OTUs annotated at the genus level for infant fecal samples at
the final visit. The top 25 OTUs are given in the legend in descending order of
abundance. UN=Undernourished, UNP=Undernourished Probiotic, N=Nourished,
NP=Nourished Probiotic, O=Obese. The y-axis denotes the relative abundance of
each taxa.
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Figure 24: Bar plot summarizing relative abundance of phyla detected in the infant
fecal samples at the final visit. The 13 phyla detected are given in the legend in
descending order of abundance. UN=Undernourished, UNP=Undernourished
Probiotic, N=Nourished, NP=Nourished Probiotic, O=Obese. The y-axis denotes the
relative abundance of each taxa.
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Figure 25: Age of infants in each of the five groups in days at the time of sample
collection for the final visit. Each symbol (
, for example) indicates a participant
sample.
As shown earlier, analysis of the gut microbial composition of this study population at
baseline did not show any differences using our definitions of nutritional status. Also, due
to filtering, numbers of the final infant fecal samples were low among the groups.
Therefore, in order to increase the power of analysis, the infant fecal samples from
mothers receiving probiotic yogurt were grouped UNP and NP and fecal samples from
infants whose mothers were not receiving probiotic yogurt were grouped UN and N, and
ALDEx2 was used to assess differences in the representative OTUs annotated at the
genus and phyla level. In addition, the results from these two groups were compared to
the infants from obese mothers. To begin, groups were analyzed at the genus level. When
performing ALDEx2 analysis between infant fecal samples from mothers who received

98

probiotic yogurt and infant fecal samples from mothers who did not receive probiotic
yogurt, there was no difference (Figure 26A). In addition, there was no difference when
comparing infant fecal samples from mothers receiving probiotic yogurt and obese
mothers, nor when comparing infant fecal samples from mothers not receiving probiotic
yogurt and obese mothers (Figure 26B and C, respectively). However when calculating
the proportional representation of the top two genera (Bifidobacterium and an unknown
Enterobacteriaceae, Figure 23) in the infant fecal samples from mothers not receiving
probiotic yogurt and from mothers who did receive probiotic yogurt, significant
differences were observed. Specifically, an unknown genera from Enterobacteriaceae
was thirteen times more abundant in the infant fecal samples from mothers who did not
receive the probiotic yogurt and Bifidobacterium was three times more abundant in infant
fecal samples from mothers who did receive probiotic yogurt (Figure 27 A and B).

99

Figure 26: ALDEx2 results showing no difference in OTUs annotated to the genus
level between infant fecal samples from mothers who received probiotic yogurt and
those who did not (A), infant fecal samples from mothers who received probiotic
yogurt and infant fecal samples from obese mothers (B) and infant fecal samples
from mothers who did not receive probiotic yogurt and infant fecal samples from
obese mothers (C).
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Figure 27: Proportion of sequences aligned to an unknown Enterobacteriaceae (A)
and Bifidiobacterium (B) in infant fecal samples from mothers who received
probiotic yogurt (blue squares, both UNP and NP groups combined) and mothers
who did not receive probiotic yogurt (red circles, both UN and N groups combined).
Each symbol (
, for example) indicates a participant sample.
When comparing the infant fecal samples at the phyla level from mothers who received
probiotic and those who did not, OTUs representing the phyla Actinobacteria were
significantly more abundant in infant fecal samples from mothers who received the
probiotic yogurt (p=0.03, using a Welch’s t-test with a Benjamini Hochberg correction)
(Figure 28A). However, there was no significant difference in either the OTUs
representing phyla between infants from the probiotic group and infants from the obese
group or between infants from the non-probiotic group and infants from the obese group
(p > 0.05) (Figure 28B and C). The differences between phyla represented in the infant
fecal samples from the UN group and infants from the UNP group were investigated
further with ALDEx2. In addition to Actinobacteria being significantly more abundant in
the infants from the UNP group (p=0.049), Proteobacteria was found to be significantly
more abundant in infants from the UN group using a Welch’s t-test with a Benjamini
Hochberg correction (p=0.044) (Figure 29).
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Figure 28: ALDEx2 results of comparisons of OTUs annotated to the phyla level
between infant fecal samples from mothers who received probiotic yogurt and those
who did not (A), infant fecal samples from mothers who received probiotic yogurt
and infant fecal samples from obese mothers (B) and infant fecal samples from
mothers who did not receive probiotic yogurt and infant fecal samples from obese
mothers (C). Representative phyla that have significantly different abundance
between and within the samples are depicted as red dots as seen in A, this dot
represents the phyla Actinobacteria.
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Figure 29: ALDEx2 results of comparisons of OTUs annotated to the phyla level
between infant fecal samples from the UN and UNP groups. The red dots indicate
significant phyla that are differentially abundant within and between the two
groups and are representative of Actinobacteria and Proteobacteria.
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3.10 Birth Data
Once a participant gave birth, herself or a family member were instructed to contact study
staff within forty-eight hours. At this time a birth visit was scheduled within three days
and the participant was invited to attend this visit with her infant. There were only two
twin sets born in the entire study and they were to mothers in the NP group. In addition,
the infant mortality rate was only 2 in 48 live births. One infant was born deceased at
approximately 25 weeks gestation, while the other passed away four days after birth at
approximately 32 weeks gestation for unknown reasons. Furthermore there were only 5
low birth weight infants out of the 48 live births. These comprised one twin set in the NP
group who were born at approximately 37.7 weeks gestation and weighed 2.1 kg and 2.3
kg. The mother of these infants lost on average 0.33 lbs per week during the course of her
pregnancy and consumed on average 1788 kcal per day. A second low birth weight infant
was born to a mother in the NP group at approximately 27 weeks gestation. This mother
only received the yogurt for 36 days, and lost on average 0.6l lbs per week. However, she
was consuming on average 2797 kcal per day. One low birth weight infant, weighing 2.4
kg, was born at approximately 39 weeks gestation to an obese mother who gained on
average 0.3 lbs per week during the course of her pregnancy and consumed 2438 kcal per
day. The last low birth weight infant was born in the UNP group at 34 weeks gestation
and weighed 2.3 kg. This infant’s mother gained on average 0.93 lbs per week and
consumed approximately 2845 kcal per day. A summary of the birth data for all groups is
given in Table 21. Gestational age at the time of birth as determined by recall of
participants LMP and the NA was fairly similar between groups, as given by the mean
difference between the LMP and NA in Table 19. Based upon the LMP, 3 births were
preterm in the UN group, 2 in the UNP group, 1 in the N group, 4 in the NP group and 1
in the O group. Based on the NA method, 4 were preterm in the UN group, 3 in the UNP
group, 3 in the N group, 4 in the NP group and none in the O group. The mean gestational
age at the time of birth by both the LMP method and NA method are given in Table 19.

38.39 ± 3.02

0.99 ± 2.57

3.14 ± 0.43

1.16 ± 1.08

1
0
0

36.96 ± 4.19

0.98 ± 2.52

3.10 ± 0.39

0.90 ± 0.69

0
0
1

Gestational Age NA
(weeks)

Difference (LMP-NA)

Birth Weight (kg)

Mother Weight Gain
(lbs/week)

Infants < 2.5 kg

Twin Sets

Deceased Infants

39.38 ± 2.86

37.93 ± 3.36

UNP (n=12)

Gestational Age LMP
(weeks)

UN (n=13)

0

0

0

0.32 ± 1.01

3.23 ± 0.37

1.06 ± 4.84

38.45 ± 3.95

39.51 ± 3.85

N (n=8)

Group

1

2

3

0.62 ± 0.72

2.96 ± 0.70

0.05 ± 1.40

35.41 ± 5.42

35.46 ± 5.57

NP (n=10)

0

0

1

0.32 ± 0.10

3.12 ± 0.51

-0.36 ± 2.88

38.54 ± 1.57

38.18 ± 1.78

O (n=4)
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Table 19: Birth data for participants in each group. Values are given as a mean and
standard deviation. LMP=last menstrual period and NA=nurse approximation of
gestational age.
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Chapter 4

4

Discussion

An individual’s nutritional status is determined by the intake and utilization of nutrients,
their overall state of health and the physical environment. During pregnancy, the need for
appropriate nutrition is increased and if these needs are not met then a number of adverse
pregnancy outcomes can result. Adverse pregnancy outcomes that result from both overand under-nutrition have been well documented in the developed and developing world
and both over- and under-nutrition are a burden on the social and economic progress of
developing countries and a major focus of intervention is in mothers and infants. In the
last decade, the human microbiota has emerged as one of the most powerful determinants
of health and disease including ones nutritional status. However, relatively little is known
about the gut, oral and vaginal mircobiota of pregnant women, especially those who are
undernourished. Furthermore, probiotics are showing increased potential to be a
modulator of health of the microbiota, especially in the gut and reproductive tract and can
easily be produced and administered in the developing world in yogurt format. Thus, it is
reasonable to propose that the maternal gut, oral and vaginal microbiome of mothers of
varying nutritional status differs and could have an effect on pregnancy outcomes. Also,
providing nutrient enriched probiotic yogurt to a subset of these mothers could help
improve their health during pregnancy as well as the health of their infants. The major
findings of this study were that the microbiome of mothers of varying nutritional status
did not differ in their second trimester, while supplementation with Moringa enriched
probiotic yogurt also did not have significant effects on anthropometrics nor nutritional
indicators of those consuming it. Furthermore, for this population, birth outcomes were
generally positive among all groups of nutritional status. However, important and unique
findings were observed in the gut microbiota of infants from mothers who consumed the
yogurt during pregnancy. In addition, probiotic yogurt consumption appeared to protect
against mercury exposure. A closer look and the implication of these findings will be
discussed below.
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4.1 Defining the Maternal Microbiota in Pregnancy
In order to determine whether the maternal gut, oral and vaginal microbiome differed in
mothers of varying nutritional status, the V4 region of the 16S rRNA gene was amplified
and sequenced from samples collected at the first visit. The sequences were then binned
into OTUs, which were matched to reference sequences in the Greengenes database to
determine their identity. The microbiome at each body site was analyzed independently.
There does not exist a consensus on defining nutritional status in pregnant women
especially in resource poor settings, furthermore, risk indicators for low birth weight
infants have been found to vary between developing countries201. The strongest assessor
of adverse pregnancy outcomes and malnutrition in pregnant women is MUAC with a
cutoff of <23 cm to define under-nutrition201. Although not as strong of an indicator, low
maternal weight for gestational age has also shown correlation with low birth weight
infants. Thus, a combination of MUAC and weight for gestational age as described by
Gueri et al. 200 was used to define the nutritional status of participants entering the study.
Based on our definition of nutritional status, there was no difference in the MUAC of
undernourished and nourished groups, however the participants in the UN and UNP
groups weighed significantly less than women in the N and NP groups even though
heights and gestational ages were the same, indicating a lack of proper nourishment in
this group (Table 7). Furthermore, the MUAC and weights of participants in the O group
were significantly greater than all other groups indicating proper assessment of overnourishment. Although the weight of the women in the five groups significantly differed
at baseline (Table 7), the maternal gut microbiota profile of mothers in their second
trimester did not differ between groups as determined from the ALDEx2 analysis at both
the genus and phyla level annotation (Figure 18). This was unexpected, especially for
participants from the O group. Turnbaugh et al.106 established that a difference exists in
the microbiome of obese and lean individuals, specifically a decrease in the phyla
Bacteroidetes and an increase in the phyla Actinobacteria in obese individuals. However,
this study was undertaken with African American and European American twin pairs,
and the V2 region of the 16s rRNA gene was analyzed by 454 FLX amplicon
pyrosequencing. For the participants of the current study, Bacteroidetes was the most
abundant phyla, across all groups, accounting for approximately 47 ± 2% of annotated
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OTUs, while Actinobacteria only accounted for 0.29 ± 0.04% of annotated OTUs at the
phyla level. Turnbaugh et al.’s study106, found that Bacteroidetes accounted for 37.52 ±
3.05% and 29.41 ± 1.49% in obese and lean African American twin pairs respectively
and that Actinobacteria accounted for 0.97 ± 0.40% and 1.27 ± 0.21% in lean and obese
African American twin pairs respectively. The percent abundance of both these phyla
were even lower in the European American obese and lean twin pairs106. Although it is
known that different sequencing platforms and amplification of different sections of the
16s rRNA variable region do lead to certain community bias216, the differences between
the current study and Turnbaugh et al.’s106 study are too large to be due just to
methodology differences. The dominant members of Bacteroidetes that inhabit the human
gut are Bacteroides and Prevotella. It has been well established that the gut microbiota of
European and North American individuals differs from that of Amerindian and African
individuals due to diet98,102. Specifically, Amerindian and native Africans have a gut
microbiota dominated by Prevotella, whereas Bacteroides dominates in European and
North American individuals. As expected, OTUs annotated to Prevotella were the most
abundant at the genus level of classification in all individuals in our study (Figure 16),
due to a diet high in carbohydrates.
Normally, obesity and overweight is attributed to an energy intake that exceeds daily
energy expenditure. However, in the current study there was no difference in any group
in caloric intake during the 48 hours prior to sample collection at baseline (Table 8).
Assessing activity levels in our population was done through an estimation of kilometers
walked per day, as well as whether or not participants held a job. As seen in Table 9,
participants in all five groups had similar levels of activity based on kilometers walked.
Furthermore, all participants in the O group were employed. Thus, it can be assumed that
energy intake and energy expenditure were not responsible for the increased weight in the
O group. It has been reported elsewhere that there are additional factors that result in
overweight/obesity in individuals that have the same energy expenditure and intake as
well as activity levels as compared to lean individuals217, thus this result is not surprising.
In studies investigating the gut microbiota of obese North American individuals, levels of
activity and caloric intake are not always taken into consideration. One study by
Santacruz et al.153, did assess the dietary intakes of obese and lean pregnant mothers and
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also did not find any difference in intake 72 hours prior to sample collection. Participants
in the Santacruz et al.153 study were also recruited during the second trimester, but gut
microbiota communities were assessed using Quantitative real-time PCR. Differences in
gut microbial composition were also observed at the genus level, but changes at the phyla
level were not done and these observations may have been due to methodology
limitations and low sample numbers (n=16 for the obese group). Recently, Le Chatelier et
al.,218 noted that the number of gut microbial genes expressed by the gut microbiome, is
reduced in individuals with increased adiposity, insulin resistance and an inflammatory
phenotype. Furthermore, they only found nine species within the gut microbiota that
could distinguish obese and lean individuals after an exhaustive analysis with lower
accuracy then the differences observed in gene richness. Taking all this together, a
greater in depth analysis into microbial gene expression by the resident flora may have
been needed in order to observe differences in the gut microbiota of the current study
population, however, this was beyond the scope of the project. In addition, the
geographical differences due to diet may result in different observations due to nutritional
status, as it has been observed that the total number of representative Firmicutes increase
and the total number of representative Bacteroidetes decrease with increasing latitudes219.
Thus, studies conducted in North America in relation to obesity/overweight may not
translate to other parts of the world and larger more in depth studies in varying
geographical locations of the world need to be conducted in order to gain a beneficial
understanding of the alterations in the gut microbiota in obese/overweight, lean and
under-nourished individuals. Furthermore, only one study has investigated the gut
microbiota in pregnancy and only analyzed samples collected in the first and third
trimesters144. Again, this study found that women in the third trimester had an altered gut
microbiota that was representative of individuals with metabolic syndromes, while
women in the first trimester had a microbiota representative of healthy non-pregnant
individuals. The authors, however, did not analyze samples collected during the second
trimester so it is not known whether shifts occur in the gut microbiome during this time.
For the purpose of this thesis and due to time constraints, the changes in the gut
microbiota of participants in this study were not analyzed between baseline (visit 1) and
the final visit. However, samples were collected on a monthly basis between recruitment
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and birth (Figure 8) and they have been sequenced and will be analyzed to determine if
changes do occur between the second and third trimester as observed in the study by
Koren et al.144
This thesis is the first to investigate the oral microbiome of pregnant women. Samples
collected at baseline were extracted and sequenced as per the methods above. There were
no significant differences in the oral community profiles observed between the five
groups at the first visit (Figure 19). The most abundant genus was Streptococcus,
followed by Prevotella, Haemophilus, Neisseria and Veillonella. Bik et al.,220 amplified
approximately 90% of the 16S rRNA gene and sequenced the entire fragment, from oral
samples collected from 10 healthy adult individuals. They found similar results with
Streptococcus representing 19.2% of the total sequences in their study and 19.1% of the
total sequences in the current study. However, the second most abundant genus in our
study was Prevotella, which represented 12.1% of the total sequences, while Bik et al.,220
found that Prevotella was only representative of 8.6% of the total sequences. Although,
studies on the oral micorbiome of individuals from different geographic locations did not
result in any significant differences in the oral microbiota composition90, the differences
in Prevotella abundance seen in the current study could be due to the diet rich in
carbohydrates consumed by study participants. The abundance of the genus Haemophilus
(11.7%), Neisseria (9.2%) and Veillonella (8.6%) found by Bik et al. were all very
similar to what we observed in our study (10.2%, 10% and 9.5% respectively). Thus, for
the current study population, the oral microbiome of pregnant women in their second
trimester in all five groups, shared similarities to the oral microbiome of healthy North
American individuals.
The vaginal microbiome of participants in their second trimester was also investigated.
At the first visit, the vaginal samples of the women in all groups were dominated by the
genus Lactobacillus (Figure 20). The abundance of Lactobacillus was greater than 80%
in 28 out of 51 women at the first visit and these samples clustered along PC2 in Figure
21. The five samples that spread out along PC1 in Figure 21 had Lactobacillus present at
an abundance of 47-43%, while women who had an intermediate or positive Nugent
score had a greater abundance of OTUs representing Megasphaera, Gardnerella and
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Sneathia which are representative organisms of BV. This indicates that the Nugent
scoring co-relates with the microbiota profiles. The abundance of Lactobacillus in the
vaginal samples of women in their second trimester is similar to the findings of
Hummelen et al.88, who investigated the vaginal microbiota of non-pregnant women from
the Mwanza region, who were also HIV positive. They targeted the V6 region of the 16S
rRNA gene so were able to achieve deeper sequencing to the genus level, however, they
did find that a Lactobacillus and Gardnerella species constituted core members of the
vaginal microbiome in Tanzanian women. Gardnerella was also present in every sample
of our participants at an average of 6.2% (range of 0.007%-20.8%) abundance.

4.2 Effect of Moringa Enriched Probiotic Yogurt on Maternal
Health Status and Birth Outcomes
It was proposed that the supplementation of Moringa enriched probiotic yogurt could
increase the health status of under-nourished mothers as well as improve birth outcomes.
In order to assess this dietary intake, nutrient blood levels, weight gain, Hb levels and the
nutrient content of breast milk were monitored. In addition, birth data and anthropometric
measurements were collected for the infants. Gut, oral, vaginal and breast milk samples at
the birth and final visits from the mothers, as well as fecal and oral samples at the birth
and final visits from the infants were collected and sequenced. However, only the gut and
vaginal samples of the mothers at the final visit, and gut samples from the infants at the
final visit are discussed in order to determine if Moringa enriched probiotic yogurt may
modulate the microbiota.

4.2.1

Supplementation with Moringa Enriched Probiotic Yogurt
Does not Increase Gestational Weight Gain

It is well known that inadequate or excessive gestational weight gain can lead to small
and large for gestational age infants, as well as an increased risk of pre-term birth221-226.
The average weight gain per week from time of recruitment to birth in the UN and UNP
groups met the IOM standards of appropriate gestational weight gain for a healthy
pregnancy, while the average weight gain per week for the NP and N groups were below
the recommendations (Figure 9). Despite this, it appeared that extremes of the IOM
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recommendations lead to low birth weight (LBW) infants (<2.5kg). Out of the four
participants in the UN, UNP, N and NP groups who lost weight during the second and
third trimesters, three had LBW infants while the fourth had a full term pregnancy and a
healthy weight infant (Appendix 8-11). Furthermore, out of eight women in the UN,
UNP, N and NP groups who had pre-term births, only three had inadequate weight gain
and only one had both inadequate weight gain and an infant who later passed away
(Appendix 8-11). Due to the small sample size statistical significance was not detected,
but it appeared that gestational weight gain outside the IOM recommendations during the
second and third trimester did not have a significant effect on infant birth weight or preterm delivery. All four women in the O group were below the IOM recommendations of
healthy gestational weight gain for obese/overweight women. In 2006, Dietz et al.,
utilized the information found in the Pregnancy Risk Assessment Monitory System
database from the United States to determine the effects of prepregnancy BMI and
pregnancy weight gain on adverse birth outcomes223. They found that as prepregnancy
BMI increased, the amount of weight gained during pregnancy decreased. Specifically,
Dietz et al. observed that 19% of women with high prepregnancy BMI had gestational
weight gain of less than 0.26 lbs/week which was similar to the average gestational
weight gain observed for the O group at 0.33 lbs/week in the present study. Furthermore,
despite the below recommended gestational weight gain for the O group, none of the
women had pre-term births (Appendix 12). Dietz et al.223, also observed that low
gestational weight gain for obese/overweight women did not result in a significant
association with pre-term delivery.
The addition of 250 mL of Moringa enriched probiotic yogurt to the diet in the current
study population did not significantly affect the daily caloric or fat intake of the UNP and
NP groups as seen in Table 10. Determining the recommended daily caloric requirements
for pregnant women is based on a calculation that takes pre-pregnancy weight into
consideration. However, individuals in this population do not maintain records of their
prepregnancy weight, it was unknown whether daily caloric intake met the recommended
requirements for pregnancy. Thus, no assessment was made to determine if low
gestational weight gain was associated with inadequate caloric intake. Furthermore, if
caloric intake from the diet was significantly below the recommended intake then the
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supplementation of 250 mL of yogurt may have been insufficient to cause a change. It
would be beneficial for future studies to recruit women prior to pregnancy in order to
gain an accurate assessment and understanding of gestational weight gain based on
dietary intakes and the appropriate amount of yogurt supplementation to appropriately
meet dietary needs.

4.2.2

Supplementation with Moringa Enriched Probiotic Yogurt
does not Affect Maternal Nutrient Blood Levels

Venous blood from study participants was collected at the first, 4th (approximately 7
months gestation) and final visits to assess nutrient blood levels of protein and Vitamin
A. The addition of Moringa enriched probiotic yogurt provides pregnant women with
13% of recommended intake of protein, and 35% of the recommended intake of Vitamin
A as outlined by the Canadian RDI Tables227. Despite supplementation, there was no
significant difference in the average daily intake from time of recruitment until birth of
protein and vitamin A in the UNP and NP group as compared to the other three groups
(Table 10). There was also no difference observed in the blood retinol and protein levels
in the UNP and NP groups as compared to the other three groups at both baseline and the
final visit (Table 19). During a normal pregnancy, blood volume increases in order to
meet the circulatory needs of the placenta and maternal organs. The exact increase in
blood volume can vary among women and is lffected by factors such as maternal prepregnancy BMI, height and ethnicity228-230. Due to this blood volume increase, levels of
blood nutrients can be altered and may not be reflective of the actual concentration. The
most common circulating form of Vitamin A in the blood is retinol. The amount of
retinol in the blood is homeostatically regulated by the liver and serum retinol levels
reflect liver stores only if severely depleted (< 0.07 µmol/L) or extremely high (> 1.05
µmol/L)231. Furthermore, decreased levels of serum retinol due to increased plasma
volume during pregnancy have been reported232. Despite this, serum retinol levels in
pregnant women are commonly monitored due to the increased occurrence of
micronutrient deficiencies in developing countries as well as the adverse consequences of
Vitamin A deficiencies such as impaired health of the mother and impaired growth,
development and health of her infant. Further, the WHO has defined a serum or plasma
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retinol concentration in pregnant women of <0.70 µmol/L as a Vitamin A deficiency,
with a serum retinol concentration below 1.05 µmol/L being reflective of low vitamin A
status among pregnant and lactating women233. The prevalence of pregnant women in
Africa with serum retinol levels < 0.70 µmol/L as assessed by the WHO between 19952005 was 13.5%. At baseline, in the current study, 15.4% of the participants had serum
retinol levels below 0.70 µmol/L, which is similar to the levels observed by the WHO for
African populations. At the final visit the average serum retinol levels of all groups were
within the reference ranges for non-pregnant Canadian individuals as provided by the
London Laboratory Services Group (Table 19). The average levels of serum retinol
observed at baseline were quite a bit lower than values observed for pregnant women in
Peru (1.46 µmol/L)234, but similar to levels observed in a study of 733 pregnant women
with gestational ages between 7 and 42 weeks, from Guinea-Bissau in West Africa (1.03
± 0.33 µmol/L)235. Sapin et al, examined the serum retinol levels in well-nourished
pregnant women immediately before delivery and observed slightly higher average levels
of serum retinol (1.27 ± 0.38 µmol/L) then what we observed in our study214. The
maternal serum retinol levels observed by Sapin et al.214 were significantly different from
a control group of healthy non-pregnant women, but when the retinol levels were
expressed as a ratio of micromoles serum retinol to grams of serum total protein, then this
difference between the pregnant and non-pregnant group disappeared. Unfortunately,
non-pregnant women were not recruited as a control for the current study, but when the
values of serum retinol and serum total protein were expressed as a ratio as done in Sapin
et al.214, the values for the UN, UNP, and NP groups were lower, while values for the N
and O group were similar to the ratio observed in Sapin et al.214 (0.021 ± 0.005 µmol/ g
protein and Table 19). In populations where pre-pregnancy weights are unavailable it
may be beneficial for future studies to recruit and collect venous samples from nonpregnant aged matched individuals of varying nutritional status to compare this ratio of
serum retinol to serum protein as an additional indicator of nutritional status in pregnant
women. Total protein levels were also assessed at baseline and the final visits, and the
average serum protein levels for all groups at both visits were within reference ranges
except for the O group, who had average serum protein levels below the reference ranges
(Table 19). Dietary analysis of protein intake between the five groups was similar based
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on percent RDI of Canadian values, so a decreased dietary protein intake by participants
in the O groups was not the reason for reduced serum protein levels. However, obesity is
associated with a greater increase in blood volume, which could account for the lower
serum protein levels observed236.
Significant increases in dietary intake of calcium in the NP and UNP groups as compared
to the groups who did not receive probiotic yogurt were observed. Unfortunately calcium
blood levels were not assessed due to the blood being collected in vacutainer tubes
containing EDTA, which bind calcium in the blood to prevent it from clotting. However,
calcium is an important nutrient during pregnancy. If dietary calcium intake does not
increase to meet the demands of calcium absorption, which significantly increases in the
second and third trimesters, then pregnant women can be at an increased risk of
preeclampsia, pre-term birth and long-term morbidities such as excessive bone loss237.
Furthermore, maternal dietary intake of calcium has been found to be associated with
positive bone outcomes for her offspring237. The recommended dietary intake of calcium
during pregnancy is 1,000 mg/day227. Probiotic yogurt consumption lead to the NP and
UNP groups meeting 61 and 56% of the RDI for calcium respectively, while the other
three groups consumed less than 30% of the RDI for calcium (Table 11). Dietary sources
of calcium are uncommon in the rural Tanzanian diet, which is based mainly on ugali
(corn flour), rice, fish, tomatoes, onions and spinach. Thus, supplementation of the diet
with probiotic yogurt to all individuals would be extremely beneficial for this population
to maintain bone health.

4.2.3

Supplementation with Moringa Enriched Probiotic Yogurt
Does not Alter Hemoglobin Concentrations During
Pregnancy

Hemoglobin concentration of all participants was monitored at every visit using a
Hemocue from time of recruitment until participants exited the study. Due to plasma
volume increases, anemia in pregnancy is defined as levels < 11.0 g/dL during the first
and third trimesters and <10.5 g/dL in the second trimester as compared to <12.0 g/dL in
non-pregnant women238. In our study population the average hemoglobin concentration
of all groups in the second trimester was above 10.5 g/dL (Table 14), while in the third
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trimester all groups had average hemoglobin concentrations below 11.0 g/dL (Table 14).
In 2008, the WHO released a report on the prevalence of anemia worldwide. In Africa,
the prevalence of anemia was 55.8% in pregnant women239. In the current study
population, the prevalence of anemia was quite a bit lower, with prevalence reaching the
continents numbers for moderate anemia in the third trimester for the UNP and N group,
and mild anemia for the N group in the second trimester (Table 15). The reduced
prevalence of anemia seen in the current study population could be due to the low sample
numbers. In addition, iron supplements were routinely handed out at the clinic where the
study was conducted. Information on who received these supplements was collected and
in the future it is important to examine the relationship between hemoglobin status of
individuals who received iron supplements and those who did not. In another study
conducted in a municipality near Mwanza, Tanzania which included 2,654 pregnant
women in their third trimester, 35.3% of the participants had mild anemia which was
similar to the prevalence observed in the present study if the five groups were combined
(26.6%)240. However, the prevalence of participants in the third trimester with moderate
anemia when all five groups were combined (38%) was substantially higher than
observed in the study by Msuya et al. (9.9%)240.
The supplementation of Moringa enriched probiotic yogurt, provided the participants
with only an additional 4% of the RDI of iron for pregnant women (Table 2). However,
based on the analysis of the dietary recalls all participants in each group meet the dietary
intake requirements for iron (Table 11). Anemia can be caused by a number of factors,
with the most common being deficiencies in either iron or folate238. Based on the dietary
recalls, participants in the present study were only meeting between 33 and 50% of the
RDI for folate (Table 11) and supplementation with Moringa enriched probiotic yogurt
did not provide an additional dietary source of folate (Table 1). In another study
conducted out of four antenatal clinics in rural northern Tanzania, low serum folate and
malaria status was also found to be associated with anemia in a study population of 2,547
pregnant women241. Rapid Malaria tests were performed, thus, future work can also
involve investigating a relationship between malarial infection and anemia. In addition,
whole blood cells were collected for folate analysis and determination of folate levels
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would investigate whether a deficiency was responsible for the anemia observed in the
present study.

4.2.4

Changes in the Vaginal Microbiota between the First and
Final Visits

The vaginal microbiota at the first and final visits were compared. At the first visit, the
vaginal samples were dominated by Lactobacillus, which is indicative of vaginal health
during pregnancy141. Samples not dominated by Lactobacillus, were dominated by
organisms associated with BV which was in agreement with the Nugent scores (Table 20
and Figure 20)242. In the only other study that looked at the vaginal microbiota in
pregnancy, a reduction in diversity was observed as compared to non-pregnant
individuals, with an increase in Lactobacillus species iners, crispatus, jensenii and
johnsonii141. However, in the present study, sequencing of the V4 region did not allow for
identification of taxa at the species level. Thus, although 29 out of 51 samples having
greater than 80% abundance of Lactobacillus were observed, it was not possible to
determine the species composition or to make conclusions about diversity within these
samples, as samples were not collected from a non-pregnant population and comparisons
between different studies cannot be done due to different methodologies used. Future
work could involve examining and comparing the diversity within samples
longitudinally, as vaginal samples were collected every month during gestation.
Furthermore, it would be beneficial to collect age-matched vaginal samples from a nonpregnant subset for comparison in a larger scale study to determine the changes in the
vaginal microbiome during pregnancy in a native African population.
The vaginal microbiota significantly changed after giving birth. Alpha diversity
comparisons using the Shannon index revealed that the vaginal microbiota of the women
significantly increased in diversity from the first visit to the final visit. Furthermore,
Sneathia and Prevotella dominated the vaginal microbiota at the final visit, which are BV
associated organisms and Prevotella species have also been previously observed as a
dominant BV associated organism in Tanzanian populations88,242. Nugent scoring of the
final visit samples did not match the microbiota profiles. In a study conducted out of
Bugando Medical Centre in Mwanza, Tanzania, Nugent scoring was performed at birth
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and BV was diagnosed in 28.5% of the participants150. Based on the Nugent scores
obtained in the current study, 41% of participants had a positive Nugent score at the final
visit. A potential reason for the increased prevalence of a positive Nugent score, could be
due to the fact a majority of the women gave birth at home, thus the birthing conditions
may not have been as sanitary as in a hospital. Based on dominance of Lactobacillus,
only two samples were BV negative (Figure 22). OTUs for Lactobacillus were present in
every sample at the final visit except for one, and the average abundance at the final visit
was 12.7% compared to 70% at the first visit. No other studies have examined the vaginal
microbiota of women at birth, thus the shifts observed in the current study may not
necessarily be indicative of disease but may be a normal disruption due to the birthing
process. The final visit samples were collected between 8 and 30 days after birth;
however, vaginal samples were collected and sequenced from 3 days after birth. Thus, it
would be extremely interesting to examine these samples and compare them to the final
visit samples to determine if this increased diversity and altered OTU dominance was
also observed at this time point. Furthermore, in order to gain greater understanding on
the shifts of the vaginal microbiota due to the birthing process, future studies should
collect vaginal samples up to six months or a year after birth to determine when the
microbiota shifts back to the pre-pregnancy profile, and the factors that might influence
this process.

4.2.5

Supplementation with Moringa Enriched Probiotic Yogurt
May Modulate the Infant Gut Microbiota

Infant fecal samples collected at the final visit had the bacterial DNA extracted and the
V4 region of the 16S rRNA gene amplified and sequenced. Studies have shown that the
infant gut microbiota during the first 3 years of life contains high interindividual
variability and does not follow a defined developmental pattern due to significant
changes caused by life events such as type of feeding, introduction of solid food and
antibiotic exposure. However, it is generally accepted that Bifidobacterium becomes the
dominant bacterial genus starting approximately three days after birth128,243,244. The age of
the infants analyzed at the final visit were between 10 and 20 days and as seen in Figure
25, Bifidobacterium was the most abundant genus in a majority of the fecal samples.
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Bifidobacterium appeared to be more abundant in the UNP and NP groups then in any
other group and members of the family Enterobacteriaceae appeared to be more
abundant in the UN and N groups (Figure 23). Studies have shown that members of the
family Enterobacteriaceae are normally the dominant organisms at birth in infants born
vaginally and numbers normally decline once Bifidobacterium begins to
dominate96,128,244. ALDEx2 analysis determined that the difference observed at the genus
level between the relative abundance of Bifidobacterium and the unknown
Enterobacteriaceae was not significant, most likely due to the low sample numbers.
However, when the actual proportion of sequences aligned to Bifidobacterium and the
unknown Enterobacteriaceae were compared between infant fecal samples from mothers
who received probiotic yogurt (UNP and NP groups) and infant fecal samples from
mothers who did not receive probiotic yogurt (UN and N groups), a significant difference
was observed (Figure 27). Specifically, Bifidobacterium was three times more abundant
in the infant fecal samples from mothers who received probiotic yogurt and the unknown
Enterobacteriaceae was thirteen times more abundant in infants from mothers who did
not receive probiotic yogurt. Further ALDEx2 analysis on the phyla level revealed that
Actinobacteria was significantly increased in infants from mothers who received
probiotic yogurt as compared to infants from mothers who did not. If the UN and UNP
groups were compared alone, Proteobacteria was also significantly increased in the UN
group as compared to the UNP group (Figures 28 and 29). Enterobacteriaceae is a
member of Proteobacteria and evidence has suggested that an increased abundance of
members of Enterobacteriaceae in the infant gut is associated with the development of
atopic disease245-247. Furthermore, members of both Proteobacteria and
Enterobacteriaceae include a number of organisms that have the potential to be
pathogenic and an increase of representative members of this taxa coinciding with a
decrease of members of Bifidobacterium (a genus belonging to the phyla Actinobacteria)
is not normally associated with health. An increase of Enterobacteriaceae and a decrease
in Bifidobacterium, has also been observed in infants receiving antibiotic treatment and
this imbalance was seen to persist even after treatment commenced248. The exact
consequences of persistence of this imbalance is not completely understood, nor has it
been investigated, however, a recent study has shown that a decrease in Bifidobacterium
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and an increase in Enterobacteriaceae is associated with Crohn’s disease in children249.
Furthermore animal models and in vitro studies have shown that members of
Bifidobacterium promote specific immune functions, which could translate to an
importance of increased Bifidobacterium diversity in infant guts for proper immune
development250-252. In addition, secreted factors from Bifidobacterium infantis (a
prominent member of the infant gut microbiota comprising up to 90% of the total
Bifidobacterium), have been shown to reduce colonic permeability and attenuate
inflammation in mouse models173. Thus, supplementation of Moringa enriched probiotic
yogurt to mothers during pregnancy, may be priming their infant’s gut microbiota for
healthy compositional and immune development, as well as protection against infection.
It could be extremely valuable and informative to conduct a large-scale, longitudinal
study on probiotic supplementation from pregnancy to three years post-partum to fully
understand the potential of this proposed modulation.

4.2.6

Nutritional Content of Breast Milk does not Differ Between
Mothers who Received Probiotic Yogurt and Mothers who
did not

Breast milk is well known for its nutritional value, immune-modulating compounds,
stimulation of cognitive development and protection against pathogenic organisms.
Recently, the role of breast milk in the development of the intestinal microbiota of the
infant has gained a lot of attention. Breast milk contains between 10 and 20 g/liter of
oligosaccharides, which are the third most abundant component after lactose and
lipids253. These oligosaccharides are not digested by the infant, however, it has been
shown that they play an important role in preventing adhesion of pathogens to the
mucosal lining, as well as stimulating the growth of Bifidobacterium in the infant
gut137,138,254. Thus, due to our findings it was further hypothesized that the probiotic
yogurt might have an affect on the nutritional content of the breast milk thereby
accounting for the increase in Bifidobacterium seen in the infant guts from mothers who
received the probiotic yogurt. Determining the exact oligosaccharide content of breast
milk can be done with a number of methods, but the most common and preferred are
Mass Spectrometry (MS) and HPLC-Chip/time-of-flight MS137. Determining the exact
oligosaccharide profile was beyond the scope of this study, however, protein, fat and the
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lactose content of breast milk were examined and the estimated total carbohydrate
content from these measurements were determined to gain an idea of the oligosaccharide
content. As seen in Figure 13, there was no difference in the fat, carbohydrate and protein
content of breast milk in the five groups. Fat, protein and carbohydrate content of breast
milk collected at the birth and final visit were averaged due to low sample numbers. The
time of collection of these two samples varied from 3 days after birth to 30 days after
birth, thus colostrum, transitional and mature milk were used in the analysis.
Concentration of proteins is normally higher in colostrum than in mature milk, however,
fat and carbohydrate concentrations remain relatively the same255. The total average
concentration of fat, protein and carbohydrate content varied from 2.69-2.81, 1.20-1.37
and 5.51-5.72 g/dL, respectively, for all five groups. The standard concentration in
Western populations of fat in breast milk is 2.6 to 4.1 g/dL from colostrum to mature
milk, 2.0 to 1.3 g/dL for protein from colostrum to mature milk, and 6.6 to 7.2 g/dL for
carbohydrates from colostrum to mature milk255. The values obtained in the present study
for fat, protein and carbohydrate content are on the lower end of the Western norms.
Normally, carbohydrate and protein content remain relatively stable in women of varying
nutritional status, while fat concentration can be affected by weight gain during
pregnancy, as well as nutritional status255. However, in the current study no major
increase in fat concentration in women with higher gestational weight gain was observed.

4.3 Supplementation of Moringa Enriched Probiotic Yogurt
Provides a Protective Effect against Mercury and
Arsenic
Although it is recommended that pregnant women consume an appropriate amount of fish
during pregnancy in order to provide the fetus and mother with essential omega-3 fatty
acids and other nutrients, it is also widely accepted that consumption of fish high in
mercury should be avoided due to the detrimental effects of the heavy metal on the
developing fetus. The clearest documented effects of mercury on fetal neurodevelopment
were observed in Minamata City in Japan during the 1950’s, where release of methyl
mercury into the water resulted in deaths and physical impairment of thousands of adults,
children and unborn babies256. These same affects were observed due to the consumption
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of grain treated with a mercury containing fungicide in Iraq in the 1970’s257. Since then,
it has been shown that high levels of maternal mercury can result in infertility as well as
spontaneous abortion and stillbirths256.
Mwanza, Tanzania is located on the shores of Lake Victoria, which is the world’s second
largest fresh water lake by surface area and is inhabited by many species of fish that are a
major source of income and food for those in the region. Specifically, 1% of the Mwanza
population is employed by the fishing sector and in 2001 63,990 tons of fish were
harvested from Lake Victoria in the Mwanza region alone258. Furthermore, gold ore
processing using mercury is common practice in the gold-mining industry of Tanzania
and three of the major gold fields (Geita, Musoma and Tarime) are located near the
shores of Lake Victoria. Mercury pollution of the water, soil sediments and fish of Lake
Victoria is commonly acknowledged due to these activities, and thus mercury exposure is
higher in the Mwanza region then in other regions of Tanzania259.
Because of Lactobacillus species observed ability to sequester mercury in vitro, it was
determined if consumption of the Moringa enriched probiotic yogurt may have an effect
on the blood mercury and heavy metal levels of the pregnant women. Despite similar
levels of fish consumption during the study (Figure 10), as well as similar consumption
of fish per kilogram of body mass before blood collection at the first visit and blood
collection at the final visit (Figure 11), participants who received the probiotic yogurt
appeared to maintain their levels of blood mercury and arsenic, while participants who
did not receive the probiotic yogurt, had a significant increase in mercury and arsenic
levels (Figure 12). Mercury levels have been shown to be relatively stable in blood
samples, unless repeated freeze thaw cycles are carried out which was not the case in the
current study260,261. Furthermore, all samples were stored under the same conditions and
for roughly the same amount of time from time of collection until analysis. Thus, the
increased levels of mercury and arsenic in the control group were not likely due to
storage conditions and length of time. Unfortunately, determining the exact mechanism
by which the probiotic yogurt maintained the levels of mercury and arsenic in the blood
of pregnant women is beyond the scope of the present study. However, the probiotic
could be acting to sequester the mercury from the gut, thereby preventing its uptake.
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Future studies could examine the mercury levels in fecal samples as has been done in
other studies262,263, to determine if mercury levels increase in the feces of participants
who consume probiotic yogurt as compared to those who do not.
Levels of lead and mercury in the blood of pregnant women in the current study were 2.5
times increased as compared to the levels observed in Canadian women (Table 18)213.
Levels as high as 14.9 nmol/L have been observed in Saudi Arabian pregnant women264,
while mercury levels of 6.6 nmol/L have been observed in pregnant women in Bermuda
who also consume a large amount of fish during pregnancy265. The increased amount of
mercury observed in the present study is most likely due to the consumption of fish, as
fish is one of the main sources of protein for individuals in this area of Tanzania and the
women consumed fish on average 2 to 3 times per week during pregnancy. The
consequences of high levels of mercury exposure during pregnancy are well known and a
recent study conducted in Hong Kong has shown that even low levels of mercury
exposure during pregnancy can result in adverse neurocognitive outcomes for infants266.
For many developing countries, making adjustments to the diet is extremely difficult, due
to the cost and availability of foods. In Bermuda, the public health sector has successfully
educated pregnant women on fish to avoid during pregnancy due to high levels of
mercury, which has resulted in decreased levels of mercury observed in the blood of
pregnant women265. However, in countries such as Tanzania, educating women to eat less
fish and to avoid species high in mercury during pregnancy may not be as successful due
to the lack of similarly priced alternatives. Thus, the positive findings in the current study
are that probiotic yogurt consumption can help maintain the levels of blood mercury and
could have huge implications for a number of developing countries where mercury
exposure is high either due to certain food consumption or pollution. An additional largescale study investigating the effects of longer probiotic yogurt consumption, as well as
investigating the mercury levels in infants born to mothers who consumed probiotic
yogurt would help support these preliminary findings.

4.4 Conclusions
This pilot study was the first of its kind to simultaneously analyze the gut, vaginal and
oral microbiota of pregnant women as well as the gut, oral, vaginal and breast milk
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microbiota of women who had just given birth and the gut and oral microbiota of their
infants. The current study produced a wealth of information. Differences in the gut
microbiota of mothers of varying nutritional status were not observed. Low sample
numbers and a lack of an accurate and reliable method for determining nutritional status
in the field and during pregnancy may have been the reason for this. Furthermore, studies
on the gut microbiota of obese individuals in different geographical locations have not
been conducted. Thus, the patterns observed in North America where high-fat diets are
consumed, may not necessarily be the same in countries where the diet is composed
largely of corn-based products, as studies have shown that a difference does exist in the
microbial profile due to different dietary intakes98. Furthermore, pregnancy does exert a
number of physiological and microbial changes141,144 on the body, so differences in the
microbiota due to nutritional status may disappear when an individual becomes pregnant.
The preliminary analysis presented here did not reveal any significant findings leading to
the benefits of Moringa enriched probiotic yogurt for improved pregnancy outcomes. As
seen in Table 19, all groups except the NP group had term pregnancies and healthy birth
weight infants, however gestational age was based on recall of the LMP and a NA, which
are not dependable methods for assessing gestational age as ultrasound has been shown to
be more accurate and reliable267. Unfortunately, due to location, ultrasound was not
available for determining the gestational age. Based on the birth data, the NP group did
appear to have the least favorable birth outcomes as compared to the other four groups
(Table 19). However, the NP group did have two sets of twins, which does add an
additional strain to the health status of the mother, and twin gestations are at an increased
risk of pre-term births and of infants being born that weigh less than 2500 g, even in
developed countries268. A study conducted in the United States in 2001, did find that the
optimal gestational age for twin pregnancies associated with the lowest perinatal
mortality rate was between 37 and 38 weeks gestation, which is just on the cusp of the
cutoff for the definition of pre-term births269. Thus, for future studies it may be beneficial
to analyze twin data separately. Due to the low sample numbers, the twin data were
included in the overall analysis.
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The Moringa enriched probiotic yogurt did not appear to affect the gestational weight
gain or nutritional status of the participants. Despite some participants having weight gain
below the IOM recommendations and dietary intake of essential nutrients not meeting the
RDI for pregnancy, the majority of birth outcomes were positive. This leads us to
consider what other factors may be at play in this population as based on the nutritional
intakes and measurements collected during the study, more adverse pregnancy outcomes
should have resulted. Intake of Moringa enriched probiotic yogurt, did significantly
increase the dietary calcium intake of participants. No other methods were available to
assess the impact of this increase, but calcium does play an important role in pregnancy
and the standard Tanzanian diet is lacking in this nutrient. Thus, it is suggested that the
intake of Moringa enriched probiotic yogurt would be extremely beneficial in improving
the bone health of mothers and infants in developing countries. Furthermore, although the
Moringa enriched probiotic yogurt did not modulate the maternal microbiome in any
way, it did appear to have an effect on the infant’s microbiome. There was a significant
increase in organisms related to healthy gut development in infants from mothers who
received the probiotic yogurt, while infants from mothers who did not receive the
probiotic yogurt had higher levels of organisms associated with disease. This could have
major implications on the long-term health of the infants and this finding warrants further
investigations. In addition, the Moringa probiotic yogurt did have a protective effect on
the mercury and arsenic levels in pregnant women. It is well known that heavy metals
exposure during pregnancy can cause a number of developmental deformities, and in
developing countries, exposure to heavy metals is increased due to pollution and unsafe
mining practices. Furthermore, diet choices are limited in developing countries due to
availability of food products and cost, so avoiding foods known to be high in heavy
metals is sometimes impossible. These findings are extremely promising and warrant
further investigation to determine the extent and length of this protection both on the
mother and her newborn infant.
A major weakness of the present study was the low sample numbers. It was decided that
the study be conducted in a rural clinic in hopes of targeting a demographic of increased
under-nourished participants. However, the majority of pregnant women attending the
clinic were well-nourished, thus, future studies may be conducted in even more remote or
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poor areas in order to target truly under-nourished individuals. Because of the rural
location of the clinic, obese/overweight participants were also limited. Higher numbers of
obese/overweight mothers are more common in urban areas, thus in order to target this
demographic, future studies should be carried out in two locations in order to gain high
enough sample numbers for each group. It would also be beneficial for future studies to
recruit women before they are pregnant. Assessing nutritional status is extremely difficult
in pregnancy and the most accurate method for assessing nutritional status in developing
countries involves knowing pre-pregnancy weight as well as pre-pregnancy MUAC.
Pregnancy rates in Tanzania are quite high with 211 out of 1,000 women aged between
15 and 34 years becoming pregnant each year15. Thus, it is feasible to recruit a large
number of women and then follow them through pregnancy. Recruiting women before
they become pregnant will also be beneficial, as pregnant women in Tanzania do not
normally attend an antenatal clinic until late in their pregnancy. By the time a number of
women were recruited into the present study, adverse developmental outcomes may have
already commenced in the fetus, thus making Moringa enriched probiotic yogurt
supplementation ineffective. Another recommendation for future studies would be to
extend the sample collection after birth. Due to time constraints we were unable to collect
from participants past one-week after birth, however, it would be extremely informative
to follow the changes in both the infant and maternal microbiota up to one-year postpartum. In addition, future studies should include age and nutritional status-matched nonpregnant controls. As mentioned, changes in the microbiota of individuals in Africa due
to obesity/overweight or under-nourishment, may be different then the changes observed
in North American populations due to the differences in diet. Thus, non-pregnant controls
are needed to accurately assess the effect of geographic location on the effect of
nutritional status.
The current study was extremely beneficial in laying the groundwork for future
microbiota related studies in developing countries. Microbiota studies in developing
countries provide a wealth of information that is not available in developed countries and
will be extremely beneficial in examining the relationship between the microbiota in
health and disease. Furthermore, increased knowledge on the dynamics of the microbiota
during pregnancy will help lead to better pregnancy outcomes globally.
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Appendix 3: English version of consent form

The National Institute for Medical Research (NIMR) P.O. Box 11936, Mwanza

THE INFLUENCE OF NUTRITION ON MATERNAL AND REPRODUCTIVE
HEALTH
Adult Participant Consent Form
Subject ID Sticker

Introduction and purpose
We are a joint research team from the National Institute for Medical Research, Mwanza
Centre and the University of Western Ontario, Canada. We are here because we are
conducting a study to investigate the influence of nutrition on an individual’s microbiome and
how this may be related to pregnancy outcome. Previous studies have shown that maternal
nutrition is one of the most important factors that influence either a good or an adverse
pregnancy outcome and new studies are showing that our normal microflora has a significant
effect on health and disease. The main objective of the study is to determine the difference in
gut, oral, vaginal and breast milk microbiomes of under-nourished pregnant women with and
without supplementation with micronutrient enriched probiotic yogurt and compare this to the
microbiome of obese and healthy pregnant women The study has been approved by the
Ministry of Health and Social Welfare. Buswelu Clinic has also given permission to conduct
this study.
We are asking if you would like to participate in this study. This form explains the study and
you can decide to take part or refuse to participate. Please take the time to read this form or
someone can read it to you. If you have any questions, require more information or need
further explanation of the study, please ask the doctor or any study worker.
Participant Selection
The study will recruit 80 pregnant women attending the neonatal service at the Buswelu
Clinic, who are approximately 20 weeks pregnant. We are asking you to participate because
you fit the criteria for participant selection, based on a clinical assessment by a doctor.
Twenty obese, 20 healthy, and 40 under-nourished women will be asked to participate.
Procedures: Twenty pregnant women who are found to be malnourished according to the
WHO criteria will be selected and given a daily supplementation of 250mL’s of yogurt which is
enriched with micronutrients (powdered Moringa oleifera leaves) and a probiotic (bacteria with
health benefits). Stool, vaginal and oral samples will be collected monthly starting with the first
visit and continuing until the baby is born and again one week after the baby is born. In
addition, blood samples will be collected three times during the course of the study. A breast
milk sample from the women and a stool and oral sample from the infant will be collected
when the infant is born and one week later. If you are selected to consume the yogurt, you will
be required during the study period of approximately 6 months, to come to the Buswelu yogurt
kitchen daily to consume the yogurt. If you are unwell and cannot travel to the kitchen a study
worker will deliver the yogurt to you. Another group of 20 well nourished pregnant women, 20
overweight pregnant women, and 20 under-nourished pregnant women will not take any
yogurt supplementation but stool, oral, and vaginal samples will also be collected at
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enrolment and monthly until the baby is born. In addition, blood samples will also be collected
three times during the course of the study. At birth, stool, oral, vaginal and breast milk
samples will be collected from the mother and again one week after, while infant oral and
stool samples will be collected Finally, stool and oral samples will be collected from all the
infants born to study participants, at birth and one week later. The stool specimens will be
tested for parasitic infections and the vaginal samples will be tested for the presence of
bacteria. Blood will be tested for malaria parasites and will be shipped to Canada to be tested
for vitamin and element levels. Urine samples will also be collected and tested for protein and
glucose. In addition, small amounts of the stool, vaginal, oral and breast milk samples will be
shipped to Canada to be sequenced in order to determine the microbial profiles of all groups.
For all subject groups anthropometric assessment will be performed at enrolment and
monthly until birth. In addition, a questionnaire will be asked to collect information on
perceived changes in energy levels, gut health (diarrhea incidence and chronicity; bloating)
and any adverse health effects. A 24 hour dietary recall will also be given to determine the
subject’s energy and nutritional intakes.
You will then be followed up to delivery and your child will be followed up to 2 years of age. At
delivery all newborns will have height and weight measurements taken, time of gestation and
general health status. Infant cognitive function will be assessed at 6 months, 12 months, 18
months and 24 months.

Responsibilities of the study participant:
You have to continue with the routine pregnancy investigations as per standard of care at
your setting, as well as come to the clinic every month for a check-up and sample collection.
There are no specific dietary requirements for participating in this study, but you cannot
consume probiotic yogurt during the study if you are not part of the group randomly selected
to consume the yogurt. You will neither be allowed to smoke nor take alcohol during the entire
study period. If you are selected to consume the probiotic yogurt, you will be asked to come to
the Buswelu Kitchen every day to consume the yogurt.
Anytime during the study, if you do not feel well or you are feeling sick, you have to contact
your study doctor immediately. Your study doctor may examine you or do tests if it is
necessary. You will be given treatment and care by your study doctor as per the standard of
care to pregnant women
Tell your doctor immediately if you have the following (1) Effects (if you do not feel well or
you are sick) (2) pain, or (3) any symptom or problem during the study period. You may
contact your study doctor, who will be available for 24 hours, day and night; you will be given
the number to call after joining the study.
Risk/Discomforts:
If you are selected in the group that will be receiving yogurt, we do not expect there to be any
adverse effects to you or to your unborn baby due to consumption of the yogurt. The
procedures and tests done in the study will also not cause harm to either you or your baby.
Vaginal swabs will be taken, but these will not cause any harm to you or your baby.
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Benefits:
If you participate in this study and are selected to consume the yogurt you will not incur any
additional costs. The yogurt will be provided free of charge. You may experience positive
effects (example you may have better health) by taking the yogurt and you may have better
pregnancy outcomes. Other pregnant women may benefit in the future from the information
generated from this study. It is possible that you may not have a direct health advantage by
participating in this study and consuming the yogurt.
Payment:
To show appreciation for your time and transport costs, a total of 5,000 Tanzanian shillings will
be paid to you when you come to the clinic for the monthly study visits
Costs:
There are no extra costs to you for taking part in this study, except for giving up the time to
participate in the study and to come to the Buswelu Kitchen to consume the yogurt.
Confidentiality:
The information obtained from you when you participate in this study, and other information
concerning your health, will remain confidential. However the laboratory results may be shared
with your clinical peers at this clinic. By signing the consent form, you have authorized the
study workers to collect information about you pertaining to the study. However the study
team will make every effort to protect your personal information and your name will not be
used on any form, or any other information released later. If you withdraw from the study we
will not continue obtaining personal information from you but we may still need to use the
information already collected from you.
Personal information considered to be necessary (example date of birth) will be collected and
prepared for study purposes alone.
The study information could be published in a research journal and disseminated, but your
name will not be mentioned in any of the information disclosed. The researchers will make
sure that your personal information is protected.
Samples collected will be sent to Canada and Europe for analysis, but your name and any
other information will be kept confidential.
Right to refuse or withdraw from this study :
Participating in this study is voluntary. You may decide not to participate or withdraw from the
study at any time. The decision not to participate or to withdraw from the study will not affect
your right to access care. After withdrawing from the study, the samples that were taken
previously will be tested as planned unless you request not to have them tested when you
leave the study.
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Questions and person to contact:
Before signing this form you may ask questions about anything that you did not understand.
The study doctor and the study worker will answer them before, during or after the study. If
you have questions about the study or how the study is run, contact:
Name of the study doctor:

, mobile phone number

Study Coordinator:

, mobile phone number

Physical address: National Institute for Medical Research, Mwanza Centre,
P.O BOX 1462, Mwanza, Tanzania.
If you have questions about your rights in the study, contact: Dr. Mwele Malecela, Chairperson
for the Medical Research Coordinating Committee (|NIMR), Tanzania,
The national Institute for Medical Research (NIMR)
P.O BOX 9653, Dar-es-salaam, Tanzania
Phone 0222121400, Fax 0222121360
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Your Consent:
I have read, (or someone read to me), in a language that I understand all the information
above. I have been told that it is up to me to consent to participate in the study and that I may
withdraw from the study at any time without any effect. If I decide not to participate or
withdraw from the study, my right to access care will not be affected. I agree to participate in
the study and I know that I will get a copy of the signed consent form
________________________________________
Name of the participant

_______________________________________________________________________
Signature of the participant
Date
Please put a date on your signature during signing
Participant’s thumbprint

(The witness signature is required if the participant does not
know how to read)
__________________________________________
Name of the witness

Not applicable

______________________________ __________________________________________
Witness signature
Date

The researcher or another person assigned to explain the study and gain consent must
also sign and date at the same time as the participant
_______________________________________________ ____
Name of the person who explained the consent form
_______________________________________________________________________
Signature of the person who explained the consent form
Date
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Appendix 5: 48-hour Dietary Recall administered at every visit

Subject ID Sticker

Maternal Nutrition and Infant Health Study

48 hour Dietary Recall
To be given every visit

IDENTITY CHECK
Question

Answer

Visit date

|___|___| - |___|___|___| - 20|___|___|

Date of birth?

|___|___| - |___|___|___| - |___|___|___|___|

Study group of the participant

1

Under-nourished

2

Healthy

3

Obese

GENERAL
Time of recall
Do you have a fridge?

|___|__|:|___|__| (24hrs clock)
1. Yes
2. No

Do you have an oven?

1. Yes
2. No

How do you cook your meals? (circle all that
apply)

1. Electric hot plate
2. Gas stove top
3. Gas stove top with oven
4. Charcoal stove
5. Fire

Water supply (circle the type used and indicate
whether it is drinking water, cooking water or
both)

1. Well …………………………………………….
2. Tap ……………………………………………..
3. Bottled ……………………………………
4. Stream …………………………………………
5. Lake ……………………………………………

How far do you walk in a day?

...................................................................................
...................................................................................
...................................................................................

Do you eat Moringa?

1. Yes
2. No

Do you drink yogurt?

1. Yes
2. No
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Maternal Nutrition and Infant Health Study

24 hour dietary recall

Do you work?

1. Yes
2. No

Describe your work

...................................................................................
...................................................................................
...................................................................................

Instructions:
Give as detailed of information as possible. All information collected will be kept confidential, so be
as truthful and honest as possible. The information gained will not be used against you in anyway. It
will allow us to better assess your nutritional status so honesty is extremely important.
Be as specific as possible with portion sizes and amounts examples of how to estimate sizes are below
Size of fist = 1 cup
Palm of hand = 3 ounces
A thumb (entire thumb) = 2 tablespoons
Thumb tip = 1 teaspoon
If practical give the number of food items (ie. 1 banana, 1 orange, etc)

Wheat/Maize/Starch Products
Have you had any wheat/maize/rice
products? ie. ugali, chapata, bread?
What Kind? (circle all that apply)

1. Yes
2. No
1. Ugali

7. Keki

2. Rice

8. Vitumbua

3. Cooked Banana

9. Uji

4. Bread

10. Chipsi

5. Chapati

11. Chipsi Mayi

6. Mandazi

12. Other:
__________________

Detailed Information: For each item circled above, give the approximate time it was consumed
(asubuhi, mchana, jioni), the amount and how it was cooked (baked, boiled, fried, etc.) Make sure to
state if you added any salt, cooked it in butter or oil, etc, and the approximate amounts of each additive.
Day 1:

Day 2:

Asubuhi

Asubuhi

Item

Amount

Cooked

Item

Amount

Cooked

Item

Mchana

Amount

Cooked

Amount

Cooked

Mchana

Item
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Maternal Nutrition and Infant Health Study

24 hour dietary recall

Jioni

Jioni

Item

Amount

Cooked

Item

Amount

Cooked

Roots and Tubers:
Have you had any roots and/or tubers?

1. Yes
2. No

What kind (circle all that apply)

1. Ginger

5. Other:___________

2. Cassava
3. Sweet potato
4. Potato
Detailed Information: For each item circled above, give the approximate time it was consumed
(asubuhi, mchana, jioni), the amount and how it was cooked (baked, boiled, fried, etc.) Make sure to
state if you added any salt, cooked it in butter or oil, etc, and the approximate amounts of each additive.
Day 1:

Day 2:

Asubuhi

Asubuhi

Item

Amount

Cooked

Mchana

Item

Amount

Cooked

Amount

Cooked

Amount

Cooked

Mchana

Item

Amount

Cooked

Item

Amount

Cooked

Item

Jioni

Jioni

Item
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Maternal Nutrition and Infant Health Study

24 hour dietary recall
Vegetables:
Have you had any vegetables? (carrots, green
peppers, onions, tomatoes etc)

1. Yes
2. No
1.
2.
3.
4.
5.
6.
7.
8.

What kind? (circle all that apply)

Cucumber
Karoti
Tomatoes
Onions
Green Pepper
Eggplant
Parachichi
Jute Mallow

9. Spinach
10. Kabichi
11. Corn
12. Other:
________________
13. Pumpkin
14. Okra
15. Amaranth

Detailed Information: For each item circled above, give the approximate time it was consumed
(asubuhi, mchana, jioni), the amount and how it was prepared (make sure to state if you added any
salt, cooked it in butter or oil, etc, and the approximate amounts of each additive).
Day 1:

Day 2:

Asubuhi

Asubuhi

Item

Amount

Cooked

Item

Amount

Cooked

Item

Mchana

Amount

Cooked

Amount

Cooked

Amount

Cooked

Mchana

Item

Jioni

Jioni

Item

Amount

Cooked

Item

Fruits:
Have you had any fruits in the last 48 hours?

1 Yes
2 No

What type of fruit did you eat?
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1. Watermelon

10. Other:___________

2. Nanasi

___________________

3. Ndazi

11. Stafeli

4. Oranges

12. Papai
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24 hour dietary recall
5. Mango

13. Pears

6. Passion fruit

14. Mapera

7. Zambarau

15. Nazi

8. Limau

16. Fenesi(la(kizungu(

9. Tende
Detailed Information: For each item circled above, give the approximate time it was consumed
(asubuhi, mchana, jioni), and the number or amount that was consumed.
Day 1:

Day 2:

Asubuhi

Asubuhi

Item

Amount

Cooked

Mchana

Item

Amount

Cooked

Amount

Cooked

Amount

Cooked

Mchana

Item

Amount

Cooked

Item

Amount

Cooked

Item

Jioni

Jioni

Item

Meat:
Did you have any meat in the last 24 hours?

1. Yes
2. No

What type of meat did you eat? (circle all that
apply)

1. Beef

5. Other (specify):……………………..

2. Chicken

………………………………………….

3. Goat
4. Pork
Detailed Information: For each item circled above, give the approximate time it was consumed (asubuhi,
mchana, jioni), the amount and how it was prepared (make sure to state if you added any salt, cooked it in
butter or oil, etc, if it was marinated and the approximate amounts of each additive).
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24 hour dietary recall

Day 1:

Day 2:

Asubuhi

Asubuhi

Item

Amount

Cooked

Amount

Cooked

Item

Amount

Cooked

Item

Mchana

Item

Amount

Cooked

Amount

Cooked

Amount

Cooked

Mchana

Item

Jioni

Jioni

Item

Eggs:
Did you have any eggs?

1. Yes
2. No

What time did you eat eggs / How many did you have and how were they prepared? Make sure to state if you
used any oils, or butter or anything else to cook the eggs and the approximate amount that you used
I__I___I:I__I___I Time consumed / Amount:…………………….. / Prepared: ………………………………………...
I__I___I:I__I___I Time consumed / Amount: ……………………. / Prepared: ………………………………………...
I__I___I:I__I___I Time consumed / Amount: ……………………. / Prepared:…………………………………………
I__I___I:I__I___I Time consumed / Amount:…………………….. / Prepared: ……………………………………….
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24 hour dietary recall
Fish:
Did you have any fish in the last 48 hours?

1. Yes
2. No

If “yes” what kind did you have? (circle all
that apply)

1. Dagaa

4. Other:__________________

2. Nile Perch

__________________________

3. Tilapia
Detailed Information: For each item circled above, give the approximate time it was consumed (asubuhi,
mchana, jioni), the amount and how it was prepared (make sure to state if you added any salt, cooked it in
butter or oil, etc, and the approximate amounts of each additive).
Day 1:

Day 2:

Asubuhi

Asubuhi

Item

Amount

Cooked

Amount

Cooked

Amount

Cooked

Mchana

Item

Amount

Cooked

Amount

Cooked

Amount

Cooked

Mchana

Item

Jioni

Item

Jioni

Item

Item

Beans:
Did you eat any beans or lentils in the last 24
hours?

1. Yes

What type did you eat?

1. Maharage

4. Other:_______________________

2. Peas

5. Hyacinth bean

3. Lentils

6. Cow peas

2. No

4. Bambara ground nut
Detailed Information: For each item circled above, give the approximate time it was consumed (asubuhi,
mchana, jioni), the amount and how it was prepared (make sure to state if you added any salt, cooked it in
butter or oil, etc, and the approximate amounts of each additive).
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24 hour dietary recall

Day 1:

Day 2:

Asubuhi

Asubuhi

Item

Amount

Cooked

Amount

Cooked

Amount

Cooked

Mchana

Item

Amount

Cooked

Amount

Cooked

Amount

Cooked

Mchana

Item

Jioni

Item

Jioni

Item

Item

Sugar Products:
Did you eat anything containing sugar or
sugar products in the last 48 hours? (ie.
candy, honey etc)

1. Yes

If “yes” what did you have? (circle all that
apply)

1. Candy

2. No

2. Refined sugar
3. Honey

What time did you eat the sugar / How much did you have? Was it mixed with anything (in Chai, in kawa, etc?
I__I___I:I__I___I Time consumed / Amount:…………………….. / Consumed: ………………………………………
I__I___I:I__I___I Time consumed / Amount: ……………………. / Consumed: …………………………………...
I__I___I:I__I___I Time consumed / Amount: ……………………. / Consumed:……………………………………
I__I___I:I__I___I Time consumed / Amount:…………………….. / Consumed: ………………………………….
Milk Products:
Did you have any milk products in the last 24
hours? (ie. yogurt, milk etc)

1. Yes

If “yes” what did you have? (circle all that
apply)

1. Cheese

2. No

2. Milk
3. Yogurt (Maziwa ya Mara)
Specify the kind: …………………………………………...

What time did you have the milk products / How much did you have?
I__I___I:I__I___I Time consumed / Amount:……………………………………..……………………………………
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Subject ID Sticker

Maternal Nutrition and Infant Health Study

48 hour Dietary Recall
To be given every visit

IDENTITY CHECK
Question

Answer

Visit date

|___|___| - |___|___|___| - 20|___|___|

Date of birth?

|___|___| - |___|___|___| - |___|___|___|___|

Study group of the participant

1

Under-nourished

2

Healthy

3

Obese

GENERAL
Time of recall
Do you have a fridge?

|___|__|:|___|__| (24hrs clock)
1. Yes
2. No

Do you have an oven?

1. Yes
2. No

How do you cook your meals? (circle all that
apply)

1. Electric hot plate
2. Gas stove top
3. Gas stove top with oven
4. Charcoal stove
5. Fire

Water supply (circle the type used and indicate
whether it is drinking water, cooking water or
both)

1. Well …………………………………………….
2. Tap ……………………………………………..
3. Bottled ……………………………………
4. Stream …………………………………………
5. Lake ……………………………………………

How far do you walk in a day?

...................................................................................
...................................................................................
...................................................................................

Do you eat Moringa?

1. Yes
2. No

Do you drink yogurt?

1. Yes
2. No
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Appendix 6: Clinical Questionnaire completed by the Clinical Officer and study
staff at each monthly visit.

Subject ID Sticker.

Maternal Nutrition and Infant Health Study

Questionnaire
Initial Visit
VISIT DATE AND IDENTITY CHECK
QNo

Question

Answer

1.1

Visit date

|___|___| - |___|___|___| - 20|___|___|

1.2

Date of birth?

|___|___| - |___|___|___| - |___|___|___|___|

What is your age today?

|___|___| Years

1.4

1.5

Is the participant eligible for the study ?

1

Yes

(Has she passed the screening process ?)

2

No

Study group of the participant

1

Under-nourished

2

Well nourished

3

Obese

Completed by (Initials): |___|___|___|
DEMOGRAPHICS& VITAL SIGNS
2.1

Time of vital signs

|___|__|:|___|__| (24hrs clock)

2.2

What is the participant’s height?

|___|___|___| cm

2.3

What is the participant’s weight?

|___|___|___|. |___| kg

2.4

What is the participants MUAC

I___I___I___I.I___I cm

2.5

What is the participant’s blood pressure?

BP systolic

|___|___|___|. |___| mmHg

(BP to be taken while the subject is seated)

BP diastolic

|___|___|___|. |___| mmHg

2.6

What is the participant’s pulse rate?

|___|___|___|. |___| beats/minute

2.7

Body temperature?

|___|___|. |___| °C

Completed by (Initials): |___|___|___|

LABORATORY INVESTIGATION
3.1

Date of specimen collection

|___|___| - |___|___|___| - 20|___|___|

3.2

HIV results

1. Positive

2. Negative

3. Indeterminate

3.3

Malaria rapid diagnostic test results

1. Positive

2. Negative

3. Indeterminate

3.4

Time of haemoglobin specimen collection

|___|__|:|___|__| (24hrs clock)

3.5

Hemoglobin results

|___|___|___|

3.6

Treponema Pallidum results

|___|___|___|
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Subject ID Sticker.

Maternal Nutrition and Infant Health Study

Questionnaire
Initial Visit
3.7

Time of blood sample collection

|___|__|:|___|__| (24hrs clock)

3.8

Number of tubes of blood collected

I___I#

3.9

Type of blood tubes collected

I__I 6mL#K2)EDTA#Royal#Blue#Vacutainer#tube##

3.10

If less than the required tubes of blood
collected state why

3.11

Has a stool sample been collected

………………………………………………………………….
………………………………………………………………….
………………………………………………………………….
1. Yes
2. No
If no give reasons
….......................................................................................
...........................................................................................

3.12

Time of stool specimen collection

|___|__|:|___|__| (24hrs clock)

3.13

Stool results for parasitic infections

…................................................................................

I__I#K2##6#mL#EDTA#lavender#top#Vacutainer#tube#

…................................... .............................................
…................................................................................
1. Yes
2. No
If no give reasons
….......................................................................................
...........................................................................................

3.14

Have vaginal samples been collected (3
swabs collected)

3.15

Time of Vaginal specimen collection

3.16

Has a BV slide been made?

3.17

pH of the vagina

3.18

Has a oral sample been collected

3.19

Time of oral sample collection

3.20

Time of urine specimen collection

|___|__|:|___|__| (24hrs clock)

3.21

Urine Protein results

|___|___|___|___I mg/dL (g/L)

3.22

Urine Glucose results

|___|___|___|___I mg/dL (mmoL/L)

3.23

Urine Urobilinogen results

|___|___|___|___I mg/dL (µmol/L)

3.24

Urine Bilirubin results

|___|___|___|___I

3.25

Urine Ketone results

|___|___|___|___I mg/dL (mmoL/L)
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|___|__|:|___|__| (24hrs clock)
1. Yes
2. No
I___I___I
1. Yes
2. No
If no give reasons
...........................................................................................
...........................................................................................
..........................................................................................
I___I__I:I___I__I (24hrs clock)
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Subject ID Sticker.

Maternal Nutrition and Infant Health Study

Questionnaire
Initial Visit

3.26

Urine S.G. results

|___I.|___|___|___I

3.27

Urine Blood results

|___|___|___|___I I______________I RBC/µL

3.28

Urine pH

|___|___|___|

3.29

Urine Nitrite

|___|___|___|___I

3.30

Urine Leukocytes

|___|___|___|___I WBC/µL

OBSTETRICAL HISTORY:
4.1

Number of previous pregnancies:

|___|___|

4.2

Number of vaginal deliveries

|___|___|

4.3

Number of C-sections:

|___|___|

4.4

Number of live births

|___|___|

4.5

Number of spontaneous abortions:

|___|___|

4.6

Number of elective terminations:

|___|___|

4.7

Number of ectopic pregnancies:

|___|___|

4.8

Number of molar pregnancies:

|___|___|

4.9

History of sub fertility

1 Yes
2 No

4.10a

st

Age of subject at delivery of the 1 pregnancy
st

|___|___|

4.10b

Dates of subjects delivery of 1 pregnancy:

|___|___| - |___|___|___| - |___|___|___|___|

4.11

Number of still birth deliveries:

|___|___|

4.12

Number of obstetrical complications

|___|___|

4.13

Does the participant experience any neusea or
vomiting in the current pregnancy

1 Yes

Is there a family history of congenital
abnormality/genetic diseases, consanguinity (or
any family relation or lineage) between parents?

1 Yes

4.14

2 No

2 No
If Yes, please specify .....................................................

…………………………..……………………………….
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Subject ID Sticker.

Maternal Nutrition and Infant Health Study

Questionnaire
Initial Visit
4.15

Number of children who are currently alive.

4.16

Is there any other obstetric history?

|___|___|
1 Yes
2 No
If Yes, please specify .....................................................

…………………………..……………………………….

OBSTETRIC EXAMINATION:
4.17

Fundal height:

|___|__|. |___| cm

4.19

Has the subject felt any fetal movements in the
past 24 hours?

1 Yes

Are the fetal movement Normal?

1 Yes

4.20

2 No

2 No
4.21

Fetal presentation ((Circle one that apply):

1 Cephalic (head down) position
2 Breech (bottom down) position
3 Transverse position
4 Unknown

4.22

Write a brief summary of the findings during obstetric examination:
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………….

GENERAL MEDICAL HISTORY/PHYSICAL EXAMINATION
MEDICAL HISTORY
Does subject have current disease
or symptoms today?

Does subject have any of the
following conditions?

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………

1 Asthma

2 Diabetes

3 Hypertension

4 Tuberculosis

5 Epilepsy

8 None of these

(Circle all that apply)
Operations or serious illnesses or
accidents
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1 Yes

If yes, specify:……………………………......….....………………
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Subject ID Sticker.

Maternal Nutrition and Infant Health Study

Questionnaire
Initial Visit

Taking any medication at the
moment?

2 No

………………………………………………......….…………………

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Do you take any alcohol at the
moment?

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………

Does the subject smoke?

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………

CVS system
Chest pain

SOB/orthopnoea

…………………………………………………….......………………
Oedema

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Palpitations

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Other CVS symptoms

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Respiratory system
Cough

1 Yes, dry cough

Specify………………………………

(Check colour, amount,
consistency for sputum)

2 Yes, productive with sputum

………………………………………

3 Yes, with haemoptysis

………………………………..…..…

4 No cough

………………………………………

Other RS symptoms

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

th
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Maternal Nutrition and Infant Health Study

Subject ID Sticker.

Questionnaire
Initial Visit

Gastrointestinal system
Abdominal pain)

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Nausea/vomiting

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Diarrhoea/alteration in bowel habit)

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Weight loss

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Other GI symptoms

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

CNS
Headaches/dizziness

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Visual/hearing problems

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Motor problems (walking, etc.)

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Sensory problems (e.g. numbness)

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Other CNS symptoms

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………

Skin

th
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Subject ID Sticker.

Maternal Nutrition and Infant Health Study

Questionnaire
Initial Visit
Skin rashes or other problems

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Summary of any abnormalities found during Physical Examination
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………………
…………………………………………………………………………………………
HISTORY-DIRECTED PHYSICAL EXAMINATION (“ND” if not done)
5.1

5.2

Cyanosis

1 Absent

2 Present,

specify ……………………………

Clubbing

1 Absent

2 Present,

specify ……………………………

Head

1 Absent

2 Present,

specify ……………………………

Neck

1 Absent

2 Present,

specify ……………………………

Lymph nodes

5.3

Axillae

1 Absent

2 Present,

specify ……………………………

Inguinal

1 Absent

2 Present,

specify ……………………………

Other Specify

1 Absent

2 Present,

specify ……………………………

Cardio Vascular System
Blood Pressure (BP)

th

|___|___|___| / |___|___|___| mm/Hg

Apex

1 Normal

Pulse

|___|___|___| beats/min

1 Regular

Heart Sounds (HS)

1 Normal

2 Abnormal,

specify ……………………………

Oedema

1 Normal

2 Abnormal,

specify ……………………………
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2 Abnormal,

specify ……………………………
2 Irregular
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Subject ID Sticker.

Maternal Nutrition and Infant Health Study

Questionnaire
Initial Visit
5.4

Respiratory System (RS)
Respiratory Rate (RR)

|___|___|___| breaths/min

Percussion Notes (PN)

1 Resonant

2 Dull,

specify ……………………………

1 Normal

2 Abnormal,

specify…………………………….

Breath Sounds (BS)
5.5

Abdomen

L

S

•
K

K

Hepatomegaly

1 Yes

2 No

Splenomegaly

1 Yes

2 No

L kidney enlarged

1 Yes

2 No

R kidney enlarged

1 Yes

2 No

(Please draw any enlargements on diagram opposite and
circle as applicable)
Tenderness

5.6

1 Non-tender

2 Tender

3 Rebound

4 Guarding

Eyes

1 Normal

2 Abnormal,

specify……………………………

Ears

1 Normal

2 Abnormal,

specify…………………………….

Cranial nerves

1 Normal

2 Abnormal,

specify…………………………….

Peripheral NS

1 Normal

2 Abnormal,

specify……………………………

1 Normal

2 Abnormal,

specify……………………………

Central Nervous System

5.7

Skin

5.8

Summary of Medical History and Examination (please detail any abnormalities found on examination):
------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ---------

Section completed by (initials): |___|___|___|

th
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Appendix 7: Birth Clinical Questionnaire

Subject ID Sticker.

Maternal Nutrition and Infant Health Study

Questionnaire
BIRTH
VISIT DATE AND IDENTITY CHECK
QNo

Question

Answer

1.1

Visit date

|___|___| - |___|___|___| - 20|___|___|

1.2

Study group of the participant

1

Under-nourished

2

Well nourished

3

Obese

Completed by (Initials): |___|___|___|

DEMOGRAPHICS& VITAL SIGNS OF MAMA
2.1

Time of vital signs

|___|__|:|___|__| (24hrs clock)

2.2

What is the participant’s weight?

|___|___|___|. |___| kg

2.3

What is the participants MUAC

I___I___I___I.I___I cm

Completed by (Initials): |___|___|___|

LABORATORY INVESTIGATION
3.1

Date of specimen collection

|___|___| - |___|___|___| - 20|___|___|

3.2

HIV results

1. Positive

2. Negative

3. Indeterminate

3.3

Malaria rapid diagnostic test results

1. Positive

2. Negative

3. Indeterminate

3.4

Time of haemoglobin specimen collection

|___|__|:|___|__| (24hrs clock)

3.5

Hemoglobin results

|___|___|___|

3.6

Treponema Pallidum results

|___|___|___|

3.7

Time of blood sample collection

|___|__|:|___|__| (24hrs clock)

3.8

Number of tubes of blood collected

I___I#

3.9

Type of blood tubes collected

I__I 6mL#K2)EDTA#Royal#Blue#Vacutainer#tube##

3.10

If less than the required tubes of blood
collected state why

3.11

Has a stool sample been collected

th
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I__I#K2##6#mL#EDTA#lavender#top#Vacutainer#tube#
………………………………………………………………….
………………………………………………………………….
1. Yes
2. No
If no give reasons
….......................................................................................
...........................................................................................
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Subject ID Sticker.

Maternal Nutrition and Infant Health Study

Questionnaire
BIRTH
3.12

Time of stool specimen collection

|___|__|: I___|__| (24hrs clock)

3.13

Stool results for parasitic infections

……............................................. ...............................
……............................................. ...............................
……................... .......................... ...............................
1. Yes
2. No
If no give reasons
….......................................................................................
...........................................................................................

3.14

Have vaginal samples been collected (3
swabs collected)

3.15

Time of Vaginal specimen collection

3.16

Has a BV slide been made?

3.17

pH of the vagina

3.18

Metabolome tube #

3.19

Has a oral sample been collected

3.20

Time of oral sample collection

3.21

Time of urine specimen collection

|___|__|:|___|__| (24hrs clock)

3.22

Urine Protein results

|___|___|___|___I mg/dL (g/L)

3.23

Urine Glucose results

|___|___|___|___I mg/dL (mmoL/L)

3.24

Urine Urobilinogen results

|___|___|___|___I mg/dL (µmol/L)

3.25

Urine Bilirubin results

|___|___|___|___I

3.26

Urine Ketone results

|___|___|___|___I mg/dL (mmoL/L)

3.26

Urine S.G. results

|___I.|___|___|___I

3.27

Urine Blood results

|___|___|___|___I I______________I RBC/µL

3.28

Urine pH

|___|___|___|

3.29

Urine Nitrite

|___|___|___|___I

3.30

Urine Leukocytes

|___|___|___|___I___I___I___I___I WBC/µL

3.31

Time of Breast milk sample collection

|___|__|:|___|__| (24hrs clock)

th
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|___|__|: I___|__| (24hrs clock)
1. Yes
2. No
I___I___I
I___I___I___I
1. Yes
2. No
If no give reasons
...........................................................................................
...........................................................................................
..........................................................................................
I___I__I:I___I__I (24hrs clock)
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Maternal Nutrition and Infant Health Study

Subject ID Sticker.

Questionnaire
BIRTH
3.32

Has a Breast milk sample been collected?

1. Yes
2. No
If no, give reasons
………………………………………………………………….
………………………………………………………………….

3.34

Has an infant stool sample been collected?

1. Yes
2. No
If no, give reasons
………………………………………………………………….
………………………………………………………………….

3.35

Time of infant stool sample collection

3.36

Has an infant oral sample been collected?

I___I__I:I___I__I (24hrs clock)
1. Yes
2. No
If no, give reasons
………………………………………………………………….
………………………………………………………………….

3.37

Time of infant oral sample collection

I___I__I:I___I__I (24hrs clock)

Section completed by (initials): |___|___|___I

NEWBORN EXAMINATION:
4.1

Date of birth

I___I___I - I___I___I – 20I___I___I (mm/dd/yy)

4.2

Time of birth

I___I___I : I___I___I (24 hour clock)

4.3

Gestation age at birth

I____I____I weeks

4.4

Sex of Infant

1. Male

4.5

Type of birth

2. Caesarean

2. Female

3. Vaginal delivery
4.6

Where did the birth occur?

1. Home
2. Nyerere Dispensary
3. Seko-toure
4. Bugando
5. Other:
______________________________

4.7

Length:

|___|__|. |___| cm

th
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Subject ID Sticker.

Maternal Nutrition and Infant Health Study

Questionnaire
BIRTH
4.8

Weight

I____I. I____I kg

4.9

Heart rate beats/min

|___|__|___| beats/min

4.10

Mid-upper arm circumference

I___I___I. I___I cm

4.11

Head circumference

I___I___I. I___I cm

4.12

Length of Labor

4.13

Problems with Delivery?

I___I____I___I hours
1. Yes
2. No

4.14

If “YES” to 4.13 explain

……………………………………………………………
……………………………………………………………
……………………………………………………………
……………………………………………………………

4.14

Preterm Birth?

1. Yes
2. No
If yes: number of weeks/months: I___I___I___I

4.15

Any health issues with infant?

1. Yes
2. No
If “Yes” explain:
……………………………………………………………
……………………………………………………………
……………………………………………………………

GENERAL MEDICAL HISTORY/PHYSICAL EXAMINATION
MEDICAL HISTORY
Does subject have current disease
or symptoms today?

Does subject have any of the
following conditions?

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………

1 Asthma

2 Diabetes

3 Hypertension

4 Tuberculosis

5 Epilepsy

8 None of these

(Circle all that apply)
Operations or serious illnesses or
accidents

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………

Taking any medication at the
moment?

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

th

Version 1. 10 April 2012

4 of 8

174

Subject ID Sticker.

Maternal Nutrition and Infant Health Study

Questionnaire
BIRTH
Do you take any alcohol at the
moment?

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………

Does the subject smoke?

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………

CVS system
Chest pain

SOB/orthopnoea

…………………………………………………….......………………
Oedema

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Palpitations

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Other CVS symptoms

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Respiratory system
Cough

1 Yes, dry cough

Specify………………………………

(Check colour, amount,
consistency for sputum)

2 Yes, productive with sputum

………………………………………

3 Yes, with haemoptysis

………………………………..…..…

4 No cough

………………………………………

Other RS symptoms

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Gastrointestinal system
Abdominal pain)

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

th
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Maternal Nutrition and Infant Health Study

Subject ID Sticker.

Questionnaire
BIRTH
Nausea/vomiting

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Diarrhoea/alteration in bowel habit)

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Weight loss

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Other GI symptoms

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

CNS
Headaches/dizziness

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Visual/hearing problems

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Motor problems (walking, etc.)

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Sensory problems (e.g. numbness)

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………
…………………………………………………….......………………

Other CNS symptoms

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………

1 Yes

If yes, specify:……………………………......….....………………

2 No

………………………………………………......….…………………

Skin
Skin rashes or other problems

…………………………………………………….......………………

th
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Subject ID Sticker.

Maternal Nutrition and Infant Health Study

Questionnaire
BIRTH
HISTORY-DIRECTED PHYSICAL EXAMINATION (“ND” if not done)
5.1

5.2

Cyanosis

1 Absent

2 Present,

specify ……………………………

Clubbing

1 Absent

2 Present,

specify ……………………………

Head

1 Absent

2 Present,

specify ……………………………

Neck

1 Absent

2 Present,

specify ……………………………

Lymph nodes

5.3

Axillae

1 Absent

2 Present,

specify ……………………………

Inguinal

1 Absent

2 Present,

specify ……………………………

Other Specify

1 Absent

2 Present,

specify ……………………………

Cardio Vascular System
Blood Pressure (BP)

5.4

1 Normal

Pulse

|___|___|___| beats/min

1 Regular

Heart Sounds (HS)

1 Normal

2 Abnormal,

specify ……………………………

Oedema

1 Normal

2 Abnormal,

specify ……………………………

specify ……………………………
2 Irregular

Respiratory Rate (RR)

|___|___|___| breaths/min

Percussion Notes (PN)

1 Resonant

2 Dull,

specify ……………………………

1 Normal

2 Abnormal,

specify…………………………….

Abdomen

L

S

•
K

K

Hepatomegaly

1 Yes

2 No

Splenomegaly

1 Yes

2 No

L kidney enlarged

1 Yes

2 No

R kidney enlarged

1 Yes

2 No

(Please draw any enlargements on diagram opposite and
circle as applicable)
Tenderness

5.6

2 Abnormal,

Respiratory System (RS)

Breath Sounds (BS)
5.5

|___|___|___| / |___|___|___| mm/Hg

Apex

1 Non-tender

2 Tender

3 Rebound

4 Guarding

Eyes

1 Normal

2 Abnormal,

specify……………………………

Ears

1 Normal

2 Abnormal,

specify…………………………….

Cranial nerves

1 Normal

2 Abnormal,

specify…………………………….

Peripheral NS

1 Normal

2 Abnormal,

specify……………………………

1 Normal

2 Abnormal,

specify……………………………

Central Nervous System

5.7

Skin

5.8

Summary of Medical History and Examination (please detail any abnormalities found on examination):
----------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------- ----------------------------------------------------------------------------------------------------th
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Maternal Nutrition and Infant Health Study

Subject ID Sticker.

Questionnaire
BIRTH

5.9

Any prescriptions given?

3. Yes
4. No

5.10 If Yes which prescriptions and what is the treatment ………………………………………………………….
for?

…………………………………………………………...
…………………………………………………………..
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Appendix 8: Raw birth data for the UN group. A (-) indicates that birth weight was
not collected, while a (D) indicates that the baby is deceased.
Study ID

GA LMP*
(weeks)

GA NA**
(weeks)

Difference
(LMPNA)

Preterm

LMP NA
N
N
MNIH09UP
38.57
38.57
0.00
N
Y
MNIH21U
38.57
34.00
4.57
Y
Y
MNIH23U
29.71
29.29
0.43
N
N
MNIH31U
37.57
37.43
0.14
N
N
MNIH39U
40.86
40.86
0.00
N
N
MNIH43N
37.86
38.00
-0.14
N
Y
MNIH45N
38.00
30.14
7.86
N
Y
MNIH48N
38.43
38.71
-0.29
N
N
MNIH49N
39.00
39.14
-0.14
N
N
MNIH50N
40.43
38.43
2.00
N
N
MNIH55N
39.57
40.71
-1.14
N
N
MNIH56N
42.14
42.71
-0.57
Y
Y
MNIH58N
32.43
32.43
0.00
*GA LMP: Gestational age calculated from last menstrual period
*GA NA: Gestational age given by a nurses approximation

Birth
Weight
(kg)

Mother
Weight
Gain
(lbs/week)

2.5
3.4
2.68
3.3
3
2.7
3.7
3.5
3
3.2
D

0.47
0.48
2.38
1.53
0.77
1.05
1.21
1.12
0.13
0.87
-0.11

Appendix 9: Raw birth data for the UNP group. A (-) indicates that birth weight
was not collected.
Study ID

MNIH01UP
MNIH02UP
MNIH05UP
MNIH14UP
MNIH16UP
MNIH20UP
MNIH83NP
MNIH84NP
MNIH88NP
MNIH90NP
MNIH92NP

GA
Difference
GA
NA**
(LMPLMP*
NA)
(weeks) (weeks)

37.14
41.57
35.86
34.43
41.43
38.71
37.43
41.43
44.14
39.86
38.57

37.86
41.71
36.14
33.43
41.86
37.29
37.43
33.43
40.14
39.86
39.43

-0.71
-0.14
-0.29
1.00
-0.43
1.43
0.00
8.00
4.00
0.00
-0.86

Preterm

LMP NA
N
N
N
N
Y
Y
Y
Y
N
N
N
N
N
N
N
Y
N
N
N
N
N
N

Birth
Weight
(kg)

Mother
Weight
Gain
(lbs/week)

2.6
2.8
3.4
2.3
3.25
3.25
3.2
3
3.4
3.8

0.49
0.43
0.64
0.93
0.71
1.63
1.93
0.69
0.62
0.58

179

N
N
MNIH95NP 42.00
42.14
-0.14
3.5
*GA LMP: Gestational age calculated from last menstrual period
*GA NA: Gestational age given by a nurses approximation

4.08

Appendix 10: Raw birth data for the N group. A (-) indicates that birth weight was
not collected.
Study ID

GA
LMP*
(weeks)

GA
NA**
(weeks)

Difference
(LMPNA)

Preterm

Birth
Weight
(kg)

LMP NA
N
N
MNIH41N
40.00
47.43
-7.43
3.85
N
N
MNIH51N
36.86
37.14
-0.29
N
N
MNIH52N
38.29
38.29
0.00
3.1
N
Y
MNIH54N
43.14
36.43
6.71
3.4
N
N
MNIH57N
46.29
38.00
8.29
3
N
N
MNIH59N
38.14
38.14
0.00
Y
Y
MNIH60N
33.86
33.71
0.14
2.8
N
Y
MNIH86NP
38.00
38.71
-0.71
3.2
*GA LMP: Gestational age calculated from last menstrual period
*GA NA: Gestational age given by a nurses approximation

Mother
Weight
Gain
(lbs/week)
0.45
0.76
0.30
-1.44
1.52
0.94

Appendix 11: Raw birth data for the NP group. A (-) indicates that birth weight was
not collected, while (D) indicates that the infant is deceased. This group contained
two twin sets and the second infant is indicated by ( _2) after the study ID.
Study ID

MNIH81NP
MNIH82NP
MNIH85NP
MNIH87NP
MNIH93NP
MNIH94NP
MNIH96NP
MNIH97NP
MNIH97NP_2
MNIH99NP
MNIH99NP_2

GA
LMP*
(weeks)

GA
NA**
(weeks)

Difference
(LMPNA)

35.43
40.14
40.43
39.43
26.71
25.86
38.86
37.71

34.14
42.00
37.43
40.29
27.57
26.29
38.86
37.57

1.29
-1.86
3.00
-0.86
-0.86
-0.43
0.00
0.14

34.57

34.57

0.00

Preterm

LMP NA
Y
Y
N
N
N
N
N
N
Y
Y
Y
Y
N
N
N
N
Y

Y

Birth
Weight
(kg)

Mother
Weight
Gain
(lbs/week)

3.6
3
3.5
3.3
1.7
D
3.1
2.1
2.3
3.2
3.8

0.64
0.92
1.39
1.13
-0.61
1.13
-0.33
0.72

180

*GA LMP: Gestational age calculated from last menstrual period
*GA NA: Gestational age given by a nurses approximation
Appendix 12: Raw birth data for the O group. A (-) indicates that birth weight was
not collected.
Study ID

GA
LMP*
(weeks)

GA NA**
(weeks)

Difference
(LMPNA)

Preterm

Birth
Weight
(kg)

LMP NA
Y
N
MNIH61O
36.14
40.29
-4.14
3.19
N
N
MNIH62O
40.00
37.14
2.86
3.6
N
N
MNIH64O
37.29
37.29
0.00
3.3
N
N
MNIH65O
39.29
39.43
-0.14
2.4
*GA LMP: Gestational age calculated from last menstrual period
*GA NA: Gestational age given by a nurses approximation

Mother
Weight
Gain
(lbs/week)
0.24
0.28
0.47
0.30
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